Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2015
Or
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-35817
CANCER GENETICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
04-3462475
(I.R.S. Employer
Identification No.)
201 Route 17 North 2nd Floor
Rutherford, NJ 07070
(201) 528-9200
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, $0.0001 par value per share
Name of each exchange on which registered
NASDAQ Capital Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No ý
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes: ¨ No: ý
Indicate by check mark if the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes: ý No: ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website; if any, every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes: ý No: ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in
definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨
Indicate by check mark if the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer”,
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):
Large accelerated filer
¨
Non-accelerated filer
¨ (do not check if a smaller reporting company)
Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes: ¨ No: ý
Accelerated filer
Smaller reporting company
ý
¨
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $91 million on June 30, 2015, the last business day of the registrant’s most
recently completed second fiscal quarter, based on the closing price of $11.76 on that date.
Indicate the number of shares outstanding of each of the registrant’s classes of common equity, as of March 1, 2016:
Class
Common Stock, $.0001 par value
Number of Shares
13,652,274
Documents incorporated by reference
Portions of the registrant’s proxy statement for the 2016 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant’s fiscal year ended
December 31, 2015, are incorporated by reference in Part III of this Form 10-K.
Table of Contents
TABLE OF CONTENTS
PART I
PART II
PART III
PART IV
1.
1A.
1B.
2.
3.
4.
5.
6.
7.
7A.
8.
9.
9A.
9B.
10.
11.
12.
13.
14.
15.
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Exhibits, Financial Statement Schedules
2
28
55
55
56
56
57
58
59
71
73
107
107
108
109
109
109
109
109
110
Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all
statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,”
“plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” or the negative of those terms, and similar expressions and comparable terminology intended
to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and
uncertainties including those set forth below under Part I, Item 1A, “Risk Factors” in this annual report on Form 10-K. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this annual report on Form 10-
K and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future
events or otherwise after the date of this annual report on Form 10-K. You should read this annual report on Form 10-K and the documents referenced in this annual report on
Form 10-K and filed as exhibits completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our
forward-looking statements by these cautionary statements. Such statements may include, but are not limited to, statements concerning the following:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
our ability to achieve profitability by increasing sales of our laboratory tests and services and to continually develop and commercialize novel and innovative
diagnostic tests and services for cancer patients;
our ability to raise additional capital to meet our liquidity
needs;
our ability to clinically validate our pipeline of genomic microarray tests currently in
development;
our ability to execute on our marketing and sales strategy for our genomic tests and gain acceptance of our tests in the
market;
our ability to keep pace with rapidly advancing market and scientific
developments;
our ability to satisfy U.S. (including FDA) and international regulatory requirements with respect to our tests and services, many of which are new and still
evolving;
our ability to obtain reimbursement from governmental and other third-party payors for our tests and
services;
competition from clinical laboratory services companies, diagnostic tests currently available or new tests that may
emerge;
our ability to maintain our clinical collaborations and enter into new collaboration agreements with highly regarded organizations in the cancer field so that, among
other things, we have access to thought leaders in the field and to a robust number of samples to validate our genomic tests;
our ability to maintain our present customer base and obtain new
customers;
potential product liability or intellectual property infringement
claims;
our dependency on third-party manufacturers to supply or manufacture our
products;
our ability to attract and retain a sufficient number of scientists, clinicians, sales personnel and other key personnel with extensive experience in oncology, who are in
short supply;
our ability to obtain or maintain patents or other appropriate protection for the intellectual property in our proprietary tests and
services;
our dependency on the intellectual property licensed to us or possessed by third
parties;
our ability to expand internationally and launch our tests in emerging markets, such as India and Brazil;
and
our ability to adequately support future
growth.
Table of Contents
Item 1.
Business.
Overview
PART I
We are an emerging leader in the field of personalized medicine, enabling precision medicine in the field of oncology through our diagnostic products and services and
molecular markers. We develop, commercialize and provide molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management
of each individual patient by providing genomic information to better diagnose, monitor and inform cancer treatment and that enable biopharmaceutical companies engaged in
oncology trials to better select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to
therapeutics. We have a comprehensive, disease-focused oncology testing portfolio. Our tests and techniques target a wide range of cancers, covering eight of the top ten
cancers in prevalence in the United States, with additional unique capabilities offered by our Tissue of Origin® test for identifying difficult to diagnose tumor types or poorly
differentiated metastatic disease.
Our vision is to become the oncology diagnostics partner for biopharmaceutical companies and clinicians by participating in the entire care continuum from bench to bedside.
We believe the diagnostics industry is undergoing a rapid evolution in its approach to oncology testing, embracing precision medicine and individualized testing as a means to
drive higher standards of patient treatment and disease management. Similarly, biopharmaceutical companies are increasingly engaging companies such as ours to provide
information on clinical trial participants' molecular profiles in order to identify biomarker and genomic variations that may be responsible for differing responses to
pharmaceuticals, and particularly to oncology drugs, thereby increasing the efficiency of trials while lowering related costs. We believe tailored therapeutics can revolutionize
oncology medicine through molecular- and biomarker-based testing services, enabling physicians and researchers to target the factors that make each patient and disease
unique. We have created a unique position in the industry by providing targeted somatic analysis of tumor sample cells alongside germline analysis of an individual's non-
cancerous cells' molecular profile as we attempt to reach the next milestone in personalized medicine. Individuals are born with germline mutations, and somatic mutations
arise in tissues over the course of a lifetime.
Cancer is genetically-driven and constitutes a heterogeneous class of diseases characterized by uncontrollable cell growth. Many cancers are becoming increasingly understood
at a molecular level and it is possible to attribute specific cancers to identifiable genetic changes in unhealthy cells. Cancer cells contain modified genetic material compared to
normal human cells. Common genetic abnormalities correlated to cancer include gains or losses of genetic material on specific chromosomal regions (loci) or changes in
specific genes (mutations) that ultimately result in detrimental cellular changes followed by cancerous or pre-cancerous conditions. Understanding the differences in these
molecular changes helps clinicians to identify and stratify different forms of cancer in order to optimize patient treatment and patient management. Therefore, understanding
and analysis of cancer at the molecular level is not only useful for diagnostic purposes, but we also believe it can play an important role in prognosis and disease management.
We believe technology that can apply predictive information has the potential to dramatically improve treatment outcomes for patients living with cancer. Our molecular- and
biomarker-based tests for cancer aim to remove subjectivity from the diagnostic phase, and add prognostic information, thus enabling personalized treatments based on cancer
analysis at its most basic level.
Our business is based on demand for molecular- and biomarker-based diagnostic services from three main sectors, including cancer centers and hospitals, biotechnology and
biopharmaceutical companies, and the research community. Clinicians and oncologists in cancer centers and hospitals seek testing since these methods often produce higher
value and more accurate cancer diagnostic information than traditional analytical methods. Our proprietary and disease-focused tests aim to provide actionable information that
can guide patient management decisions, potentially resulting in decreased costs for care providers and patients while streamlining therapy selection. Our services are also
sought by biotechnology and biopharmaceutical companies engaged in designing and running clinical trials to determine the value and efficacy of oncology treatments and
therapeutics. We believe trial participants' likelihood of experiencing either favorable or adverse responses to the trial treatment may be influenced or dependent on genomic
factors. Our testing services may increase trial efficiency, subject safety and trial success rates. Our services are also sought by researchers and research groups seeking to
identify biomarkers and develop methods for diagnostic technologies and tests for disease. We aggressively pursue the strategy of trying to demonstrate increased value and
efficacy with payors who are trying to contain costs and academic collaborators seeking to develop new insights and cures.
Our market strategy is organized to align with the three aforementioned industry segments. We utilize relatively the same technologies across each of these businesses to
deliver results-oriented information which we believe is or will become important to cancer treatment and patient management. Our tests address the limitations of traditional
cancer diagnostic approaches, including reliance on human inspection of specimens and interpretation of clinical measurements, and inter-
2
Table of Contents
institutional variability. Our suite of clinical and biopharma services aim to remove subjectivity from diagnoses and additionally provide information that may influence
treatment selection that cannot be obtained from anatomic pathology and staining techniques alone. We believe the level of personalized treatment required to optimize a
patient's treatment regimen and to maximize clinical trial success rates may be significantly improved through the use of molecular- and biomarker-based cancer
characterization.
The following table lists our market strategy by customer category:
Customer Category
Types of Customers
Nature of Services
Clinical Services
Biopharma Services
Discovery Services
• Hospitals
• Cancer Centers
• Clinics
• Biopharma and Biotech
companies performing clinical
trials
• Biopharma and Biotech
companies
• Researchers and Academic
Institutions
Clinical services provide information on diagnosis, prognosis and
predicting treatment outcomes (theranosis) of cancers to guide
patient management.
Biopharma services provide companies with customized solutions for
patient stratification and treatment selection through an extensive
suite of molecular- and biomarker-based testing services, customized
assay development and trial design consultation.
Discovery services provide the tools and testing methods for
companies and researchers seeking to identify new molecular-based
biomarkers for disease.
In 2015, we generated approximately 64% of our revenue from Biopharma Services, approximately 31% from Clinical Services and approximately 5% from Discovery
Services. In 2014, we generated approximately 43% of our revenue from Clinical Services, approximately 55% from Biopharma Services and approximately 2% from
Discovery Services, a new line of service launched in 2014.
We utilize relatively the same proprietary and nonproprietary molecular diagnostic tests and technologies across all of our service offerings to deliver results-oriented
information important to cancer treatment and patient management. Our portfolio primarily includes comparative genomic hybridization (CGH) microarrays, gene expression
tests, next generation sequencing (NGS) panels, and DNA fluorescent in situ hybridization (FISH) probes. We provide our testing services from our CLIA-certified and CAP-
accredited laboratories in Rutherford, NJ, Los Angeles, CA, and Raleigh, NC, as well as our laboratories in Hyderabad, India and Shanghai, China.
Market Overview
United States Clinical Oncology Market Overview
Despite many advances in the treatment of cancer, it remains one of the greatest areas of unmet medical need. In 2012, the World Health Organization attributed 8.2 million
deaths worldwide to cancer-related causes. In 2014, the World Health Organization projected that over the next two decades this number will rise to 13 million deaths per
year. Within the United States, cancer is the second most common cause of death, exceeded only by heart disease, accounting for nearly one out of every four deaths. The
incidence and deaths caused by the major cancer categories are staggering. The following table published by The American Cancer Society shows estimated new cases and
deaths in 2015 in the United States for the major cancers:
3
Table of Contents
Cancer Type
Breast............................
Cervical.........................
Colorectal......................
Endometrial...................
Kidney...........................
Leukemia.......................
Lung...............................
Melanoma.....................
Multiple Myeloma........
Non-Hodgkin's
Lymphomas...................
Ovarian.........................
Pancreatic......................
Prostate.........................
Estimated New Cases For 2015 Estimated Deaths For 2015
40,290
4,100
59,700
10,170
14,080
24,450
158,040
9,940
11,240
234,190
12,900
132,700
54,870
61,560
54,270
221,200
73,870
26,850
71,850
21,290
48,960
220,800
19,790
14,180
40,560
27,540
United States Clinical Trials Market Overview
The United States is currently the world leader in biopharmaceutical research and development and manufacturing. In 2013 it is estimated that over $50 billion dollars was
spent in pharmaceutical research and development, increasing 20% from spending in 2005. The average cost to develop a drug can be as high as $1.2 billion and the approval
process from development to market may be as long as 15 years. Since 1980, approximately 83% of life expectancy increases in cancer patients are due to new treatments and
oncology medications.
While oncology drugs have the potential to be among the most personalized therapeutics, oncology clinical trials continue to have some of the poorest approval rates. The
application of pharmacogenomics to oncology clinical trials enables researchers to better predict differences in drug response, efficacy and toxicity among trial participants, as
well as to optimize treatment regimens based on these differences. According to IMS Health, it is estimated that by 2020, half of all pharmaceutical sales in the United States
will be from specialty drugs, a category of drugs including oncology treatments tailored to patients’ genomic profiles. A study by Grand Market Research places the oncology
market at 34% of revenue for molecular diagnostics services in 2013, with the pharmacogenomics market following closely at 26.3%. Pharmacogenomics is the study of
genetic analysis based on a patient's response to a particular therapy or drug. We believe a growing demand for personalized medicine as a diagnostic tool is a growth driver of
this market.
India Clinical Oncology and Biopharma Market Overview
India has a growing market for molecular diagnostics and oncology services. According to a 2010 study published in the Asian Pacific Journal of Cancer Prevention, each
year, approximately 1 million new cases of cancer are diagnosed in India. In those cancer types for which we provide diagnostic and prognostic proprietary tests and services,
incidences are also predicted to rise steadily over the next decade even while the population is expected to experience a decrease in population growth rate. Gynecological
cancers account for approximately 30% of the total cancer incidence among women in India. Furthermore, over 80% of cancers in India are first detected in advanced or
terminal stages, indicating an important opportunity in this market for DNA-based oncology diagnostic tools that can provide early-stage information to guide treatment
resulting in greater survival rates.
It is estimated by the India Brand Equity Foundation that the Indian biopharma and biotech markets are expected to experience over a 20% increase in compound annual
growth rate by 2017 due to favorable business conditions and increasing government expenditures in these sectors. The biopharmaceutical services segment accounted for the
largest share of sector growth in 2013 and 2014, accounting for approximately 64% of total revenues, and experienced the highest growth rate in this period, with an
approximately 17% compound annual growth rate. Over the next decade, growth in this industry is anticipated to come largely from India’s strong position in biosimilars and
molecular diagnostics, as well as from personalized medicine. The Indian government has been increasing spending on the biotech and biopharma sectors through 5-year
budget allocation plans aimed at research and development as well as health care.
In the fourth quarter of 2015 we entered into an agreement with a hospital network in India to validate FHACT® in the Indian
4
Table of Contents
rural population, enabling our proprietary test to be used as an accurate screening tool for cervical cancer and HPV-associated cancer risk in the Indian population. In the first
quarter of 2014 we launched FHACT® in collaboration with Kamineni Hospitals in Hyderabad, India for the detection and management of cervical cancer. This was the first
broad-scale adoption of FHACT® in India. The launch culminates a collaboration that was begun in July 2013 to assess the value and clinical utility of FHACT® in India.
China Clinical Oncology and Biopharma Market Overview
Cancer is one of the leading public health problems in both urban and rural China. The disease is among the leading causes of death in the Chinese population, representing
approximately 25% of all deaths in urban areas and 21% in rural areas. Over the past 30 years, the risk factors for cancer in China have been increasing, including an aging
population, decreased environmental conditions and westernization of diet and lifestyle. The Chinese biopharma is currently the third largest pharma market globally, after the
United States and Japan. With more than one fifth of the world’s population, China is an important market for biopharma and biotech products and China’s minister of health
has pledged that the country will spend an additional $11.8 billion to advance biotech innovation from 2015 to 2020 in its 13thfive-year plan. Our Shanghai laboratory performs
clinical trials services for biopharma companies in China, where governmental regulations prevent human samples from being exported from the country.
Our Strategy
Our strategy is to serve a diverse group of market participants - biotechnology and pharmaceutical companies, cancer centers and community hospitals, and research centers
both public and private - that all require biomarker-based assessment of cancer and biomarker-based information to understand and manage the patient, their cancer and
customized therapy choices. We believe that our integrated approach to testing combined with our ability to rapidly translate research insights about the genetics and molecular
mechanisms of cancer into the clinical setting will improve patient treatment decision-making, and will become a key component in the standard of care for personalized
cancer treatment. Our approach is to develop and commercialize proprietary genomic tests and services to enable us to provide a full service solution to improve the diagnosis,
prognosis and treatment of targeted cancers and to better predict differences in drug response, efficacy and toxicity among clinical trial participants, as well as to optimize
treatment regimens based on these differences. To achieve this, we intend to:
•
•
•
Leverage our specialized, disease-focused genomic knowledge, insights and proprietary portfolio to secure additional collaborations or partnerships with leading
biopharmaceutical companies and clinical research organizations. Oncology drugs have the potential to be among the most personalized of therapeutics, and yet
oncology trials have one of the worst approval success rates. In an effort to improve the outcome of these trials, and more rapidly advance targeted therapeutics, the
biotechnology and pharmaceutical community is increasingly looking to companies like us that have both proprietary disease insights and comprehensive testing
services as they move toward biomarker-based therapeutics. We believe our comprehensive, disease-focused testing portfolio, which covers 8 of the 10 most
prevalent solid and hematological cancers positions us to help the biopharmaceutical community with clinical trials and companion diagnostic development in areas of
our core expertise.
Leverage our expanded clinical sales force and our relationship with ICON to expand our customer base. Through our acquisition of Response Genetics in the fourth
quarter of 2015, we increased the size of our sales force and our geographic presence, particularly in the Western and Southeastern United States. We believe that our
joint clinical sales force is among the largest oncology-focused clinical sales groups in the molecular diagnostics field. Leveraging our expanded clinical sales group,
we plan to continue to focus on partnering with community hospitals, where according to the National Cancer Database approximately 85% of cancer patients in the
United States are initially diagnosed, by targeting our sales and marketing efforts on this important customer segment though our branded Expand Dx™ program.
Furthermore in mid-2015, we entered into a strategic alliance with the laboratory services group of ICON plc, a global CRO, which we plan to leverage to expand our
biopharma customer base.
Continue our focus on translational oncology and drive innovation and cost efficiency in diagnostics by continuing to develop next generation sequencing offerings
independently and through our joint venture with Mayo Clinic. Translational oncology refers to our focus on bringing novel research insights that characterize cancer
at the genomic level directly and rapidly into the clinical setting with the overall goal of improving value to patients and providers in the treatment and management of
disease. We believe that continuing to develop our existing platforms and next generation sequencing panels will enable significant growth and efficiencies within our
business. We will continue to develop next generation sequencing panels independently as well as leverage our joint venture with Mayo to advance this diagnostic
technology.
5
Table of Contents
•
Continue to aggressively manage our cost structure. We are focused on aggressively managing our operating costs while continuing to seek additional revenue growth
opportunities. We are implementing measures to streamline costs across our laboratory facilities. We also continue to seek to identify cost efficiencies as we integrate
our operations with those of Gentris and Response Genetics.
• Work with health care providers and payors to demonstrate the value of our testing in providing cost efficient and accountable care. We seek to increase market
access by entering into contracts with key payors, cost management organizations and insurance providers and to secure additional coverage for FHACT, TOO and
Focus::NGS panels.
Our Service Offerings
Our business is based on demand for molecular- and biomarker-based characterization of cancers from three main sectors: cancer centers and hospitals, biotechnology and
biopharmaceutical companies, and the research community. Clinicians and oncologists in cancer centers and hospitals seek molecular-based testing since these methods often
produce higher value and more accurate cancer diagnostic information than traditional analytical methods. Our proprietary and disease-focused tests aim to provide actionable
information that can guide patient management decisions, potentially resulting in decreased costs for care providers and patients while streamlining therapy selection. Our
services are also sought by biotechnology and biopharmaceutical companies engaged in designing and running clinical trials for their value and efficacy in oncology treatments
and therapeutics. We believe trial participants' likelihood of experiencing either favorable or adverse responses to the trial treatment can be determined by biomarker testing,
increasing trial efficiency, participant safety and trial success rates. Our services are also sought by researchers and research groups seeking to identify biomarkers and panels
and develop methods for diagnostic technologies and tests for disease. We aggressively pursue the strategy of trying to demonstrate increased value and efficacy with payors
who are trying to contain costs and academic collaborators seeking to develop new insights and cures.
Our market strategy is organized to align with the three aforementioned industry segments. We utilize relatively the same proprietary tests, non-proprietary test and
technologies across each of these businesses to deliver results-oriented information important to cancer treatment and patient management.
Clinical Services
We provide our proprietary tests and services, along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services, to oncologists and
pathologists at hospitals, cancer centers, and physician offices. Our proprietary tests target cancers that are difficult to prognose and predict treatment outcomes through
currently available mainstream techniques. We utilize an expansive range of non-proprietary test and technologies to provide a comprehensive profile for each patient we
serve. Clinical testing is available through anatomic pathology, flow cytometry, karotype, FISH and molecular diagnostics (including next generation sequencing and gene
expression panels).
Our comprehensive oncology-focused testing services for cancer are utilized in the diagnosis, prognosis and prediction of treatment outcomes (theranosis) of cancer patients
and are growing rapidly as clinicians demand more precise and more comprehensive diagnostic evaluation of their patients. We believe our ability to rapidly translate research
insights about the genetics and molecular mechanisms of cancer into the clinical setting will improve patient treatment and management and that this approach can become a
key component in the standard of care for personalized cancer treatment. We utilize highly skilled scientists, pathologists and hematologists in our laboratories, with 32% of
individuals holding advanced degrees. These individuals assist our customers in integrating and technically assessing the testing results for their patients.
We believe that our proprietary tests provide superior diagnostic and prognostic values than other currently available tests and services. For example, prior to the introduction
of MatBA®, the assessment of the gain or loss on only four chromosomal regions and potentially one gene mutation was available to clinicians when testing for and stratifying
a CLL patient. MatBA® improves on this by identifying information on five additional chromosomal regions, providing more valuable diagnostic data and critical information
about the risk of progression and overall prognosis of the patient. For particular cases, patient results indicating a “favorable outcome” that would have been reported to the
clinician was determined by MatBA® to be inaccurate, leading to a change in the prognosis and consequently decision-making by the clinician regarding the management of
these patients.
Our clinical services strategy is focused on direct sales to oncologists and pathologists at hospitals, cancer centers, and physician offices in the United States, and expanding
our relationships with leading distributors and medical facilities in emerging markets. As part of our market strategy for our clinical services, we offer the branded testing
programs described below.
6
Table of Contents
CompleteTM Program. Our CompleteTM program is our branded program offering a unique suite of common and proprietary tests that assist clinicians in determining the best
treatment options to improve patient outcomes. Each CompleteTM program integrates the latest diagnostic and prognostic biomarkers across multiple testing methodologies.
We offer Complete testing for a number of hematological cancers and solid tumors, including AML, CLL/SLL, DLBCL, MCL, MDS, myeloproliferative neoplasms (MPN),
colorectal, lung and breast cancers.
Expand DX®/Technical-Only Testing. According to the American Hospital Association, there are nearly 5,000 community hospitals in the United States. Community hospitals
represent a large target market for our genomic tests and services because approximately 85% of cancer patients in the United States are initially diagnosed in such hospitals as
reported to the National Cancer Database. Our Expand DX®/Technical-Only Testing program is a partnership initiative offered by us to help community-based hospitals
expand their clinical services. By partnering with us community-based hospitals and pathology labs have cost-effective access to advanced testing technologies and specialized
testing capabilities and deep experience in hematological and solid-tumor oncology diagnostics of our clinical reference laboratories in New Jersey and California. Through
this program, clinicians can send patient specimens to our laboratories, where the technical component of the testing is performed, and then access the test results through an
online portal in order to perform the professional component and provide a diagnosis. We believe our Expand DX®/Technical-Only Testing program will enable community
hospitals and pathology laboratories to optimize and expand their oncology services to better serve their cancer patients and reduce costs associated with cancer care.
Tissue of Origin® Test. Our Tissue of Origin® test, or TOO®, is a gene expression test that is indicated when there is clinical uncertainty about a poorly differentiated or
undifferentiated, or a metastatic tumor where the primary tissue of cancer development is unknown. The Tissue of Origin® test we believe is the only FDA-cleared test of its
kind, and can determine the most likely tissue of origin of a patient tumor sample from the fifteen most common tumor types - including thyroid, breast, pancreas, colon,
ovarian and prostate - which account for ninety percent of all incidences of solid tissue tumors, by measuring the expression levels of 2,000 individual genes. TOO® is
supported by extensive analytical and clinical validation data from robust, multi-center clinical studies. We believe TOO® can reduce the need for repeated testing,
examinations, imaging and biopsy procedures by providing clinicians with the primary tissue type with greater certainty than traditional diagnostic techniques. This in turn
empowers physicians to select the correct type of treatment earlier in the course of the patient’s therapy.
In addition, we have developed the Summation Report which, we believe, provides an integrated view of a patient's test results and diagnosis in a user-friendly, visually
appealing format for clinicians. Our pathologists and laboratory directors prepare these Summation Reports based on the clinical information and diagnosis provided by our
laboratory professionals. All of our testing technologies are integrated into a Summation Report to allow oncologists to efficiently arrive at a definitive diagnosis and drive
complete and effective decisions.
Biopharma Services
Biopharma services include laboratory and testing services performed for biopharmaceutical companies engaged in clinical trials. Our biopharma services focus on providing
pharmaceutical companies with oncology specific and non-oncology genetic testing services for phase I-III trials along with ancillary services including biorepository and
trials logistics, design and customized assay development support. These services include DNA and RNA extraction and purification, genotyping, gene expression and
biomarker analyses, custom assay design and biorepository sample storage solutions. We also seek to apply our expertise in LDTs to assist in developing and commercializing
drug-specific companion diagnostics.
Industry research has shown many promising drugs have produced disappointing results in clinical trials. For example, a study by Princess Margaret Hospital in Toronto
estimated that 85% of the phase III trials testing new therapies for solid tumors studied over a five-year period failed to meet their primary endpoint. Given such a high failure
rate of oncology drugs, combined with constrained budgets for biopharmaceutical companies, there is a significant need for drug developers to utilize molecular diagnostics to
decrease these failure rates. For specific molecular-targeted therapeutics, the identification of appropriate biomarkers indicative of disease type or prognosis may help to
optimize clinical trial patient selection and increase trial success rates by helping clinicians identify patients that are most likely to benefit from a therapy based on their
individual genomic profile.
Our Select One® offering was created specifically to help the biopharmaceutical community with clinical trials and companion diagnostic development in areas of our core
expertise. We believe that oncology drugs have the potential to be among the most personalized of therapeutics, and yet oncology clinical trials continue to have some of the
poorest approval rates. In an effort to improve the outcome of these trials, and more rapidly advanced targeted therapeutics, the biotechnology and pharmaceutical
7
Table of Contents
community is increasingly looking to companies that have both proprietary disease insights and comprehensive testing services as they move toward biomarker-based
therapeutics.
In June 2015, the United States National Institutes of Health reported over 74,000 clinical trials were currently being conducted in the United States, and over 14,000 of these
trials were actively recruiting participants for studies with oncology pharmaceuticals or biologics. Molecular- and biomarker-based testing services have been altering the
clinical trials landscape by providing biopharmaceutical companies with information about trial subjects' genetic profiles that may be able to inform researchers whether or not
a subject will benefit from the trial drug or will experience adverse effects. Streamlined subject selection and stratification, and tailored therapies selected to maximally benefit
each group of subjects may increase the number of trials that result in approved therapies and make conducting clinical trials more efficient and less costly for
biopharmaceutical companies. In 2015, 51 new drugs were approved by the FDA. This is the highest number of FDA approvals since 1950, and nearly a third of these drugs
were oncology-focused, highlighting the potential value of incorporating genomic information into oncology clinical trial design.
In addition to the tests and services provided to biopharmaceutical companies, we are developing NGS panels focused on pharmacogenomics and oncology that will inform
researchers of trial subjects' drug sensitivities.
We provide the following services to biopharmaceutical companies and researchers conducting clinical trials:
Genotyping and Pharmacogenomics Testing Services
• Over 400 genotyping assays including drug metabolizing enzymes, transporters and
receptors.
• Over 19 validated gene expression
assays.
•
•
Testing for the FDA's Pharmacogenomic (PGx) Biomarkers in Drug Labels recommended
panel.
Loss of heterozygosity and copy number detection
assays.
We also utilize our laboratories to provide clinical trial services to biopharmaceutical companies and clinical research organizations to improve the efficiency and economic
viability of clinical trials. Our clinical trials services leverage our knowledge of clinical oncology and molecular diagnostics and our laboratories’ fully integrated capabilities.
Our Select One® program integrates clinical information into the drug discovery process in order to provide customized solutions for patient stratification and treatment. By
utilizing biomarkers, we intend to optimize the clinical trial patient selection. This may result in an improved success rate of the clinical trial and may eventually help
biopharmaceutical companies to select patients that are most likely to benefit from a therapy based on their genetic profile. We believe we are one of only a few laboratories
with the capability to combine somatic and germline mutational analyses in clinical trials.
Our Select One® clinical trial services are aimed at developing customizable tests and techniques utilizing our proprietary tests and laboratory services to provide enhanced
genetic signature analysis and more comprehensive understanding of complex diseases at earlier stages. We leverage our knowledge of clinical oncology and molecular
diagnostics and provide access to our genomic database and assay development capabilities for the development and validation of companion diagnostics. This potentially
enables companies to reduce the costs associated with development by determining earlier in the development process if they should proceed with additional clinical studies.
We have been chosen by Gilead Sciences Inc. to provide clinical trial services and molecular profiling of CLL patients, and we performed the biomarker-based testing for
Gilead’s FDA-approved Zydelig® (idelalisib) for relapsed CLL, FL and SLL. We believe our clinical trial services may allow Gilead and others to improve patient responder
selection, thereby potentially increasing the likelihood our customer's product is approved by FDA. Additionally, through our services we gain further insights into disease
progression and the latest drug development that we can incorporate into our proprietary tests and services.
We also provide genetic testing for drug metabolism to aid biopharmaceutical companies identify subjects' likely responses to treatment, allowing these companies to conduct
more efficient and safer clinical trials. We believe pharmacogenomics drug metabolism testing helps deliver the promise of personalized medicine by enabling researchers to
tailor therapies in development to differences in patients' genomic profiles.
Discovery Services
Our discovery services provide the tools and testing methods for companies and researchers seeking to identify new molecular- and biomarker-based indicators for disease.
Discovery services we offer include validation of biomarkers for diseases including
8
Table of Contents
cancers, from which tests for diagnosis or prognosis may be established. We also provide consulting, guidance and preparation of samples and clinical trial design. We believe
the ability to analyze variations in biomarkers and interpret these changes into meaningful predictors of disease or indicators of diagnosis is essential to discovering new
molecular markers for cancer and targets for therapies.
Our Disease-Focused Testing Portfolio
Our disease-focused testing portfolio includes our portfolio of proprietary tests, along with a comprehensive range of non-proprietary oncology-focused tests and laboratory
services. We have a comprehensive oncology testing portfolio, spanning eight of the ten most prevalent solid and hematological cancers, including the FDA-cleared test for
tumors of unknown origin, our Tissue of Origin®, or TOO® test. With the exception of the TOO® test, we offer our proprietary tests in the United States as laboratory-
developed tests, or LDTs, and internationally as CE-marked in vitro diagnostic medical devices. The non-proprietary testing services we offer are focused in part on the
specific oncology categories where we are developing our proprietary tests. We believe that there is significant synergy in developing and marketing a complete set of tests and
services that are disease-focused and delivering those tests and services in a comprehensive manner to help guide and inform treatment decisions. The insights that we develop
in delivering non-proprietary services are often leveraged in the development of our proprietary programs and in the validation of our proprietary programs.
Our proprietary tests are molecular- and biomarker-based genomic tests: microarrays, probes, gene expression panels and next generation sequencing. Each is directed at
identifying specific genetic aberrations in cancer cells that serve as markers for diagnosis, prognosis and theranosis. We offer microarrays, next generation sequencing, gene
expression and FISH probes because each serves a unique diagnostic or prognostic function. FISH- based tests, or probes, offer great sensitivity while microarrays provide a
more comprehensive analysis of the cancer genome, and NGS panels offer a method of detecting mutations or chromosomal aberrations of lesser frequency while gene
expression can identify which genes are affected when the cancer type is unknown.
Hematological Cancers
As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display significant clinical, pathologic and genetic complexity. Traditionally, diagnosis
relies mostly on pathologic examination, flow cytometry and detection of only a few genetic markers. Importantly, the clinical course of the six main subtypes of these
neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic
lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL). Most risk-stratification for treatment decisions were traditionally based on clinical features of the disease.
Few molecular prognostic biomarkers were utilized in a clinical setting. There remains an unmet medical need for robust biomarkers for the diagnosis, prognosis, theranosis
and overall patient management in B-cell cancers. Given the higher frequency of these malignancies in the United States than in other countries due to relatively long lifespans
and an aging population, we expect significant clinical demand for our tests and services that are focused on hematological cancers.
Mature B-cell Neoplasm Array - MatBA®
MatBA® is the first targeted oligonucleotide-based microarray we developed for the analysis of genomic alterations to determine prognosis and theranosis in mature B-cell
neoplasms. MatBA® incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. We currently offer
the following applications of MatBA®: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell
Lymphoma (MCL) and Follicular Lymphoma (FL).
MatBA® is designed to detect genomic copy number changes in mature B-cell neoplasms either solely or in a unique combination, thus assisting the clinician in the
management of a patient’s disease. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the
cancer specimen (array-CGH). We have optimized the utility of the MatBA® array-CGH so that it can be routinely applied to the study of a range of specimen types including
blood and bone marrow and FFPE biopsy specimens, which are often the only specimen available for analysis of FL, DLBCL and MCL. MatBA® was custom-designed to
represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our
research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA® simultaneously permits the detection of genomic gains and losses at multiple
locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. MatBA® is designed to improve prognostication by determining each patient’s
unique genetic profile, allowing doctors to more accurately select the best treatment options.
Focus::NGSTM
9
Table of Contents
Focus::NGST M is our family of next generation sequencing tests developed for the analysis of genomic alterations to determine, guide and inform diagnosis, prognosis and
theranosis of particular hematological cancers and solid tumors. Next generation sequencing performs massively parallel sequencing, which is able to detect biomarker
mutations and aberrations that are present at very low levels and which may be missed by other, less sensitive methodologies. We currently offer Focus::CLL™ and
Focus::Myeloid™ in the United States for the characterization of hematological cancers.
Our proprietary Focus::CLL™ panel is the only test that assesses 7 genes in a single test, providing clinically relevant data for prognosis, disease management and treatment
selection. The panel is available both for routine clinical patient diagnosis and management, as well as for patient stratification in clinical trials for CLL or SLL. CLL is often a
slow-moving cancer, and many patients can survive for years after a diagnosis; however, chronic leukemias are difficult to treat and some forms of CLL grow faster, requiring
that the patient undergo treatment fairly immediately. The American Cancer Society predicts that in 2016 there will be nearly 19,000 new cases of CLL and approximately
4,600 deaths, mostly among individuals over 40 years of age.
Our proprietary Focus::Myeloid™ panel is designed to target 54 genes, and we believe it will provide important prognostic information for myelodysplastic syndromes (MDS)
and acute myeloid leukemia (AML), as well as diagnostic and prognostic information for myeloproliferative neoplasms (MPN). MDS are a group of bone marrow disorders in
which the bone marrow does not produce enough healthy blood cells. Approximately 30% of patients diagnosed with MDS will progress to AML, which is a cancer of the
myeloid line of blood cells characterized by rapid growth of abnormal white blood cells which interferes with the normal production of other blood cells. MPNs consist of a
group of diseases where there is an overproduction of different types of blood cells. The form of MPN is defined by the type of cell that is overproduced. MPNs also have a
high possibility of progressing to AML depending on the mutations responsible for the MPN. AML is the most common acute leukemia in adults and its incidence increases
with age. AML is expected to account for approximately 20,800 new leukemia cases in 2015, and its prevalence is expected to increase as the population ages.
Solid Tissue Cancers
Tissue of Origin® (TOO®)
Through our acquisition of substantially all the assets of Response Genetics, Inc. in the fourth quarter of 2015, we acquired the FDA-cleared and Medicare-approved Tissue of
Origin® (TOO®) test. TOO® is a gene expression test that is used to identify the origin in cancer cases that are metastatic and/or poorly differentiated and unable to be typed
by traditional testing methods. Metastatic tumors with an uncertain primary site can be a difficult clinical problem. In tens of thousands of oncology patients every year, no
confident diagnosis is ever issued, making standard-of-care treatment impossible. TOO® assesses 2,000 genes, covering 15 of the most common tumor types and 90% of all
solid tumors. These tumors include thyroid, breast, non-small cell lung, pancreas, gastric, colorectal, liver, bladder, kidney, non-Hodgkin’s lymphoma, melanoma, ovarian,
sarcoma, testicular germ cell and prostate. TOO® is FDA-cleared, Medicare-approved, and provides extensive analytical and clinical validation for statistically significant
improvement in accuracy over other methods. Our TOO® test increases diagnostic accuracy and confidence in site-specific treatment decisions. Our TOO® test leads to a
change in patient treatment based on results 65% of the time it is used.
Other
Through our acquisition of substantially all the assets of Response Genetics, Inc. in the fourth quarter of 2015, we also acquired a clinically actionable and validated portfolio
of tests for solid tumors. The tests include a variety of methodologies--from IHC and FISH to gene-expression, microarrays as well as next-generation sequencing (NGS). This
portfolio includes proprietary tests for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma, thyroid cancer, breast cancer and glioma.
HPV-Associated Cancers
FHACT® HPV-Associated Cancer Test
We have developed a proprietary, 4-color FISH-based DNA probe designed to identify aberrations in four important chromosomal regions that have been implicated in cancers
associated with infection by the human papilloma virus (HPV): cervical, anal and oropharyngeal. We have obtained CE marking for FHACT®, which allows us to market the
test in the European Economic Area (which includes the 27 Member States of the EU plus Norway, Liechtenstein and Iceland). We anticipate that we will need to conduct
additional developmental activities for this test and to submit it for regulatory clearance or approval by FDA or other
10
Table of Contents
regulatory agencies prior to commercialization outside of our reference laboratories in each of the markets where we plan to introduce it.
We currently offer an application of FHACT® as an LDT for cervical cancer. According to the National Cancer Institute, about 50 million PAP smear tests to detect HPV are
performed in the United States each year. It is estimated that approximately 2 million patients have abnormal PAP smear test results and are referred for biopsy/colposcopy as
a result of such tests. However, only approximately 12,000 of these patients will develop cervical cancer. It is believed that early detection of HPV-associated cancers and
lesions most likely to progress to cancer could eliminate unnecessary biopsies/colposcopies and thereby reduce health care costs.
FHACT® is designed to determine copy number changes of four particular genomic regions by FISH. These regions of DNA give specific information about the progression
from HPV infection to cervical cancer, in particular the stage and subtype of disease. FHACT® is designed to enable earlier detection of abnormal cells and can identify the
additional genomic biomarkers that allow for the prediction of cancer progression. FHACT ® is designed to leverage the same PAP smear sample taken from the patient during
routine screening, thus reducing the burden on the patient while delivering greater information to the clinician.
Sales and Marketing
Our sales and marketing efforts consist of both direct and indirect efforts, with the majority of efforts focused on direct sales in both the United States and India. The table
below summarizes our sales approach by geography and customer segment:
United States
India
Clinical Sales
Biopharma Sales
Clinical Sales
Biopharma &
Discovery Sales
China
Biopharma Sales
-
-
-
-
-
-
-
-
-
-
Collaborate with leading research universities and institutions that enable the validation of our new tests.
Work with community-based cancer centers that need a reliable and collaborative partner for cancer testing.
Build relationships with individual thought leaders in oncology, hematology and pathology to deliver services
that provide value to their patients.
Collaborate with scientific development teams at pharmaceutical companies on studies involving translational
medicine and genotyping.
Build relationships in the research and development segment to identify partners with a need for biomarker
discovery studies.
Develop relationships with oncologists, corporate hospitals and reference labs, as well as with physicians in
local clinics.
Engage the population of oncology patients in India, where a majority of oncology drugs are paid for out-of-
pocket.
Work with academic and research institutions for validation of our tests in the Indian population.
Collaborate with scientific development teams at biopharma companies and government agencies on studies
involving tests and services.
Leverage US-based companies conducting clinical trials with a component of those trials occurring in China.
Our sales force professionals have backgrounds in hematology, pathology, and laboratory services, and many years of experience in clinical oncology sales, esoteric laboratory
sales from leading biopharmaceutical, pharmaceutical or specialty reference laboratory companies. We currently have a team of 12 sales professionals in the United States and
6 in India. We support our sales force with clinical specialists who bring deep domain knowledge in the design and use of our tests and services.
In addition to our direct sales force, we entered into an agreement with the Laboratory Services group of ICON plc, the global CRO (Nasdaq:ICLR) to work together to offer
biotech and pharmaceutical customers a comprehensive, integrated and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV.
Through our joint service offering, we and ICON can provide biotech and pharmaceutical customers access to combined expertise ranging from complex, oncology-focused
molecular and biomarker-based testing to core central laboratory analysis, project and data management and sample logistics on a global basis.
We also promote our tests and services through marketing channels commonly used by the biopharma and pharmaceutical industries, such as internet, medical meetings and
broad-based publication of our scientific and economic data. In addition, we provide easy-to-access information to our customers over the internet through dedicated websites.
Our customers value easily accessible information in order to quickly review patient or study information.
11
Table of Contents
Our Laboratory Facilities
Rutherford, New Jersey, United States
Our Rutherford location is a 17,900 square foot facility and also serves as our corporate headquarters. We offer our clinical services, biopharma services and discovery services
out of our Rutherford location. This location has been accredited by the College of American Pathologists, or CAP, which is an approved accreditation entity under CLIA, to
perform high complexity testing. CLIA certification and accreditation are required before any laboratory may perform clinical testing on human samples for the purpose of
diagnosis, prevention, treatment of disease or assessment of health.
Our Rutherford location is licensed by the appropriate state departments of health and able to receive and test patient samples from all 50 states, as well as from oversees
locations. Additionally, our Rutherford laboratory is self-certified under the US-EU and US-Swiss Safe Harbor Frameworks governing use of personal information received on
patients or clinical trial participants from the European Union. Our Rutherford laboratory also holds the requisite licenses from the New Jersey State Department of Health to
operate and perform clinical testing on patient samples. In addition, certain states, such as New York, require out-of-state laboratories to obtain licenses in order to accept
patient specimens from such states. Our Rutherford location holds clinical laboratory licenses from the New York Department of Health, Florida Department of Health,
Maryland Department of Health, Pennsylvania Department of Health, and California Department of Health for all of our clinical departments.
Los Angeles, California, United States
Our Los Angeles location is an approximately 27,000 square foot facility. We offer clinical services and biopharma services out of our Los Angeles location. We provide
proprietary tests and panels for lung, colon, gastric, and melanoma cancers, as well as our FDA-cleared Tissue of Origin® Test, or TOO®, from our Los Angeles location. This
location is CLIA-certified, GLP-compliant and CAP accredited. Our Los Angeles laboratory also holds the requisite licenses from the California State Department of Health to
operate and perform clinical testing on patient samples. Our Los Angeles location holds clinical laboratory licenses from the New York Department of Health, Florida
Department of Health, Maryland Department of Health, Pennsylvania Department of Health, and Rhode Island Department of Health for all of our clinical departments.
Morrisville, North Carolina, United States
We offer our biopharma services, including biopharmaceutical trials testing services, pharmacogenomics testing, and sample storage and biorepository services from our
25,000 square foot facility located in Research Triangle Park, Morrisville, North Carolina. Our facility in Morrisville is CLIA-certified and subject to Good Laboratory
Practices ("GLP") requirements, and has received accreditation by CAP for its industry-leading biorepository capabilities. We do not believe that our Morrisville laboratory
requires individual state licensure since it is not performing clinical testing on patient samples and is only involved in clinical trials testing. Our Morrisville laboratory is also
self-certified under US-European and US-Swiss Safe Harbor frameworks.
Hyderabad, India and Shanghai, China
We also have two laboratories operating outside of the United States: one in Hyderabad, India and one in Shanghai, China. Our 10,000 square foot Hyderabad facility services
government entities, academic institutions, and health and cancer centers. It is a Department of Scientific and Industrial Research ("DSIR") recognized laboratory and is
ISO9001-2008 and National Accreditation Board for Testing and Calibration Laboratories ("NABL") certified. Our 2,700 square foot Shanghai facility is both CLIA-certified
and subject to GLPs, and provides biopharma services to companies performing clinical trials in China.
Research and Development Expenses
We incurred research and development expenses of $5.5 million, which represented 30% of our net revenue, for the year ended December 31, 2015; $4.6 million, which
represented 45% of our net revenue for the year ended December 31, 2014; and $2.2 million, which represented 33% of our net revenue, for the year ended December 31,
2013. Research and development expenses represented 22% of our total operating expenses for the year ended December 31, 2015, 22% of our total operating expenses for the
year ended December 31, 2014, and 22% of our total operating expenses for the year ended December 31, 2013. Major components of the research and development expenses
included direct personnel costs, laboratory equipment and consumables and overhead expenses.
Research and Development Collaborations
12
Table of Contents
We formally and informally collaborate with leading oncology centers and community-based hospitals to develop our proprietary diagnostic tests, and we work closely with
leading cancer researchers at these institutions to develop proprietary tests tailored to their needs and specifications. Additionally, many of these centers have obtained
Specialized Programs of Research Excellence status, as designated by the National Cancer Institute. Our collaborations with these centers give us access to large datasets of
information that we use to develop our proprietary tests.
Below is a summary of our active key collaborations. In certain cases we have formal written agreements with collaborators and in other cases we have no written agreement
with our collaborators or only informal written arrangements.
Collaborating Institution
North Shore-Long Island Jewish Health System,
New York
Memorial Sloan-Kettering Cancer Center, New
York
National Cancer Institute, Maryland
Kamineni Hospital, Hyderabad, India
University of Iowa Cancer Center, Iowa
Columbia University, New York
Principle Investigator(s)
Dr. Kanti Rai
Dr. Nicholas Chiorazzi
Dr. Julie Teruya-Feldstein
Dr. Raju S.K. Chaganti
Dr. Jonathan Coleman
Dr. Jeremy Durack
Dr. Nicolas Wentzensen
Dr. Annie Hassan
Dr. Sergei Syrbu
Dr. Azra Raza
Dr. Siddhartha Mukherjee
Beth Israel Deaconess Medical Center, New York Dr. Rajan Dewar
Dr. Imran Siddiqi
Keck Medicine of University of Southern
California, California
University of Southern California, California, &
HTG Molecular, Arizona
University of Southern California, California, &
HTG Molecular, Arizona
Dr. Pamela Ward
Dr. Heinz-Josef Lenz and Dr. Yu
Sunakawa
Focus of Collaboration
Clinical validation of MatBA®-CLL and search for additional DNA-based
biomarkers of CLL
Clinical validation of MatBA®
Validation of a CGH microarray-based assay
Evaluation of FISH-based CGH-array tests
Evaluation of FISH-based and CHG-array tests
Evaluation of FISH-based tests
Evaluation of FHACT®
Evaluation methods to improve the diagnosis, prognosis and management of
DLBCL
Identification of genomic biomarkers
Analysis of genomic biomarkers
Identification and evaluation of genomic biomarkers
MicroRNA whole transcription assay validation
Gene expression analysis for immuno-oncology panel
Groupe Hospitalier Pitié Salpétriere, Paris
Analyze the variability of genomic alterations
Huntsman Cancer Center Institute, University of
Utah, Utah
Moffitt Cancer Center, Florida
University of Alabama, Alabama
University of Virginia School of Medicine,
Virginia, & HTG Molecular, Arizona
Scientific and Clinical Advisory Boards
Examine and validate genomic biomarkers
Examine a number of genetic variants
Investigate biomarkers
Evaluation of genomic signatures of immuno-oncology biomarkers
We have two advisory boards to counsel our scientific and clinical direction. Our Scientific Advisory Board is comprised of preeminent scientists and physicians from the
fields of cancer biology, cancer pathology, cancer medicine and molecular genetics. We have scientists and clinicians from leading cancer centers, including Memorial Sloan-
Kettering Cancer Center, Mt. Sinai and the Institute for Cancer Genetics at Columbia University. These distinguished scientists and clinicians help oversee and review the
scientific innovation, integrity and clinical relevancy of our program. The board of directors appoints members to the Scientific Advisory Board. Our Clinical Advisory Board
is comprised of preeminent clinicians and scientists focused on clinical implementation of our proprietary tests and services and mapping those tests and services to patient
needs.
Competition
13
Table of Contents
With respect to our clinical services, our principal competition comes from existing mainstream diagnostic methods and laboratories that pathologists and oncologists use and
have used for many years or decades. It may be difficult to change the methods or behavior of the referring pathologists and oncologists to incorporate our molecular
diagnostic testing in their practices. In addition, companies offering capital equipment and kits or reagents to local pathology laboratories represent another source of potential
competition. These kits are used directly by the pathologist, which can facilitate adoption.
With respect to our clinical services and our biopharma services, we also face competition from companies that offer products or have conducted research to profile genes, gene
expression or protein biomarkers in various cancers. In particular, Quest Diagnostics market arrays which are competitive to our MatBA®-CLL and MatBA®-SLL arrays, and
both Foundation Medicine and LabCorp offer NGS based tests and panels for oncology. Personalized genetic diagnostics is a new area of science, and we cannot predict what
tests others will develop that may compete with or provide results superior to the results we are able to achieve with the tests we develop. Our competitors include public
companies such as: NeoGenomics, Inc., Quest Diagnostics, Abbott Laboratories, Inc., Johnson & Johnson, Roche Molecular Systems, Inc., bioTheranostics, Inc. (part of the
bioMérieux S.A.), Genomic Health, Inc., LabCorp, Inc., Clarient, Inc. (acquired by GE), Myriad Genetics, Inc., Qiagen N.V., Genoptics Inc. (acquired by Novartis
Pharmaceuticals), Caris Life Sciences (acquired by Miraca), Rosetta Genomics Ltd., and Foundation Medicine, Inc., and many private companies. We expect that
pharmaceutical and biopharmaceutical companies will increasingly focus attention and resources on the personalized diagnostic sector as the potential and prevalence
increases of molecularly targeted oncology therapies approved by FDA along with companion diagnostics. For example, FDA has recently approved two such agents- Xalkori
crizotinib from Pfizer Inc. along with its companion anaplastic lymphoma kinase FISH test from Abbott Laboratories, Inc. and Zelboraf vemurafenib from Genentech USA
Incorporated and Daiichi-Sankyo Inc. along with its companion B-RAF kinase V600 mutation test from Roche Molecular Systems, Inc. These two recent FDA approvals are
only the second and third instances ever of simultaneous approvals of a drug and companion diagnostic, the first being the 1998 approval of Genentech, Inc.’s Herceptin
trastuzumab for HER2 positive breast cancer along with the HercepTest from partner Dako A/S. Our competitors may invent and commercialize technology platforms or tests
that compete with ours.
Additionally, projects related to the molecular mechanisms driving cancer development have received increased government funding, both in the United States and
internationally. As more information regarding cancer genomics and biomarkers becomes available to the public, we anticipate that more products aimed at identifying
targeted treatment options will be developed and that these products may compete with ours. In addition, competitors may develop their own versions of our tests in countries
where we did not apply for patents or where our patents have not issued and compete with us in those countries, including encouraging the use of their test by physicians or
patients in other countries.
Third-Party Suppliers and Manufacturers
We maintain control, validation and quality assurance over our NGS panels, DNA microarrays and probes. Our microarrays are designed in our facility by our scientists and
technicians using state of the art genomic mapping and analysis software. The specifications are sent to Agilent for final manufacturing. Agilent manufactures our microarrays
under strict quality control and compliance with ISO 9001 and ISO 13485 at its Santa Clara, California facility. Agilent also has another manufacturing facility in Europe that
can be made available for microarray printing. Upon manufacturing our custom, proprietary microarrays, Agilent ships them back to our Rutherford facility for testing and
acceptance.
The DNA component of our DNA FISH probes is produced under strict adherence to regulatory procedures in our Rutherford facility and also at a third party facility
depending on demand and workflow. The DNA is shipped for final manufacture to our partner in India. In February 2012 we entered in to an agreement with Kamineni Life
Sciences to supply outsourced manufacturing for the production of our DNA FISH probes. The manufacturing operations became fully operational in India in the fourth
quarter of 2012 and several batches of DNA FISH probes have been successfully manufactured. We control overall quality and process management and the final quality
assurance in a manner that is CE compliant and adheres to our Quality Management System.
We also currently rely on contracted manufacturers and collaborative partners to produce materials necessary for our Tissue of Origin® test. We plan to continue to rely on
these manufacturers and collaborative partners to manufacture these materials, including those materials required for use in our FDA-cleared TOO® test.
Patents and Proprietary Technology
Our business develops proprietary tests that enable oncologists and pathologists at hospitals, cancer centers, and physician offices to properly diagnose and inform cancer
treatment. We rely on a combination of patents, patent applications, trademarks, trademark applications, trade secrets, industry know-how, as well as various contractual
arrangements, in order to protect the proprietary aspects of our technology.
14
Table of Contents
Our patent portfolio consists of 49 issued U.S. patents, several pending U.S. applications, and 175 foreign patents. We have a disease-focused portfolio of patents. Our key
patents include:
•
•
Hematological cancers. We have two U.S. patents (U.S. Patent Nos. 8,580,713 and 8,557,747), as well as patents in the EU, India and Canada directed to MatBA®, a
microarray for detecting (and distinguishing) particular types of mature B cell neoplasms present in typical non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and
chronic lymphocytic leukemia. These patents and foreign application cover our trademarked MatBA® microarray and are directed to both the microarray itself as
well as associated methodologies designed to detect the particular type of mature B cell neoplasm present in a patient. These patents and foreign application also
cover the use of computer-assisted means to facilitate and expedite that detection process. The MatBA® microarray patents issued from the first of our family of
applications in the microarray space. The term of these patents runs through 2030.
Solid Tumors. We have 13 U.S. patents, including (U.S. Patent Nos. 7,049,059, 7,560,543, 7,732,144, 8,586,311, 8,026,062, 6,956,111, 6,905,821, 7,005,278,
6,686,155, 7,138,507, as well as numerous foreign patents, including patents in Australia, Canada, China and Japan. These patents relate to certain aspects of the gene
expression technology used in our solid tumor tests. The solid tumor markers covered by these patents include thymidylate synthase (TS), dihydropyrimidine
dehydrogenase (DPD), excision repair gene CC1 (ERCC1), glutathione-s transferase pi (GST-p), epidermal growth factor receptor (EGFR) and HER2/neu gene,
though our patents are not directed to all aspects of expression of such markers. The term of these patents runs through 2023.
• We have four U.S. patents (U.S. Patent Nos. 8,977,506, 8,321,137, 7,747,547 and 8,473,217) covering our Tissue of Origin® Test. These patents are directed at
systems and methods for detecting biological features in solid tumors. The term of these patents run through 2030.
•
•
•
Urogenital cancers. We have two U.S. patents (U.S. Patent Nos. 8,603,948 and 8,716,193) and one EU patent. These patents directed to a novel, highly sensitive and
specific probe panel which detects the type of renal cortical neoplasm present in a biopsy sample. These patents cover a probe that permits diagnosis of the
predominant subtypes of renal cortical neoplasms without the use of invasive methods and provides a molecular cytogenetic method for detecting and analyzing the
type of renal cortical neoplasm present in a renal biopsy sample. The term of these patents runs through 2027. We also have two patent applications for methods and
tools for the diagnosis of female gynecological cancers and precancers (US Patent Application No. 61/581,350) and methods and tools for the diagnosis and prognosis
of urogenital cancers (US Patent Application No. 61/765,678).
HPV-Associated Cancers. We have three U.S. patents (U.S. Patent Nos. 9,157,129, 8,865,882 and 8,883,414) and an EU patent. These patents cover methods for
detecting HPV-associated cancers used in our FHACT® test. The term of these patents run through 2031.
FISH Probes. We have two patents covering our FISH probes. These patents cover probes and methodologies designed to detect and analyze particular chromosomal
translocations (genetic lesions) associated with a wide range of cancers using a technique known as FISH and serve as the backbone for several of our other pending
patent applications, which are more specifically geared towards other probes (and methodologies). The term of these patents run through 2022.
In addition to patents, we hold twenty U.S. registered trademarks, including a federal registration for “CGI” as well as four U.S. trademark applications and one foreign
trademark registration for certain of our proprietary tests and services. Our strategic use of distinctive trademarks has garnered increased name recognition and brand
awareness for our tests and services within the industry.
Through our clinical laboratories, we provide several clinical services that utilize our proprietary trade secrets. In particular, we maintain trade secrets with respect to specimen
accessioning, sample preparation, and certain aspects of cytogenetic analysis. All of our trade secrets are kept under strict confidence, and we take all reasonable steps,
including the use of non-disclosure agreements and confidentiality agreements, to ensure that our confidential information is not unlawfully disseminated. We also conduct
training sessions on the importance of maintaining and protecting trade secrets with our scientific staff and laboratory directors and supervisors.
In addition to our proprietary intellectual property, we exclusively license from University of Southern California, or USC, the use of extraction methodologies and related
technologies used in our solid tumor tests, which have been patented in the United States and a number of other jurisdictions, including Australia, Austria, Belgium, Canada,
China, Denmark, France, Germany,
15
Table of Contents
Hong Kong, Ireland, Israel, Italy, Luxembourg, Mexico, The Netherlands, Norway, Russia, South Korea, Spain, Sweden, Switzerland and the United Kingdom. Currently, this
exclusive license includes seven United States patents claiming methods related to this technology. Our USC licensed patents are scheduled to expire between December 2019
and December 2020.
We also entered into nonexclusive licenses with the National Cancer Institute for the use of its intellectual property relating to a 3q marker and with Stanford University for use
and development of a diagnostic assay and predictive model that has been granted two patents for the stratification and risk prediction for DLBCL patients. Under the terms of
the license, we are permitted to use the National Cancer Institute’s proprietary intellectual property for use in our patent pending FHACT® DNA probe, which is directed to
the diagnosis and prognosis of certain HPV-associated cancers.
Operations and Production Facilities
We work with electronic medical records providers to facilitate seamless communication between our clinical laboratories and the oncologist or pathologist at the test ordering
site. Currently, we have the ability to integrate with electronic medical record systems, as we have already done with MDL, an electronic medical record provider. We do this
integration through utilizing HL7 interfaces, which are standard in health care information technology systems. We currently employ HL7 for its integration with a revenue
cycle management company, XiFin, as well as with its electronic medical records partners such as MDL. The use of the HL7 interface allows systems written in different
languages and running on different platforms to be able to talk to each other through the use of an abstracted data layer. This means that we do not have to spend significant
extra time designing and developing common communications protocols when integrating with other electronic health records systems or billing systems providers.
When a customer obtains a specimen from a patient for oncology testing, he or she will complete a requisition form (either by hand or electronically, or via electronic medical
records technology), and package the specimen for shipment to us. Once we receive the specimen at our laboratory and we enter all pertinent information about the specimen
into our clinical laboratory information system, one of our laboratory professionals prepares the specimen for diagnosis. The prepared specimen is sent to one of our
pathologists or medical directors who is experienced in making the diagnosis requested by the referring oncologist or pathologist.
After diagnosis, our pathologist uses our laboratory information systems to prepare a comprehensive report, which includes any relevant images associated with the specimen.
Our clinical reporting portal, cgireports.com, allows a referring oncologist or pathologist to access his/her test results in real time in a secure HIPAA compliant manner. The
reports are generated in industry standard PDF formats which allows for high definition color images to be reproduced clearly. This portal has been fully operational at our
facilities since 2011.
In most cases we provide both the technical analysis and professional diagnosis, although we also fulfill requests from oncologists and pathologists for only one service or the
other. If an oncologist or pathologist at the hospital, cancer center, reference laboratory or physician office requires only the analysis, we prepare the data and then return it to
the referring oncologist or pathologist for assessment and diagnosis.
Quality Assurance
We are committed to providing reliable and accurate diagnostic services to our customers. Accurate specimen identification, timely communication of diagnoses, and prompt
correction of errors, is critical. We monitor and improve our performance through a variety of methods, including performance improvement indicators, proficiency testing
(CAP and New York State), external audits and satisfaction surveys. All quality concerns and incidents are subject to root cause analysis and our procedures are put through
annual evaluation to ensure that we are providing the best services possible to our patients and customers. Protection of patient results from misuse and improper access is
imperative and thus electronic and paper results are guarded via password- protection and identification cards.
We have established a comprehensive Quality Assurance and Management Program for our laboratories designed to drive accurate and timely test results and to ensure the
consistent high quality of our testing services. The Quality Assurance and Management Program documents the quality assurance/performance improvement plans and policies
and the laboratory quality assurance and quality control procedures that are necessary to ensure that we offer the highest quality of diagnostic testing services. This program is
designed to satisfy all the requirements necessary for local and state licensures applicable to our business, including requirements from the New Jersey Health Department, the
California Department of Health and the New York Department of Health Clinical Laboratory Evaluation Program, and accreditation for clinical diagnostic laboratories by
CAP. We follow the policies and procedures for patient and employee safety, hazardous waste disposal and fire codes stated in the general laboratory procedure manual. We
believe that all pertinent regulations of CLIA, Occupational Safety and Health Administration (“OSHA”), Environmental Protection Agency and FDA are satisfied by
following the established guidelines
16
Table of Contents
and procedures of our Quality Assurance and Management Program.
In addition to the compulsory proficiency programs and external inspections required by CMS and other regulatory agencies, we have developed a variety of internal systems
and procedures to emphasize, monitor and continuously improve the quality of our operations. We maintain internal quality controls by routinely processing specimens with
known diagnoses in parallel with patient specimens. We also have an extensive, internally administered program of specimen proficiency testing, in which our laboratory staff
are blinded to the results.
We participate in numerous externally administered quality surveillance programs and our laboratories are accredited by CAP. The CAP accreditation program involves both
unannounced on-site inspections of our laboratories and our participation in CAP’s ongoing proficiency testing program. CAP is an independent, non- governmental
organization of board-certified pathologists that accredits laboratories nationwide on a voluntary basis and that has been recognized by CMS as an accreditation organization to
inspect laboratories to determine adherence to the CLIA standards. Successful participation in CAP’s proficiency testing program satisfies the CLIA requirement for
participation in proficiency testing programs administered by an external source.
Each of our facilities maintains its own quality assurance processes, which are coordinated across sites to maintain consistency in standard operating procedures, employee
training and safety manuals.
Third-Party Payor Reimbursement
Depending on the billing arrangement and applicable law, we are reimbursed for clinical services by: third-party payors that provide coverage to the patient, such as an
insurance company, managed care organization or a governmental payor program; physicians or other authorized parties (such as hospitals or independent laboratories) that
order testing service or otherwise refer the services to us; or the patient. For the year ended December 31, 2015, we derived approximately 12% of our total revenue from
private insurance, including managed care organizations and other health care insurance providers, 10% from Medicare, and 9% from other health care facilities, including
hospitals.
Where there is a coverage policy, contract or agreement in place, we bill the third-party payor, the hospital or referring laboratory as well as the patient (for deductibles and
coinsurance or copayments, where applicable) in accordance with the policy or contractual terms. Where there is no coverage policy, contract or agreement in place, we pursue
reimbursement on behalf of each patient on a case-by-case basis and rely on applicable billing standards to guide our claims. In addition, we have implemented a new patient
financial assistance program (CGI MAP Program) that complies with Federal guidelines.
We are reimbursed for three categories of tests: (1) genetic and molecular testing; (2) anatomic pathology and IHC and (3) general immunology and flow cytometry.
Reimbursement under the Medicare program for the diagnostic services that we offer is based on either the Medicare Physician Fee Schedule or Medicare Clinical Laboratory
Fee Schedule (CLFS), each of which in turn is subject to geographic adjustments and is updated annually. Medical services provided to Medicare beneficiaries that require a
degree of physician supervision or other involvement, such as pathology tests, are generally reimbursed under the Medicare Physician Fee Schedule, whereas clinical
diagnostic laboratory tests are generally reimbursed under the Clinical Laboratory Fee Schedule. Most of the services that we provide are for genetic and molecular testing,
which are reimbursed as clinical diagnostic laboratory tests.
Medicare fee schedule amounts for clinical diagnostic laboratory tests are established for each billing code, or CPT code. In addition, for its laboratory fee schedule, Medicare
also sets a cap on the amount that it will pay for any individual test. This cap, usually referred to as the National Limitation Amount, is set at a percentage of the median of all
the contractor fee schedule amounts for each billing code. In the past, Congress has lowered the percentage of the median used to calculate the National Limitation Amount in
order to achieve budget savings. Currently, the National Limitation Amount ceiling is set at 74% of the median for established tests and 100% of the median for certain new
tests that were not previously reimbursed. In billing Medicare for clinical laboratory services, we are required to accept, as payment in full, the lowest of our actual charge, the
fee schedule amount for the state or local geographical area or the National Limitation Amount. There is currently no copayment or deductible required for tests paid under the
CLFS, although Congress periodically has considered implementing such a requirement.
In addition, Congress routinely lowers or eliminates the update factor that would otherwise apply to the applicable clinical laboratory fee schedule (CLFS) payment. For
example, under the health care reform legislation, passed in 2010, payments under the CLFS are reduced by 1.75% through 2015 and, in addition, a productivity adjustment,
further reducing payment rates is also imposed. In addition, in February 2012, Congress passed the Middle Class Tax Relief and Job Creation Act of 2012, which required that
the CLFS be “rebased” by -2%. As a result of these changes, for 2015 the CLFS was reduced by -.25%.
17
Table of Contents
Further, in 2014, Congress passed the Protecting Access to Medicare Act or PAMA which also makes significant changes in the way the Medicare will pay for laboratory
services. Under PAMA, laboratories were required to report the amount that they are paid by third party payors for each test beginning in January 2016. CMS will use this
data to calculate a weighted median for each test. That new price is supposed to become effective on January 1, 2017, although any resulting reductions will be phased in over
time. This data reporting process will be repeated every three years for most tests, although Advanced Diagnostic Laboratory Tests (ADLTs) will have to be reported every
year. It is possible that some of our tests could be considered ADLTs, which will require us to report prices annually. In addition, we may also be required to obtain a code
from CMS or an entity that it designates for our tests that have not previously had a code. Although CMS was also required to issue a Final Rule implementing PAMA by June
30, 2015, it failed to do so. It did issue a Proposed Rule, however, on October 1, 2015. As a result of this delay, many of the statutory deadlines will likely not be met. It is not
known at this time how the implementation of PAMA will affect our reimbursement.
Certain of our tests are paid under the Physician Fee Schedule, rather than the CLFS. Tests paid for under the PFS are based on “relative value units” established for each
service. These RVUs are then multiplied by a conversion factor to arrive at a monetary amount. Each year, CMS calculates an update to this conversion factor based on a
formula included in the Medicare law, referred to as the Sustainable Growth Rate (SGR) Formula. When it is applied, this SGR formula often would require a decrease in
reimbursement unless Congress acts to overturn this result. As a result, Congress consistently passes legislation to prevent implementation of significant cuts that would
otherwise be effective. For 2014, CMS had projected the reimbursement cut resulting from the SGR formula would be approximately 20 percent, unless Congress acted to
prevent the reduction. On December 18, 2013, Congress passed legislation that enacted a 0.5 percent increase in the conversion factor, which was effective until March 31,
2014. On April 1, 2014, President Obama signed the Protecting Access to Medicare Act of 2014, or PAMA. PAMA extended the 0.5 percent increase through March 31, 2015
and made other changes to laboratory reimbursement discussed below.
On April 16, 2015, President Obama signed the Medicare and CHIP Reauthorization Act (MACRA), which had previously been passed by both houses of Congress. MACRA
repealed the provisions related to the Medicare SGR formula and implements a new physician payment system that is designed to reward the quality of care. In addition, it
extends the current Medicare Physician Fee Schedule rates through June 2015, and then increases them by 0.5 percent for the remainder of 2015. Beginning on January 1,
2016, the rates will be increased annually by 0.5 percent, through 2019. For 2020 through 2025 payments will be frozen, although payment will be adjusted to account for
performance on certain quality metrics under the Merit-Based Incentive Payment Systems (MIPS) or to reflect physician participation in alternative payment models (APMs).
For 2026 and subsequent years, qualified APM participants receive an annual 0.75% update on Medicare physician payment rates, while those not participating receive a
0.25% annual payment update, plus any applicable MIPS-based payment adjustments. At this time, it is too early to determine how these changes may impact our business
beyond 2015.
Medicare also has policies that may limit when we can bill directly for our services and when we must instead bill another provider, such as a hospital. When the testing that
we perform is done on a specimen that was collected while the patient was in the hospital, as either an inpatient or outpatient, we may be required to bill the hospital for some
of our services, rather than the Medicare program, depending on whether or not the service was ordered more than 14 days after the patient’s discharge from the hospital.
These requirements are complex and time- consuming and, depending on what they require, may affect our ability to collect for our services.
Our reimbursement rates from private third-party payors can vary based on whether we are considered to be an “in-network” provider, a participating provider, a covered
provider or an “out-of-network” provider. These definitions can vary from insurance company to insurance company, but we are generally considered an “out of network” or
non- participating provider in the vast majority of our cases. It is not unusual for a company that offers highly specialized or unique testing to be an “out of network” provider.
An “in-network” provider usually has a contracted arrangement with the insurance company or benefits provider. This contract governs, among other things, service-level
agreements and reimbursement rates. In certain instances an insurance company may negotiate an “in-network” rate for our testing rather than pay the typical “out-of-
network” rate. An “in-network” provider usually has rates that are lower per test than those that are “out-of-network”, and that rate is based on the laboratory fee schedule.
The discount rate varies based on the insurance company, the testing type and the often times the specifics of the patient’s insurance plan.
We have contracts with commercial insurance carriers that provide access to certain out our tests to approximately 35 million lives. When a test is covered as part of these
contracts it is paid at the rate stated in the contract. The Company also has agreements with preferred provider agreements that cover approximately 130 million lives. When a
claim is processed through one of these organizations reimbursement is based on usual and customary fees in the specific geography with a discount applied.
18
Table of Contents
In addition, as part of the Middle Class Tax Relief and Job Creation Act of 2012 (“MCTRJCA”), signed into law by the President on February 22, 2012, Congress eliminated
the special billing rule that had allowed laboratories to bill Medicare for the technical component of certain pathology services furnished to patients of qualifying hospitals.
Effective July 1, 2012, independent laboratories, like our laboratories, are required to bill the hospital, rather than the Medicare Program, for the technical component of these
services in most instances.
Billing Codes for Third-Party Payor Reimbursement
CPT codes are the main data code set used by physicians, hospitals, laboratories and other health care professionals to report separately-payable clinical laboratory tests for
reimbursement purposes. The CPT coding system is maintained and updated on an annual basis by the American Medical Association. Although there is no specific code to
report microarrays for oncology, such as our MatBA®-CLL, there are existing codes that describe all of the steps in our MatBA®-CLL testing process. We currently use a
combination of different codes to describe the various steps in our testing process. Many of the CPT codes used to bill for molecular pathology tests such as ours have been
significantly revised by the CPT Code Editorial Panel. These new codes replace the more general “stacking” codes that were previously used to bill for these services with
more test-specific codes, which became effective January 2013. In the Final Physician Fee Schedule Rule, which was issued in November 2012, CMS stated that it had
determined it would pay for the new codes as clinical laboratory tests, which are payable on the Clinical Laboratory Fee Schedule (CLFS). CMS also stated that it planned to
“gapfill” the new codes; that is, it will ask the contractors to determine a reasonable price for the new codes. This process was completed in 2013, and these tests are now paid
for under the new "gapfilled" rates.
Among the new codes that were created by CPT were a specific subset of codes called Multi-analyte Assays with Algorithmic Analysis (MAAAs). These tests typically use an
algorithm applied to certain specific components to arrive at a score that is used to predict a particular clinical outcome. CMS recently stated that it will not issue a categorical
determination for all MAAA tests, but will consider each individual test that is classified by the CPT as a MAAA on its own merits. On September 25, 2015, CMS released its
Preliminary Determinations for new CPT codes effective in 2016, including several new MAAA CPT codes. CMS had proposed "crosswalking" these codes to an unrelated
test, resulting in a significant cut in their reimbursement. However, on November 17, 2015, CMS reversed its policy and directed that the tests be gapfilled by the local
contractors. It is expected that when PAMA is fully implemented, many of these MAAA codes will be considered and reimbursed as ADLTs. For 2015, less than 5% of our
revenue is derived from tests that may be considered MAAAs.
As of January 1, 2014 we are utilizing the “Not Otherwise Classified” (NOC) codes when billing for some of our MAAA tests. The reimbursement policies for the NOC codes
vary from payor to payor with regard to specific tests and many of the payors have followed suit. This extends our revenue cycle for these particular tests, where the normal
timeframe for reimbursement of a claim is approximately 45-90 days. These tests can take upwards of a year to be reimbursed. There can be no guarantees that Medicare and
other payors will establish positive or adequate coverage policies or reimbursement rates in the future. We are moving forward with plans to obtain billing codes for our tests.
A specific code for our tests, however, does not assure an adequate coverage policy or reimbursement rate. Please see the section entitled “Legislative and Regulatory Changes
Impacting Clinical Laboratory Tests” for further discussion of certain legislative and regulatory changes to these billing codes and the impact on our business.
On October 30, 2015, CMS issued its Final Physician Fee Schedule Rule for 2016, which set out policies that were effective January 2016. Among those policy changes are
reductions in the payments for flow cytometry and immunohistochemistry, two types of tests that we frequently perform. CMS has also stated that certain of these same tests
may be considered "misvalued" which means they could be subject to additional scrutiny in the future. At this time, we are still assessing the potential impact of these
changes.
Coverage and Reimbursement for Our Proprietary Tests
We have been able to receive reimbursement for our tests from some payors based on their established policies, including major commercial third-party payors.
The current landscape with payors is generally as follows:
Commercial Third-party Payors and Patient Pay. Where there is a coverage policy in place, we bill the payor and the patient in accordance with the established policy. Where
there is no coverage policy in place, we pursue reimbursement on behalf of each patient on a case-by-case basis. Our efforts in obtaining reimbursement based on individual
claims, including pursuing appeals or reconsiderations of claims denials, take a substantial amount of time, and bills may not be paid for many months, if at all. Furthermore, if
a third-party payor denies coverage after final appeal, payment may not be received at all. We are working to decrease risks of nonpayment by implementing a revenue cycle
management system. Third party payors are still establishing payment policies for panel-based tests.
19
Table of Contents
Medicare and Medicaid. We believe that as much as 30% to 40% of our future market for our tests may be derived from patients covered by Medicare and Medicaid.
We cannot predict whether, or under what circumstances, payors will reimburse our proprietary tests. Payment amounts can also vary across individual policies. Denial of
coverage by payors, or reimbursement at inadequate levels, would have a material adverse impact on market acceptance of our tests.
Legislative and Regulatory Changes Impacting Clinical Laboratory Tests
From time to time, Congress has revised the Medicare statute and the formulas it establishes for both the Medicare Clinical Laboratory Fee Schedule and the Physician Fee
Schedule. The payment amounts under the Medicare fee schedules are important not only for our reimbursement under Medicare, but also because the schedule often is used
as a basis for establishing the payment amounts set by other third party payors. For example, state Medicaid programs are prohibited from paying more than the Medicare fee
schedule limit for clinical laboratory services furnished to Medicaid recipients.
Under the statutory formula for clinical laboratory fee schedule amounts, increases are made annually based on the Consumer Price Index for All Urban Consumers as of June
30 for the previous twelve-month period. From 2004 through 2008, Congress eliminated the Consumer Price Index for All Urban Consumers update in the Medicare
Prescription Drug, Improvement and Modernization Act of 2003. In addition, for years 2009 through 2013, the Medicare Improvements for Patients and Providers Act of 2008
(“MIPPA”) mandated a 0.5% cut to the Consumer Price Index for All Urban Consumers. Accordingly, the update for 2009 was reduced to 4.5% and negative 1.9% for 2010.
In March 2010, the President signed into law the Affordable Care Act (ACA), which, among other things, imposed additional cuts to the Medicare reimbursement for clinical
laboratories. The ACA replaced the 0.5% cut enacted by MIPPA with a “productivity adjustment” that reduced the Consumer Price Index update in payments for clinical
laboratory tests. In 2011, the productivity adjustment was -1.2%. In addition, the ACA includes a separate 1.75% reduction in the CPI update for clinical laboratories for the
years 2011 through 2015. On February 22, 2012, President Obama signed the MCTRJCA, which mandated an additional change in reimbursement for clinical laboratory
services payments. This legislation requires CMS to reduce the Medicare clinical laboratory fee schedule by 2% in 2013, which in turn will serve as a base for 2014 and
subsequent years. Based on the changes required by ACA and MCTRJCA, payment for clinical laboratory services will be reduced by approximately 0.25% for 2015.
With respect to our diagnostic services for which we are reimbursed under the Medicare Physician Fee Schedule, because of the statutory formula, the “Sustainable Growth
Rate” (SGR), the rates would have decreased for the past several years if Congress failed to intervene. In the past, when the application of the statutory formula resulted in
lower payment, Congress has passed interim legislation to prevent the reductions. On November 1, 2012, the Centers for Medicare & Medicaid Services (CMS) issued its 2013
Physician Fee Schedule Final Rule (the “Final Rule”). In the Final Rule, CMS called for a reduction of approximately 26.5% in the 2013 conversion factor that is used to
calculate physician reimbursement. However, the American Taxpayer Relief Act of 2012, which was signed into law on January 2, 2013, prevented this proposed reduction and
kept the existing reimbursement rate in effect until December 31, 2013.
For 2014, CMS projected the cut would be about 24%, unless Congress acted. However, on December 18, 2013, Congress passed legislation that enacted a 0.5% update in the
conversion factor, which will be effective until March 31, 2014. On April 1, 2014, President Obama signed the Protecting Access to Medicare Act of 2014, or PAMA. PAMA
extended the 0.5 percent increase through March 31, 2015 and made other changes to laboratory reimbursement discussed below. As discussed above, on April 16, 2015,
President Obama signed MACRA, which will replace the SGR process with an alternative payment system.
In addition to the reductions described above, our Medicare payments under both the CLFS and the PFS are also subject to an additional 2% reduction, as a result of
“sequestration.” This automatic cut results because the Joint Select Committee on Deficit Reduction, which was created by congress in 2011, was unable to agree on a set of
deficit reduction recommendations for Congress to vote on. The reduction is scheduled to continue until 2024.
For the years ended December 31, 2015 and December 31, 2014, approximately 10% and 11%, respectively, of our total revenues are derived from Medicare generally and any
changes to the physician fee schedule that result in a decrease in payment could adversely impact our revenues and results of operations.
In addition, periodically CMS also changes its payment policies related to laboratory reimbursement in ways that could have an impact on the revenues of the Company. For
example, in 2013 Final Rule, CMS included a reduction of certain relative value units and geographic adjustment factors used to determine reimbursement for a number of
commonly used pathology codes, including CPTs 88300, 88302, 88304, and 88305. In particular, the 2013 Final Rule implemented a cut of approximately 33% in the global
20
Table of Contents
billing code for 88305 and a 52% cut in the Technical Component of that code. These codes describe services that we must perform in connection with our tests and we bill for
these codes in connection with the services that we provide. In the 2013 Final Rule, CMS also announced how it intended to set prices for the new molecular diagnostic tests,
for which the American Medical Association had adopted over 100 new codes. In that Rule, CMS announced it intended to continue to pay for the new molecular codes on the
CLFS rather than move them to the Physician Fee Schedule, as some stakeholders had urged. It would then request that the Medicare Administrative Contractors “gapfill” the
new codes and set an appropriate price for them. That “gapfilling” process took place over 2013 and CMS announced the new prices for these codes in September, 2013. The
median of the prices set by the contractors became the new prices for these codes, effective January 1, 2014. We do not yet know what impact, if any, these changes will have
on the Company’s operations.
In the Proposed Physician Fee Schedule Rule for 2014, issued on July 8, 2013, CMS made two proposals that could affect laboratory reimbursement. First, CMS made a
proposal to change how it calculates the RVUs used to calculate payments under the PFS. Under this proposal, where a service was paid at a lower rate in the hospital based on
the hospital Outpatient Prospective Payment System (OPPS) than it is under the PFS, CMS proposed to reduce the RVUs for that service in order to equalize the payment
between the two systems. This change, if implemented, would have resulted in approximately a 25% cut in aggregate payments to independent laboratories. In the Final
Physician Rule for 2014, however, CMS chose not to implement this proposal, although it stated that it would develop a revised proposal in the future. At this point, it is
impossible to know what the impact of such a proposal might be on the Company.
In addition, in the 2014 Proposed Rule, CMS also noted that payments for many codes paid under the Clinical Laboratory Fee Schedule have not been revised to reflect
technological advances that have occurred since the CLFS was first developed in 1984. CMS therefore proposed that it would begin to review all codes on the CLFS and
adjust them to reflect technological changes, a process that it expected would take about five years. However, in April of 2014, Congress passed the Protecting Access to
Medicare Act (PAMA), which eliminated CMS’s authority to implement its plan to adjust payments based on technological advances. CMS has since stated it will not
implement this proposal.
In PAMA, Congress also changed the way the Medicare will pay for clinical laboratory services. Under PAMA, laboratories will be required to report the amount that they are
paid by third party payors for each test beginning in January 2016. CMS will use this data to calculate a weighted median for each test. That new price will become effective
on January 1, 2017, although any resulting reductions will be phased in over time. This data reporting process will be repeated every three years for most tests, although
Advanced Diagnostic Laboratory Tests (“ADLTs”) will have to report every year. It is possible that some of our tests could be considered ADLTs, which will require us to
report prices annually. In addition, we may also be required to obtain a code from CMS or an entity that it designates for our tests that have not previously had a code. It is not
known at this time how these changes will affect our reimbursement. As noted above, because of CMS’s delay in issuing a Final Rule implementing these requirements, it is
unlikely that all of the statutory deadlines will be met.
In addition, CMS made several other changes in the 2014 Final Rule that could impact our business. First, CMS implemented a policy that will bundle payment for the
examination of 10 or more prostate biopsies for an individual patient, rather than paying separately for each individual procedure as had been done previously. This will result
in a significant reduction in reimbursement on each of these procedures. In addition, CMS also has developed new codes applicable to billing for Immunohistochemistry
procedures, which are a common staining procedure used in pathology. Those codes will reduce the reimbursement that we will receive when we provide these services.
Finally, CMS has also implemented a set of edits under its National Correct Coding Initiative, which will only pay for a single unit of service when we perform a FISH
(Fluorescent In Situ Hybridization) test. As many FISH tests require two or more probes, this change will also reduce the reimbursement received by the Company.
Further, with respect to the Medicare Program, Congress has proposed on several occasions to impose a 20% coinsurance on patients for clinical laboratory tests reimbursed
under the clinical laboratory fee schedule, which would require us to bill patients for these amounts. Because of the relatively low reimbursement for many clinical laboratory
tests, in the event that Congress were to ever enact such legislation, the cost of billing and collecting for these services would often exceed the amount actually received from
the patient and effectively increase our costs of billing and collecting.
Finally, some of our Medicare claims may be subject to policies issued by Palmetto GBA, the current Medicare Administrative Contractor for North Carolina, South Carolina,
Virginia and West Virginia. The Medicare contractor has recently issued a Local Coverage Decision that affects coverage, coding and billing of many molecular diagnostic
tests. Under this Local Coverage Determination, Palmetto will not cover any molecular diagnostic tests, including our tests, unless the test is expressly included in a National
Coverage Determination issued by CMS or a Local Coverage Determination or coverage article issued by Palmetto. Currently, laboratory providers may submit coverage
determination requests to Palmetto for consideration and apply for a unique billing code for each test (which is a separate process from the coverage determination). In the
event that a non-coverage determination is issued, the laboratory must wait six months following the determination to submit a new request. In addition,
21
Table of Contents
effective May 1, 2012, Palmetto implemented its new Molecular Diagnostic Services Program, under which, among other things, laboratories must use newly-assigned billing
codes specific to the test. These new billing codes enable Palmetto to measure utilization and apply coverage determinations. Denial of coverage by Palmetto, or
reimbursement at inadequate levels, would have a material adverse impact on market acceptance of our tests. Other Medicare contractors are also following the policies
adopted by Palmetto.
Governmental Regulations
Clinical Laboratory Improvement Amendments of 1988 and State Regulation
As a diagnostic service provider, we are required to hold certain federal, state and local licenses, certifications and permits to conduct our business. As to federal certifications,
in 1988, Congress passed the Clinical Laboratory Improvement Amendments (“CLIA”) establishing quality standards for all laboratories testing to ensure the accuracy,
reliability and timeliness of patient test results regardless of where the test was performed. Our U.S.-based laboratories are CLIA accredited. Under CLIA, a laboratory is
defined as any facility which performs laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or
treatment of disease, or the impairment of, or assessment of health. CLIA also requires that we hold a certificate applicable to the type of work we perform and comply with
certain standards. CLIA further regulates virtually all clinical laboratories by requiring they be accredited by the federal government and comply with various operational,
personnel, facilities administration, quality and proficiency requirements intended to ensure that their clinical laboratory testing services are accurate, reliable and timely. CLIA
compliance and accreditation is also a prerequisite to be eligible to bill for services provided to governmental payor program beneficiaries. CLIA is user-fee funded. Therefore,
all costs of administering the program must be covered by the regulated facilities, including certification and survey costs.
We are subject to survey and inspection every two years to assess compliance with program standards, and may be subject to additional unannounced inspections. Laboratories
performing high complexity testing are required to meet more stringent requirements than laboratories performing less complex tests. In addition, a laboratory like ours that is
certified as “high complexity” under CLIA may obtain analyte specific reagents, which are used as the basis for diagnostic tests that are developed and validated for use in
examinations the laboratory performs itself known as laboratory-developed tests (“LDTs”).
In addition to CLIA requirements, we participate in the oversight program of the College of American Pathologists (“CAP”). Under CMS requirements, accreditation by CAP
is sufficient to satisfy the requirements of CLIA. Therefore, because we are accredited by CAP, we are deemed to also comply with CLIA. CLIA also provides that a state may
adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory
schemes. State laws may require that laboratory personnel meet certain qualifications, specify certain quality controls, or prescribe record maintenance requirements.
As to state laws, our clinical operations at our Rutherford and Los Angeles laboratories are required to meet certain state laboratory licensing and other requirements, which in
some areas are more stringent than CLIA. Our laboratories are required hold the required licenses and accreditations obtained from the applicable state agencies in which we
operate. State clinical laboratory laws generally require that laboratories and/or laboratory personnel meet certain qualifications. State clinical laboratory laws also generally
require laboratories to specify certain quality assurance metrics and to maintain certain records. Several states, including Rhode Island, Florida, Maryland, New York and
Pennsylvania, require that clinical laboratories hold licenses to test specimens from patients residing in those states, even though the laboratory is not located in such state.
From time to time, other states may require out of state laboratories to obtain licensure in order to accept specimens from the state. If we identify any other state with such
requirements or if we are contacted by any other state advising us of such requirements, we intend to follow instructions from the state regulators as to how we should comply
with such requirements. In addition, the New York Department of Health separately approves certain LDTs offered in New York State. The Company has obtained the
requisite approvals for its LDTs.
Our Rutherford laboratory is licensed and in good standing under the State Departments of Health standards for New Jersey, New York, Pennsylvania, California, Florida and
Maryland . Our Los Angeles laboratory is licensed and in good standing in California, New York, Pennsylvania, Rhode Island, Florida and Maryland. If we are found to be out
of compliance with applicable state statutory or regulatory standards we may be subject to suspension, restriction or revocation of our laboratory license or assessed civil
money penalties. A noncompliant laboratory may also be found guilty of a misdemeanor under applicable state laws. A finding of noncompliance, therefore, may result in
harm to our business.
FDA
The U.S. Food and Drug Administration (“FDA”) regulates the sale or distribution, in interstate commerce, of medical devices under the Federal Food, Drug, and Cosmetic
Act (“FDCA”), including in vitro diagnostic test kits, reagents and instruments used
22
Table of Contents
to perform diagnostic testing. Such devices must undergo pre-market review by FDA prior to commercialization unless the device is of a type exempted from such review by
statute or pursuant to FDA’s exercise of enforcement discretion. FDA, to date, has not exercised its authority to actively regulate the development and use of LDTs such as ours
as medical devices and therefore we do not believe that our LDTs currently require pre-market clearance or approval.
Section 1143 of the Food and Drug Administration Safety and Innovation Act, signed by the President on July 9, 2012, requires FDA to notify Congress at least 60 days prior
to issuing a draft or final guidance regulating LDTS and provide details of the anticipated action. On July 31, 2014, FDA notified Congress pursuant to the FDASIA that it
intended to issue draft Guidances that would regulate LDTs. On October 3, 2014, the FDA issued two separate draft guidances: “Framework for Regulatory Oversight of
Laboratory Developed Tests (LDTs)” (“The Framework Draft Guidance”) and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests” (the
“Notification Draft Guidance.”). In the Framework Draft Guidance, FDA states that after the Guidances are finalized, it will no longer exercise enforcement discretion with
respect to most LDTs and will, instead, regulate them in a risk-based manner consistent with the existing classification of medical devices. Thus, the FDA plans to begin to
enforce its medical device requirements, including premarket submission requirements, on LDTs that have historically been marketed without FDA premarket review and
oversight. Comments on the Draft Guidances were due on February 2 and those comments are now being considered by the FDA. It is not known when the FDA may issue
final Guidances or what form those Guidances may take.
The Framework Draft Guidance states that within six months after the Guidances are finalized, all laboratories will be required to give notice to the FDA and provide basic
information concerning the nature of the LDTs offered. The FDA will then begin a phased review of the LDTs available, based on the risk associated with the test. For the
highest risk LDTs, which the FDA classifies as Class III devices, the Framework Draft Guidance states that the FDA will begin to require premarket review within 12 months
after the Guidance is finalized. Other high risk LDTs will be reviewed over the next four years and then lower risk tests, which will be classified as Class II, will be reviewed in
the following four to nine years. The Framework Draft Guidance states that FDA expects to issue a separate Guidance describing the criteria for its risk-based classification 18-
24 months after the Guidances are finalized.
If the FDA regulates LDTs as proposed, then it would classify LDTs according to the current system used to regulate medical devices. Under that system, there are three
different classes of medical devices, with the requirements becoming more stringent depending on the Class. Class I devices are those for which reasonable assurance of the
safety and effectiveness can be provided by adherence to FDA’s general regulatory controls for medical devices, which include compliance with the applicable portions of
FDA’s Quality System Regulations, facility registration and product listing, reporting of adverse medical events and appropriate, truthful and non-misleading labeling,
advertising and promotional materials, or general controls. Many Class I devices are exempt from pre-market regulation, however, some Class I devices require pre-market
clearance by FDA through the 510(k) pre-market notification process described below.
Class II devices are subject to FDA’s general controls, and any other special controls as deemed necessary by FDA to provide reasonable assurance of the safety and
effectiveness of the devices. Pre-market review and clearance by FDA for Class II devices are generally accomplished through the 510(k) pre-market notification procedure.
Pre- market notification submissions are subject to user fees, unless a specific exemption applies. To obtain 510(k) clearance for a medical device (or for certain modifications
to devices that have received 510(k) clearance), a manufacturer must submit a pre-market notification demonstrating that the proposed device is substantially equivalent to a
previously cleared 510(k) device or to a pre-amendment device that was in commercial distribution before May 28, 1976 (a “predicate device”) for which FDA has not yet
called for the submission of a pre-market approval (“PMA”) application. In making a determination that the device is substantially equivalent to a predicate device, FDA
compares the proposed device to the predicate device or predicate devices and assesses whether the subject device is comparable to the predicate device or predicate devices
with respect to intended use, technology, design and other features which could affect the safety and effectiveness. If FDA determines that the subject device is substantially
equivalent to the predicate device or predicate devices, the subject device may be cleared for marketing. FDA’s 510(k) clearance pathway generally takes from three to twelve
months from the date the application is completed, but can take significantly longer. Moreover, in January 2011, FDA announced twenty-five specific action items it intended
to take to improve transparency and predictability of the 510(k) program. We anticipate that the changes may also result in additional requirements with which manufacturers
will need to comply in order to obtain or maintain 510(k) clearance for their devices. These additional requirements could increase the costs or time for manufacturers’ seeking
marketing clearances through the 510(k) process. Moreover, the 510(k) process could result in a not-substantially equivalent determination, in which case the device would be
regulated as a Class III device, discussed below, or could be eligible for de novo classification available for novel low and moderate risk devices. In the de novo process, FDA
can classify a device into Class I or Class II based on a risk- based determination without the submission of a 510(k) or within 30 days after receipt of a not-substantially
equivalent determination. In 2013, several assays and diagnostic tests received pre-market approval through the de novo process.
23
Table of Contents
Class III devices are those devices which are deemed by FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, have a new intended use,
or use advanced technology that is not substantially equivalent to that of a legally marketed device. Reasonable assurance of the safety and effectiveness of Class III devices
cannot be assured solely by the general controls and the other requirements described above. These devices are required to undergo the pre-market approval (“PMA”) process
in which the manufacturer must demonstrate reasonable assurance of the safety and effectiveness of the device to FDA’s satisfaction. A PMA application must provide
extensive preclinical and clinical trial data and also information about the device and its components regarding, among other things, device design, manufacturing and labeling.
Premarket approval applications (and supplemental pre-market approval applications) are subject to significantly higher user fees than are 510(k) pre-market notifications.
After approval of a PMA, a new PMA or PMA supplement is required in the event of a modification to the device, its labeling or its manufacturing process. The PMA process,
including the gathering of clinical and nonclinical data and the submission to and review by FDA, can take several years.
A clinical trial may be required in support of a 510(k) submission and generally is required for a PMA application. These trials generally require an effective Investigational
Device Exemption from FDA for a specified number of patients, unless the product is exempt from Investigational Device Exemption requirements or deemed a non-
significant risk device eligible for more abbreviated Investigational Device Exemption requirements. The Investigational Device Exemption application must be supported by
appropriate data, such as animal and laboratory testing results. Clinical trials may begin 30 days after the submission of the Investigational Device Exemption application
unless FDA or the appropriate institutional review boards at the clinical trial sites place the trial on clinical hold.
Under the Guidances, LDTs would also be subject to significant post-market requirements as well. After a device is placed on the market, regardless of the classification or
pre-market pathway, it remains subject to significant regulatory requirements. Even if regulatory approval or clearance of a medical device is granted, FDA may impose
limitations or restrictions on the uses and indications for which the device may be labeled and promoted. Medical devices may be marketed only for the uses and indications
for which they are cleared or approved.
Device manufacturers must also establish registration and device listings with FDA. A medical device manufacturer’s manufacturing processes and those of its suppliers are
required to comply with the applicable portions of the Quality Systems Regulations, which cover the methods and documentation of the design, testing, production, processes,
controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled
inspections by FDA. FDA also may inspect foreign facilities that export products to the United States.
Failure to comply with applicable regulatory requirements can result in enforcement action by FDA, which may include any of the following sanctions: warning letters, fines,
injunctions, civil or criminal penalties, recall or seizure of current or future products, operating restrictions, partial suspension or total shutdown of production, denial of 510(k)
clearance or PMA applications for new products, or challenges to existing 510(k) clearances or PMA applications.
We are monitoring developments and anticipate that our products (CGH-Microarrays and FISH Probes) will be able to comply with requirements that are ultimately imposed
by the FDA. In the meantime, we maintain our CLIA accreditation, which permits the use of LDTs for diagnostics purposes.
We believe that our LDTs and, should we reach that point, our in vitro diagnostic test kits, would likely be regulated as either Class II or Class III devices should FDA decide
to proceed in the way that it has outlined in the Guidances. It is also possible under those circumstances that some may fall into one Class and some into the other.
Accordingly, some level of premarket review-either a 510(k), PMA or de novo approval-would likely be required for each test. While the data requirements are typically
greater for Class III devices, the data required for Class II devices has increased, and it is likely that some amount of clinical data (retrospective or prospective or both) would
be required for either type of submission. FDA continues to review the adequacy of its 510(k) process. It is difficult to predict what changes may result, but it should be
assumed that any changes will increase, not decrease, the regulatory requirements.
In addition to the Draft Guidances discussed above, the FDA has taken other actions that could have an impact on our business. In 2013, FDA issued Final Guidance for
industry regarding appropriate labeling and distribution practices for in vitro diagnostic products intended for research or investigational use only. FDA’s guidance cautions
that labeling or distribution practices that conflict with research or investigational use (e.g., use in clinical diagnostic applications) could subject products shipped with research
or investigational use labeling to all applicable requirements of the FDCA as well as enforcement action. As a result of FDA’s recent guidance, component suppliers for our
LDTs may no longer be willing to distribute components to our clinical laboratory. If this were to occur, we could not produce our LDTs.
24
Table of Contents
On August 6, 2014, the FDA also issued its Final Guidance on In Vitro Companion Diagnostic Devices. According to the Guidance, companion diagnostic devices are in vitro
diagnostic devices that provide information that is essential for the safe and effective use of a corresponding therapeutic product. The Guidance notes that in most
circumstances, FDA expects to approve or clear a companion diagnostic device and its corresponding therapeutic product contemporaneously, based on the label of the
therapeutic product. If it were determined that our tests qualified as Diagnostic Devices then we might be required to file for either a 510(k) or a PMA, depending on the nature
of the particular test.
Post-market Regulation
Our Tissue of Origin® test obtained clearance under section 510(k) of the FDC Act. After a device, such as our Tissue of Origin® test, is cleared or approved for marketing,
numerous and pervasive regulatory requirements continue to apply.
The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a company has failed to comply with applicable regulatory requirements, it
can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:
•
•
•
•
•
•
•
warning letters, untitled letters, fines, injunctions, consent decrees and civil
penalties;
recalls, withdrawals, or administrative detention or seizure of
products;
operating restrictions or partial suspension or
production;
total shutdown of
refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified
products;
withdrawing 510(k) clearances or PMA approvals that have already been
granted;
refusal to grant export approvals for products;
or
criminal
prosecution.
In addition, FDA could publicly issue a safety notice related to our test or request updates to our product labeling, including the addition of warnings, precautions, or
contraindications.
Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”)
Under the administrative simplification provisions of HIPAA, as amended by HITECH, the United States Department of Health and Human Services has issued regulations
which establish uniform standards governing the conduct of certain electronic health care transactions and protecting the privacy and security of Protected Health Information
used or disclosed by health care providers and other covered entities. For further discussion of HIPAA and the impact on our business, see the section entitled “Risk Factors-
Risks Related to Our Business-We are required to comply with laws governing the transmission, security and privacy of health information that require significant compliance
costs, and any failure to comply with these laws could result in material criminal and civil penalties.”
Federal, State and Foreign Fraud and Abuse Laws
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for
purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under a governmental payor program. The definition
of “remuneration” has been broadly interpreted to include anything of value, including gifts, discounts, credit arrangements, payments of cash, waivers of co-payments,
ownership interests and providing anything at less than its fair market value. Recognizing that the Anti-Kickback Statute is broad and may technically prohibit many
innocuous or beneficial arrangements within the health care industry, the Department of Health and Human Services has issued a series of regulatory “safe harbors.” These
safe harbor regulations set forth certain provisions, which, if met, will assure health care providers and other parties that they will not be prosecuted under the federal Anti-
Kickback Statute. Although full compliance with these provisions ensures against prosecution under the federal Anti-Kickback Statute, the failure of a transaction or
arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the federal Anti-Kickback
Statute will be pursued. For further discussion of the impact of federal and state health care fraud and abuse laws and regulations on our business, see the section entitled “Risk
Factors-
25
Table of Contents
Risks Related to Our Business-We are subject to federal and state health care fraud and abuse laws and regulations and could face substantial penalties if we are unable to
fully comply with such laws.”
In addition to the administrative simplification regulations discussed above, HIPAA also created two new federal crimes: health care fraud and false statements relating to
health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors. A
violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs such as the Medicare and Medicaid programs. The
false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement
in connection with the delivery of or payment for health care benefits, items or services. A violation of this statute is a felony and may result in fines, imprisonment or
exclusion from governmental payor programs.
Finally, another development affecting the health care industry is the increased enforcement of the federal False Claims Act and, in particular, actions brought pursuant to the
False Claims Act’s “whistleblower” or “qui tam” provisions. The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or
causes to be presented, a false or fraudulent claim for payment by a federal governmental payor program. The qui tam provisions of the False Claims Act allow a private
individual to bring actions on behalf of the federal government alleging that the defendant has defrauded the federal government by submitting a false claim to the federal
government and permit such individuals to share in any amounts paid by the entity to the government in fines or settlement. In addition, various states have enacted false claim
laws analogous to the federal False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely a governmental
payor program. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the
government, plus civil penalties ranging from $5,500 to $11,000 for each false claim.
Additionally, in Europe various countries have adopted anti-bribery laws providing for severe consequences, in the form of criminal penalties and/or significant fines, for
individuals and/or companies committing a bribery offence. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our
business, results of operations and reputation. For instance, in the United Kingdom, under the new Bribery Act 2010, which went into effect in July 2011, a bribery occurs
when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities,
including any function of a public nature. Bribery of foreign public officials also falls within the scope of the Bribery Act 2010. Under the new regime, an individual found in
violation of the Bribery Act of 2010, faces imprisonment of up to 10 years. In addition, the individual can be subject to an unlimited fine, as can commercial organizations for
failure to prevent bribery.
Physician Referral Prohibitions
Under a federal law directed at “self-referral,” commonly known as the “Stark Law,” there are prohibitions, with certain exceptions, on Medicare and Medicaid payments for
laboratory tests referred by physicians who personally, or through a family member, have an investment or ownership interest in, or a compensation arrangement with, the
clinical laboratory performing the tests. A person who engages in a scheme to circumvent the Stark Law’s referral prohibition may be fined up to $100,000 for each such
arrangement or scheme. In addition, any person who presents or causes to be presented a claim to the Medicare or Medicaid programs in violation of the Stark Law is subject to
civil monetary penalties of up to $15,000 per bill submission, an assessment of up to three times the amount claimed and possible exclusion from participation in federal
governmental payor programs. Bills submitted in violation of the Stark Law may not be paid by Medicare or Medicaid, and any person collecting any amounts with respect to
any such prohibited bill is obligated to refund such amounts. Many states have comparable laws that are not limited to Medicare and Medicaid referrals.
We are also subject to California’s Physician Ownership and Referral Act, or PORA as well as other state laws with self-referral restrictions.
Both the Stark Law and PORA contain an exception for referrals made by physicians who hold investment interests in a publicly traded company that has stockholders’ equity
exceeding $75 million at the end of its most recent fiscal year or on average during the previous three fiscal years, and which satisfies certain other requirements. In addition,
both the Stark Law and PORA contain an exception for compensation paid to a physician for personal services rendered by the physician. Following our acquisition of
Response Genetics in the fourth quarter of 2015, we have compensation arrangements with a number of physicians for personal services, such as speaking engagements and
specimen tissue preparation. These arrangements were structured with terms intended to comply with the requirements of the personal services exception to Stark Law and
PORA.
26
Table of Contents
However, we cannot be certain that regulators would find these arrangements to be in compliance with Stark Law, PORA or similar state laws. If we are deemed to not be in
compliance by the applicable regulators, we would be required to refund any payments we receive pursuant to a referral prohibited by these laws to the patient, the payor or the
Medicare program, as applicable.
Corporate Practice of Medicine
Numerous states have enacted laws prohibiting business corporations, such as us, from practicing medicine and employing or engaging physicians to practice medicine,
generally referred to as the prohibition against the corporate practice of medicine. These laws are designed to prevent interference in the medical decision-making process by
anyone who is not a licensed physician. Violation of these laws may result in civil or criminal fines, as well as sanctions imposed against us and/or the professional through
licensure proceedings.
Other Regulatory Requirements
Our laboratory is subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste,
including chemical, biological agents and compounds, blood and bone marrow samples and other human tissue. Typically, we use outside vendors who are contractually
obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste.
OSHA has established extensive requirements relating to workplace safety for health care employers, including requirements to develop and implement programs to protect
workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.
Segment and Geographical Information
We operate in one reportable business segment and derive revenue from multiple countries, with 95%, 97%, and 97% coming from the United States in fiscal year 2015, 2014
and 2013, respectively.
Employees
As of December 31, 2015, we had a total of 223 full-time and 14 part-time employees, with 33 employees in sales and marketing, 156 employees in research and development
and laboratory operations and 48 employees in general and administrative. None of our employees are represented by a labor union, and we consider our employee relations to
be good.
Corporate and Available Information
We were incorporated in the State of Delaware on April 8, 1999. On July 16, 2014 we purchased substantially all of the assets of Gentris Corporation ("Gentris"), a laboratory
specializing in pharmacogenomics profiling for therapeutic development, companion diagnostics and clinical trials. On August 18, 2014 we entered into two agreements by
which we acquired BioServe Biotechnologies (India) Pvt. Ltd. (“BioServe”), a premier genomics services provider serving both the research and clinical markets in India, and
as a result of the acquisition, BioServe became a subsidiary of ours. On October 9, 2015, Cancer Genetics acquired substantially all the assets and assumed certain liabilities of
Response Genetics, Inc. ("Response Genetics") in connection with Response Genetics' filing of a chapter 11 petition for bankruptcy in the Delaware Bankruptcy Court for
approximately $12.9 million, comprised of $7.5 million, in cash, and 788,584 shares of the Company's common stock, with the common stock being valued at $5.4 million.
Our principal executive offices are located at 201 Route 17 North, 2nd Floor, Rutherford, New Jersey 07070. Our telephone number is (201) 528-9200 and our corporate
website address is www.cancergenetics.com. We include our website address in this annual report on Form 10-K only as an inactive textual reference and do not intend it to be
an active link to our website. The information on our website is not incorporated by reference in this annual report on Form 10-K.
This annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports, as well as other documents we file with
the U.S. Securities and Exchange Commission (“SEC”), are available free of charge through the Investors section of our website as soon as reasonably practicable after such
material is electronically filed with or furnished to the SEC. The public can obtain documents that we file with the SEC at www.sec.gov.
This report includes the following trademarks, service marks and trade names owned by us: MatBA®, UroGenRA®, FHACT®, FReCaD™, Expand Dx™, Summation™,
Select One®, DLBCL Complete™, Cervixcyte™, Leuka™, CGI®, CLL Complete®,
27
Table of Contents
Focus::NGS™, Focus::Myeloid™, Focus::CLL™, Tissue of Origin®, TOO®, Powered by CGI™ and Empowering Personal Cancer Treatment®. These trademarks, service
marks and trade names are the property of Cancer Genetics, Inc. and its affiliates.
Item 1A.
Risk Factors.
Risks Relating to Our Financial Condition and Capital Requirements
We are an early stage company with a history of net losses; we expect to incur net losses in the future, and we may never achieve sustained profitability.
We have historically incurred substantial net losses. We incurred losses of $20.2 million, $16.6 million and $12.4 million for fiscal years ended December 31, 2015, 2014 and
2013, respectively. From our inception in April 1999 through December 31, 2015, we had an accumulated deficit of $98.2 million. Response Genetics incurred losses of
$8.9 million, $13.7 million, and $8.0 million for the first six months of fiscal 2015, and for the fiscal years ended December 31, 2014 and 2013, respectively. From its
inception in September 1999 through October 9, 2015, Response Genetics had an accumulated deficit of $93.7 million. We expect losses for the combined company to
continue principally as a result of ongoing research and development expenses and increased sales and marketing costs. These losses have had, and will continue to have, an
adverse effect on our working capital, total assets and stockholders' equity. Because of the numerous risks and uncertainties associated with our research, development and
commercialization efforts, we are unable to predict when we will become profitable, and we may never become profitable. Even if we do achieve profitability, we may not be
able to sustain or increase profitability on a quarterly or annual basis. Our inability to achieve and then maintain profitability would negatively affect our business, financial
condition, results of operations and cash flows.
We may need to raise additional capital to fund our existing operations, to develop, validate and commercialize new tests and technologies, to expand our operations and
repay indebtedness.
We may need to raise additional financing to fund our operations, to develop, validate and commercialize new tests and technologies, to expand our operations and repay
indebtedness. At December 31, 2015, we had cash and cash equivalents of $19.5 million. Net cash used in operating activities was $13.6 million and $12.3 million for the years
ended December 31, 2015 and 2014, respectively. We also need capital to fund our capital contributions of up to $4 million to our joint venture with Mayo, which payments
are subject to achievement of operational milestones, and to satisfy indebtedness to our New Credit Facility with Silicon Valley Bank. Our New Credit Facility with Silicon
Valley Bank consists of the Term Note and Line of Credit. As of December 31, 2015, the aggregate principal amount due under our New Credit Facility was approximately
$6.0 million. The Term Note requires interest only payments through April 30, 2016 and beginning May 1, 2016, monthly principal payments of approximately $167,000 will
be required plus interest through maturity on April 1, 2019. Pursuant to the amendment dated January 28, 2016, we are restricted from using the Line of Credit until $13
million of additional equity is raised.
We believe that our current cash will support operations for the next 15 to 24 months. We can provide no assurances that any additional sources of financing will be available
to us on favorable terms, if at all, when needed. Our forecast of the period of time through which our current financial resources will be adequate to support our operations and
the costs to support our general and administrative, sales and marketing and research and development activities are forward-looking statements and involve risks and
uncertainties.
Additional financing, which is not in place at this time, may be from the sale of equity or convertible or other debt securities in a public or private offering, from an additional
or new credit facility or from strategic partnership coupled with an investment in us or a combination of forms. We may be unable to raise sufficient additional financing on
terms that are acceptable to us, if at all. Our failure to raise additional capital and in sufficient amounts when needed may significantly impact our ability to expand our
business. For further discussion of our liquidity requirements, see the section titled “Liquidity and Capital Resources-Capital Resources and Expenditure Requirements.”
We also may need to raise capital to expand our business to meet our long-term business objectives, including to:
•
•
•
•
•
increase our sales and marketing efforts to drive market adoption and address competitive
developments;
fund development, validation and marketing efforts of current and future
tests;
comply with current and evolving regulatory
requirements;
further expand our clinical laboratory
operations;
expand our technologies into other types of
cancer;
28
Table of Contents
•
•
•
acquire, license or invest in
technologies;
acquire or invest in complementary businesses or assets;
and
finance capital expenditures and general and administrative
expenses.
Our present and future funding requirements and our forecast of the period of time through which our current financial resources will be adequate to support our operations
will depend on many factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
our ability to achieve revenue
growth;
the costs for funding the operations of Response Genetics, which we recently acquired, and our ability to successfully integrate those operations with and into our
own;
our ability to obtain approvals for our new diagnostic
tests;
our ability to execute on our marketing and sales strategy for our tests and gain acceptance of our tests in the
market;
our ability to obtain adequate reimbursement from governmental and other third-party payors for our tests and
services;
the costs, scope, progress, results, timing and outcomes of the clinical trials of our diagnostic
tests;
the costs of operating and enhancing our laboratory
facilities;
the costs of additional general and administrative
personnel;
the timing of and the costs involved in regulatory compliance, particularly if the regulations relating to laboratory developed tests ("LDTs")
change;
the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and
liabilities;
our ability to manage the costs of manufacturing our NGS panels, microarrays and FHACT
probe;
our rate of progress in, and cost of research and development activities associated with, products in research and early
development;
the effect of competing technological and market
developments;
costs related to international expansion;
and
our ability to secure financing and the amount
thereof.
The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our stockholders could result. Any equity
securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt
securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit
agreement could impose significant restrictions on our operations and increase our interest expense. If we raise funds through collaborations and licensing arrangements, we
might be required to relinquish significant rights to our technologies or tests, or grant licenses on terms that are not favorable to us.
Additional equity or debt financing might not be available on reasonable terms, if at all. If we cannot secure additional funding when needed, we may have to delay, reduce the
scope of or eliminate one or more research and development programs or sales and marketing initiatives. In addition, we may have to work with a partner on one or more of
our development programs, which could lower the economic value of those programs to us.
Risks Relating to Our Business and Strategy
If we are unable to increase sales of our laboratory tests and services or to successfully develop and commercialize other proprietary tests, our revenues will be insufficient
for us to achieve profitability.
We currently derive substantially all of our revenues from our laboratory testing services. We have only recently begun offering our proprietary NGS panels and microarrays
through our CLIA-certified, CAP-accredited and state licensed laboratory. We also only recently launched FHACT for use as a diagnostic tool for cervical cancer in non-U.S.
markets. We are in varying stages of research and development for other diagnostic tests that we may offer.
We also have only recently begun to provide our Biopharma Services. Biopharma Services are services and tests provided to biopharmaceutical companies and clinical
research organizations in connection with phase I, phase II or phase III studies for development of therapeutic drugs. The nature of these services is that they tend to come in
relatively large projects but episodically, rather than providing steady sources of revenues. It is unclear at this stage of our development whether we will be able to maintain
and grow the number of biopharmaceutical companies and clinical research organizations who will avail themselves of our services, or how regular a flow of drug
development projects we will be able to obtain from existing customers.
29
Table of Contents
If we are unable to increase sales of our laboratory tests and services or to successfully develop, validate and commercialize other diagnostic tests, we will not produce
sufficient revenues to become profitable.
Our quarterly operating results may be subject to significant fluctuations and may be difficult to forecast.
In recent years, we have been expanding our Biopharma Services business. The nature of these services is that they tend to come in relatively large projects but episodically,
rather than providing steady sources of revenues. The timing, size and duration of our contracts with biopharmaceutical companies and clinical research organizations depend
on the size, pace and duration of such customer's clinical trial, over which we have no control and sometimes limited visibility. In addition, our expense levels are based, in
part, on expectation of future revenue levels. A shortfall in expected revenue could, therefore, result in a disproportionate decrease in our net income. As a result, our quarterly
operating results may be subject to significant fluctuations and may be difficult to forecast.
If pathologists and oncologists decide not to order our diagnostic tests and/or biopharmaceutical companies and clinical research organizations decide not to use our
diagnostic tests and services in connection with their clinical trials, we may be unable to generate sufficient revenue to sustain our business.
To generate demand for our Clinical Services, we will need to educate oncologists and pathologists on the clinical utility, benefits and value of each type of test we provide
through published papers, presentations at scientific conferences and one-on-one education sessions by members of our sales force. In addition, we will need to assure
oncologists and pathologists of our ability to obtain and maintain coverage and adequate reimbursement from third-party payors. To generate demand for our Biopharma
Services and Discovery Services, we need to educate biopharmaceutical companies and clinical research organizations on the utility of our tests and services to improve the
outcomes of clinical trials for new oncology drugs and more rapidly advance targeted therapies through the clinical development process through published papers,
presentations at scientific conferences and one-on-one education sessions by members of our sales force. We may need to hire additional commercial, scientific, technical and
other personnel to support this process. If we cannot convince medical practitioners, biopharmaceutical companies or clinical research organizations to order our diagnostic
tests or other future tests we develop, we will likely be unable to create demand for our tests in sufficient volume for us to achieve sustained profitability.
If we are unable to successfully validate our laboratory tests and services, we will not be able to increase revenues.
Pathologists and oncologists may not order our proprietary tests unless we are able to provide compelling evidence that the tests are useful to patient treatment and produce
actionable information with respect to the diagnosis, prognosis and theranosis of the various cancers on which our work is focused. In addition, biopharmaceutical companies
and clinical research organizations may not order our proprietary tests unless we are able to provide compelling evidence that such tests improve the outcomes of clinical trials
for new oncology drugs and allow biopharmaceutical companies to more rapidly advance targeted therapeutics. While we have validated all of the tests that we currently offer,
we believe that we will need to finance and successfully complete additional and more powerful studies, and then effectively disseminate the results of those studies, to drive
widespread adoption of our tests and thereby increase our revenues.
The commercial success of our Clinical Services business could be compromised if third-party payors, including managed care organizations and Medicare, do not provide
coverage and reimbursement, breach, rescind or modify their contracts or reimbursement policies or delay payments for our molecular diagnostic tests.
Pathologists and oncologists may not order our molecular diagnostic tests unless third-party payors, such as managed care organizations and government payors, such as
Medicare and Medicaid, pay a substantial portion of the test price. Coverage and reimbursement by a third-party payor may depend on a number of factors, including a payor's
determination that tests using our technologies are:
•
not experimental or
investigational;
•
•
• medically
necessary;
appropriate for the specific
patient;
cost-
effective;
supported by peer-reviewed publications;
and
included in clinical practice
guidelines.
•
•
Uncertainty surrounds third-party payor coverage and reimbursement of any test incorporating new technology, including tests developed using our microarrays and NGS
panels. Technology assessments of new medical tests and devices conducted by
30
Table of Contents
research centers and other entities may be disseminated to interested parties for informational purposes. Third-party payors and health care providers may use such technology
assessments as grounds to deny coverage for a test or procedure.
Because each payor generally determines for its own enrollees or insured patients whether to cover or otherwise establish a policy to reimburse our diagnostic tests, seeking
payor approvals is a time-consuming and costly process. We cannot be certain that coverage for our tests will be provided in the future by additional third-party payors or that
existing contracts, agreements or policy decisions or reimbursement levels will remain in place or be fulfilled under existing terms and provisions. If we cannot obtain
coverage and reimbursement from private and governmental payors such as Medicare and Medicaid for our current tests, or new tests or test enhancements that we may
develop in the future, our ability to generate revenues from our clinical services could be limited, which may have a material adverse effect on our financial condition, results
of operations and cash flow. Further, we have experienced in the past, and will likely experience in the future, delays and temporary interruptions in the receipt of payments
from third-party payors due to missing documentation and other issues, which could cause delay in collecting our revenue.
Our business depends on our ability to successfully commercialize novel cancer diagnostic tests and services, which is time consuming and complex, and our development
efforts may fail.
Our current business strategy focuses on discovering, developing and commercializing molecular diagnostic tests and services. We believe the success of our business depends
on our ability to fully validate and commercialize our existing diagnostic tests and services and to develop and commercialize new diagnostic tests. We have multiple tests we
are currently offering and in development, but research, development and commercialization of diagnostic tests is time-consuming, uncertain and complex.
Tests we currently offer in our laboratory, or any additional technologies that we may develop, may not succeed in reliably diagnosing or predicting the recurrence of cancers
with the sensitivity and specificity necessary to be clinically useful, and thus may not succeed commercially. In addition, prior to or an in continuing in conjunction with
commercializing our diagnostic tests, we must undertake time-consuming and costly development activities, including clinical studies, and obtain regulatory clearance or
approval, which may be denied. This development process involves a high degree of risk, substantial expenditures and will occur over several years. Our development efforts
may fail for many reasons, including:
•
•
•
failure of the tests at the research or development
stage;
difficulty in accessing archival tissue samples, especially tissue samples with known clinical results;
or
lack of sufficient clinical validation data to support the effectiveness of the
test.
Tests that appear promising in early development may fail to be validated in subsequent studies, and even if we achieve positive results, we may ultimately fail to obtain the
necessary regulatory clearances or approvals. There is substantial risk that our research and development projects will not result in commercial tests, and that success in early
clinical trials will not be replicated in later studies. At any point, we may abandon development of a test or be required to expend considerable resources repeating clinical
trials, which would adversely impact the timing for generating potential revenues from that test. In addition, as we develop tests, we will have to make significant investments
in research, development and marketing resources. If a clinical validation study of a particular test then fails to demonstrate the outlined goals of the study, we might choose to
abandon the development of that test. Further, our ability to develop and launch diagnostic tests will likely depend on our receipt of additional funding. If our discovery and
development programs yield fewer commercial tests than we expect, we may be unable to execute our business plan, which may adversely affect our business, financial
condition and results of operations.
Failure of the Response Genetics acquisition to achieve anticipated revenue levels and other potential benefits could harm the business and operating results of the
combined company.
We expect that the acquisition of the Response Genetics business will result in increased revenue and other potential benefits for the combined company, including the
expansion of the number and geographic coverage or our marketing team, the expansion of our menu of tests offered to cover 8 of the 10 most common solid tumor types, the
expansion of the geographic coverage of our laboratories and introductions to additional potential biopharmaceutical partners for our testing services. No assurance can be
given that we will achieve any or all of these potential benefits. Even if we are able to achieve any of these potential benefits, we cannot predict with certainty when the
benefits will occur, or to the extent to which they actually will be achieved. For example, the benefits from the acquisition may be offset by costs incurred in integrating the
businesses or in obtaining or attempting to obtain regulatory or court approvals for the acquisition. The failure to achieve anticipated benefits could harm the business,
financial condition and operating results of the combined company.
Any acquisition exposes a company to additional risks.
31
Table of Contents
Acquisitions may entail numerous risks for us, including:
•
•
•
•
competing claims for capital
resources;
ability to retain and grow relationships with the acquired company's key
customers;
difficulties in assimilating acquired operations, technologies or products;
and
diversion of management's attention from our core
business.
Our management has limited experience in purchasing and integrating new businesses. Our failure to successfully complete the integration of Response Genetics or any other
new acquisition could have a material adverse effect on our business, financial condition and operating results.
If the market for our tests and services does not experience significant growth or if our tests and services do not achieve broad acceptance, our operations will suffer.
We cannot accurately predict the future growth rate or the size of the market for our tests and services. The expansion of this market depends on a number of factors, such as:
•
•
•
•
the results of clinical
trials;
the cost, performance and reliability of our tests and services, and the tests and services offered by
competitors;
customers' perceptions regarding the benefits of our tests and
services;
customers' satisfaction with our tests and services;
and
• marketing efforts and publicity regarding our tests and
services.
If we are unable to manage growth in our business, our prospects may be limited and our future results of operations may be adversely affected.
We intend to expand our research and development activities, our sales and marketing programs and other activities as needed to meet future demand. Any significant
expansion may strain our managerial, financial and other resources. If we are unable to manage such growth, our business, operating results and financial condition could be
adversely affected. We will need to improve continually our operations, financial and other internal systems to manage its growth effectively, and any failure to do so may lead
to inefficiencies and redundancies, and result in reduced growth prospects and diminished operational results.
We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our
stockholders’ ownership, increase our debt or cause us to incur significant expense.
As part of our business strategy, we may pursue other acquisitions of businesses and assets. We also may pursue strategic alliances and joint ventures that leverage our core
technology and industry experience to expand our offerings or distribution. For example, we entered into a joint venture in May 2013 with Mayo Foundation for Education and
Research. We have limited experience with acquiring other companies and forming strategic alliances and joint ventures. We may not be able to find suitable partners or
acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate these
acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in significant write-offs
or the incurrence of debt and contingent liabilities, any of which could have a material adverse effect on our financial condition, results of operations and cash flows.
Integration of an acquired company also may disrupt ongoing operations and require management resources that would otherwise focus on developing our existing business.
We may experience losses related to investments in other companies, which could have a material negative effect on our results of operations. We may not identify or
complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license,
strategic alliance or joint venture.
To finance any acquisitions or joint ventures, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our stockholders. If
the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration. Alternatively,
it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to
us, or at all.
Our agreement with Mayo may not proceed successfully.
In November 2011, we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research, subsequently amended. Under the agreement, we
formed a joint venture in May 2013 to focus on developing oncology
32
Table of Contents
diagnostic services and tests utilizing next generation sequencing. We have made $2.0 million in capital contributions to that joint venture through December 31, 2015. The
agreement requires additional capital contributions by us of up to $4.0 million, subject to the joint venture achieving certain operational milestones. The operation of the joint
venture may also divert management time from operating our business. No assurances can be given that we will be able to fully fund our obligations under the joint venture
agreement, or that, even if funded, the joint venture will ever achieve the research, development and commercial objectives currently contemplated by the parties, such as the
discovery and commercialization of new diagnostic tests utilizing next-generation sequencing. If the development efforts of the joint venture do not result in commercially
successful tests or services, it will have an adverse effect on our business, financial condition and results of operations.
We conduct business in a heavily regulated industry, and if we are unable to obtain regulatory clearance or approvals in the United States, if we experience delays in
receiving clearance or approvals, or if we do not gain acceptance from other laboratories of any cleared or approved diagnostic tests at their facilities, our growth strategy
may not be successful.
We currently offer our proprietary tests in conjunction with our comprehensive panel of laboratory services in our CLIA-certified and CAP-accredited laboratory. Because we
currently offer these tests and services solely for use within our laboratory, we believe we may market the tests as laboratory developed tests (LDTs), which are tests designed,
manufactured and used within a single laboratory. Although the Food and Drug Administration (“FDA”) has statutory authority to assure that medical devices, including
LDTs, are safe and effective for their intended uses, the FDA has generally exercised its enforcement discretion and not enforced applicable regulations with respect to LDTs.
Specifically, under current FDA enforcement policies and guidance, LDTs generally do not require FDA premarket clearance or approval before commercialization, and we
have marketed our LDTs on that basis (although, the FDA has recently announced that such policy may be changing). While we believe that we are currently in material
compliance with applicable laws and regulations as historically enforced by the FDA, we cannot assure you that the FDA will agree with our determination, and a
determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our
business, prospects, results of operations or financial condition.
In addition, an element of our long-term strategy is to place molecular diagnostic tests on-site with other laboratories to broaden access to our technology and increase demand
for our tests and any future diagnostic tests that we may develop. If we were to offer our tests through third-party laboratories, these tests would most likely not be subject to
the FDA's current exercise of enforcement discretion over LDTs, and would be subject to the applicable medical device regulations. For example, these tests could become
subject to the FDA's requirements for premarket review. Unless an exemption applies, generally, before a new medical device or a new use for a medical device may be sold
or distributed in the United States, the medical device must receive either FDA clearance of a 510(k) pre-market notification or pre-market approval. As a result, before we can
market or distribute our tests in the United States for use by other clinical testing laboratories, we must first obtain pre-market clearance or pre-market approval from FDA. We
have not yet applied for clearance or approval from FDA, and would need to complete additional validations before we are ready to apply. We believe it would likely take two
years or more to conduct the studies and trials necessary to obtain approval from FDA to commercially launch any of our proprietary products outside of our clinical
laboratory. Once we do apply, we may not receive FDA clearance or approval for the commercial use of our tests on a timely basis, or at all. If we are unable to obtain
clearance or approval or if clinical diagnostic laboratories do not accept our tests, our ability to grow our business by deploying our tests could be compromised.
Recent announcements from the Federal Food and Drug Administration may impose additional regulatory obligations and costs upon our business.
On October 3, 2014 the FDA issued two draft guidance documents regarding its intent to modify its policy of enforcement discretion and increase oversight over LDTs. The
two draft guidance documents are entitled “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)” (the “Framework Guidance”) and “FDA Notification
and Medical Device Reporting for Laboratory Developed Test (LDTs)" (the "Notification Guidance”). According to the Framework Guidance, FDA plans to modify its policy
of enforcement discretion with respect to LDTs using a phased-in, risk-based approach consistent with the existing classification of medical devices. Thus, the FDA plans to
begin to enforce its medical device requirements, including premarket submission requirements, to many LDTs that have historically been marketed without FDA premarket
review and oversight. The FDA states its intention in the Framework Guidance to publish general LDT classification guidance within 18 months of the date on which the
Framework Guidance is finalized. According to the Framework Guidance, devices that are already in use at the time FDA initiates enforcement of the premarket review
requirements will be permitted to remain in use-pending FDA's review and consideration of the premarket submission-so long as a premarket submission is timely made. For
the highest risk LDTs, the Framework Guidance provides that enforcement of the premarket submission requirements will begin 12 months after the guidance is finalized. For
lower risk LDTs, enforcement will be phased in over the following four to nine years. Under this new risk based approach, it is possible that some level of pre-market review
may be required for our LDTs-either a 510(k) or PMA-which may require us to generate additional clinical data. While the FDA has proposed that
33
Table of Contents
devices that are already in use at the time FDA initiates enforcement of the premarket review requirements will be permitted to remain in use-pending FDA's review and
consideration of the premarket submission-so long as a premarket submission is timely made, we may nevertheless be required to cease commercial sales of our products and
conduct additional clinical testing prior to making submissions to the FDA to obtain premarket clearance or approval.
The draft guidance documents are subject to public comment. The final date for comments was February 2, 2015. We cannot tell at this time what additional costs and
regulatory burdens, any final FDA guidance or FDA enforcement of its regulations may have on our business or operations.
If we and our tests become subject to FDA's enforcement of its medical device regulations pursuant to the FDA's plans to modify its policy of enforcement discretion with
respect to LDTs, we may be subject to significant and onerous regulatory obligations. See section entitled “Risk Factors-Regulatory Risks Relating to Our Business-If the FDA
regulates LDTs as proposed, then it would classify LDTs according to the current system used to regulate medical devices. Under that system, there are three different classes
of medical devices, with the requirements becoming more stringent depending on the Class.”
If we are unable to execute our marketing strategy for our tests and our tests are unable to gain acceptance in the market, we may be unable to generate sufficient revenue
to sustain our business.
Although we believe that our tests represent promising commercial opportunities, our tests may never gain significant acceptance in the marketplace and therefore may never
generate substantial revenue or profits for us. We need to continue to develop a market for our tests through physician education and awareness programs. Gaining acceptance
in medical communities requires that we perform additional studies after validating the efficacy of our tests and services for the diagnosis, prognosis and treatment of cancer,
and that we obtain acceptance of the results of those studies using our tests for publication in leading peer-reviewed medical journals. The results of any studies are always
uncertain and even if we believe such studies demonstrate the value of our tests, they process of publication in leading medical journals is subject to a peer review process and
peer reviewers may not consider the results of our studies sufficiently novel or worthy of publication. Failure to have our studies published in peer-reviewed journals would
limit the adoption of our tests. Our ability to successfully market the tests that we may develop will depend on numerous factors, including:
•
•
•
whether health care providers believe our diagnostic tests provide clinical
utility;
whether the medical community accepts that our diagnostic tests are sufficiently sensitive and specific to be meaningful in patient care and treatment decisions;
and
whether health insurers, government health programs and other third-party payors will cover and pay for our diagnostic tests and, if so, whether they will adequately
reimburse us.
Failure to achieve widespread market acceptance of our diagnostic tests would materially harm our business, financial condition and results of operations.
If we cannot develop tests to keep pace with rapid advances in technology, medicine and science, our operating results and competitive position could be harmed.
In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There are several new cancer drugs under development
that may increase patient survival time. There have also been advances in methods used to analyze very large amounts of genomic information. We must continuously develop
new tests and enhance our existing tests to keep pace with evolving standards of care. Our existing tests could become obsolete unless we continually innovate and expand
them to demonstrate benefit in patients treated with new therapies. New cancer therapies typically have only a few years of clinical data associated with them, which limits our
ability to perform clinical studies and correlate sets of genes to a new treatment's effectiveness. If we cannot adequately demonstrate the applicability of our tests to new
treatments, sales of our tests and services could decline, which would have a material adverse effect on our business, financial condition and results of operations.
If our tests do not continue to perform as expected, our operating results, reputation and business will suffer.
Our success depends on the market's confidence that we can continue to provide reliable, high-quality diagnostic tests. We believe that our customers are likely to be
particularly sensitive to test defects and errors. As a result, the failure of our tests or services to perform as expected would significantly impair our reputation and the public
image of our tests and services, and we may be subject to legal claims arising from any defects or errors.
34
Table of Contents
There is a scarcity of experienced professionals in our industry. If we are not able to retain and recruit personnel with the requisite technical skills, we may be unable to
successfully execute our business strategy.
The specialized nature of our industry results in an inherent scarcity of experienced personnel in the field. Our future success depends upon our ability to attract and retain
highly skilled personnel (including medical, scientific, technical, commercial, business, regulatory and administrative personnel) necessary to support our anticipated growth,
develop our business and perform certain contractual obligations. Given the scarcity of professionals with the scientific knowledge that we require and the competition for
qualified personnel among life science businesses, we may not succeed in attracting or retaining the personnel we require to continue and grow our operations. The loss of a
key employee, the failure of a key employee to perform in his or her current position or our inability to attract and retain skilled employees could result in our inability to
continue to grow our business or to implement our business strategy.
Our inability to attract, hire and retain a sufficient number of qualified sales professionals would hamper our ability to increase demand for our tests, to expand
geographically and to successfully commercialize any other diagnostic tests or products we may develop.
Our success in selling our clinical laboratory services, biopharma services, discovery services, diagnostic tests and any other tests or products that we are able to develop will
require us to expand our sales force in the United States and internationally by recruiting additional sales representatives with extensive experience in oncology and close
relationships with medical oncologists, surgeons, pathologists and other hospital personnel, as well as biopharmaceutical companies and clinical research organizations. To
achieve our marketing and sales goals, we will need to substantially expand our sales and commercial infrastructure, with which to date we have had little experience. Sales
professionals with the necessary technical and business qualifications are in high demand, and there is a risk that we may be unable to attract, hire and retain the number of
sales professionals with the right qualifications, scientific backgrounds and relationships with decision-makers at potential customers needed to achieve our sales goals. We
may face competition from other companies in our industry, some of whom are much larger than us and who can pay greater compensation and benefits than we can, in
seeking to attract and retain qualified sales and marketing employees. If we are unable to hire and retain qualified sales and marketing personnel, our business will suffer.
We have indebtedness with restrictive covenants that limit our ability to obtain additional debt financing and that requires us to comply with certain financial covenants,
which could have a material adverse effect on our financial condition, our ability to fund operations, and react to changes in our business.
As of December 31, 2015, we had indebtedness for borrowed money due on April 1, 2019 in the aggregate principal amount of $6.0 million under our New Credit Facility
with Silicon Valley Bank. We are required to comply with certain financial covenants and restricts us from, among other things, paying cash dividends, incurring debt and
entering into certain transactions without the prior consent of the lenders. Repayments of amounts borrowed under the credit facility may be accelerated if an event of default
occurs, which includes, among other things, a violation of such financial covenants and negative covenants. Our debt and related covenants could limit our ability to satisfy
our obligations, limit our ability to operate our business and impair our competitive position. For example, it could:
•
•
•
•
require us to dedicate a substantial portion of our cash flow from operations to payments on our debt, reducing the availability of our cash flow from operations to
fund working capital, capital expenditures or other general corporate purposes;
limit our flexibility in planning for, or reacting to, changes in our business and
industry;
place us at a disadvantage compared to competitors that may have proportionately less debt;
and
increase our cost of
borrowing.
If our laboratory facilities become damaged or inoperable, or we are required to vacate any facility, our ability to provide services and pursue our research and
development efforts may be jeopardized.
We currently derive substantially all of our revenues from our laboratory testing services. We do not have any clinical reference laboratory facilities outside of our facilities in
Rutherford, New Jersey, Morrisville, North Carolina, Hyderabad, India and Los Angeles, California. Our facilities and equipment could be harmed or rendered inoperable by
natural or man-made disasters, including fire, flooding and power outages, which may render it difficult or impossible for us to perform our tests or provide laboratory services
for some period of time. The inability to perform our tests or the backlog of tests that could develop if any of our facilities is inoperable for even a short period of time may
result in the loss of customers or harm to our reputation or relationships with collaborators, and we may be unable to regain those customers or repair our reputation in the
future. Furthermore, our facilities and the equipment we use to perform our research and development work could be costly and time-consuming to repair or replace.
35
Table of Contents
Additionally, a key component of our research and development process involves using biological samples and the resulting data sets and medical histories, as the basis for our
diagnostic test development. In some cases, these samples are difficult to obtain. If the parts of our laboratory facilities where we store these biological samples are damaged or
compromised, our ability to pursue our research and development projects, as well as our reputation, could be jeopardized. We carry insurance for damage to our property and
the disruption of our business, but this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at
all.
Further, if any of our laboratories became inoperable we may not be able to license or transfer our proprietary technology to a third-party, with established state licensure and
CLIA certification under the scope of which our diagnostic tests could be performed following validation and other required procedures, to perform the tests. Even if we find a
third-party with such qualifications to perform our tests, such party may not be willing to perform the tests for us on commercially reasonable terms. Moreover, we believe our
tests are currently subject to an exercise of enforcement discretion by the FDA because the tests are considered LDTs. If we are required to find a third-party laboratory to
conduct our testing services, we believe the FDA would consider our tests to be medical devices that are no longer subject to its exercise of enforcement discretion for LDTs.
In that case, we may be required to obtain premarket clearance or approval prior to offering our tests, which would be time-consuming and costly and could result in delays in
our ability to sell or offer our tests.
If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenues or achieve and sustain profitability.
We face competition from mainstream diagnostic methods that pathologists and oncologists use and have used for many years. It may be difficult to change the methods or
behavior of the referring pathologists and oncologists to incorporate our molecular diagnostic testing in their practices. We believe that we can introduce our diagnostic tests
successfully due to their clinical utility and the desire of pathologists and oncologists to find solutions for more accurate diagnosis, prognosis and personalized treatment
options for cancer patients.
We also face competition from companies that currently offer or are developing products to profile genes, gene expression or protein biomarkers in various cancers.
Personalized genetic diagnostics is a new area of science, and we cannot predict what tests others will develop that may compete with or provide results superior to the results
we are able to achieve with the tests we develop. Our competitors include public companies such as NeoGenomics, Inc., Quest Diagnostics, Abbott Laboratories, Inc.,
Johnson & Johnson, Roche Molecular Systems, Inc., bioTheranostics, Inc. (part of bioMérieux SA), Genomic Health, Inc., Myriad Genetics Inc., and Foundation
Medicine, Inc., and many private companies. We expect that pharmaceutical and biopharmaceutical companies will increasingly focus attention and resources on the
personalized diagnostic sector as the potential and prevalence increases for molecularly targeted oncology therapies approved by FDA along with companion diagnostics. For
example, FDA has recently approved two such agents-Xalkori crizotinib from Pfizer Inc. along with its companion anaplastic lymphoma kinase FISH test from Abbott
Laboratories, Inc. and Zelboraf vemurafenib from Genentech USA Incorporated and Daiichi-Sankyo Inc. along with its companion B-RAF kinase V600 mutation test from
Roche Molecular Systems, Inc. These two recent FDA approvals are only the second and third instances of simultaneous approvals of a drug and companion diagnostic, the
first being the 1998 approval of Genentech, Inc.'s Herceptin trastuzumab for HER2 positive breast cancer along with the HercepTest from partner Dako A/S.
With respect to our clinical laboratory sciences business we face competition from companies such as Genoptix, Inc. (a Novartis AG Company), Clarient, Inc. (a division of
GE Healthcare, a unit of General Electric Company), Bio-Reference Laboratories, Inc., and Genzyme Genetics (a LabCorp Specialty Testing Group).
Many of our present and potential competitors have widespread brand recognition and substantially greater financial and technical resources and development, production and
marketing capabilities than we do. Others may develop lower-priced, less complex tests that payors, pathologists and oncologists could view as functionally equivalent to our
tests, which could force us to lower the list price of our tests and impact our operating margins and our ability to achieve profitability. In addition, technological innovations
that result in the creation of enhanced diagnostic tools may enable other clinical laboratories, hospitals, physicians or medical providers to provide specialized diagnostic
services similar to ours in a more patient-friendly, efficient or cost-effective manner than is currently possible. If we cannot compete successfully against current or future
competitors, we may be unable to increase market acceptance and sales of our tests, which could prevent us from increasing or sustaining our revenues or achieving or
sustaining profitability.
A small number of test ordering sites account for most of the sales of our tests and services. If any of these sites orders fewer tests from us for any reason, our revenues
could decline.
36
Table of Contents
Due to the early stage nature of our business and our limited sales and marketing activities to date, we have historically derived a significant portion of our revenue from a
limited number of test ordering sites, although the test ordering sites that generate a significant portion of our revenue may change from period to period. Our test ordering
sites are largely hospitals, cancer centers, reference laboratories and physician offices, as well as biopharmaceutical companies as part of a clinical trial. Oncologists and
pathologists at these sites order the tests on behalf of the needs of their oncology patients or as part of a clinical trial sponsored by a biopharmaceutical company in which the
patient is being enrolled. The top five test ordering sites during 2015, 2014 and 2013 accounted for 49%, 56% and 69% respectively, of our clinical testing volumes, with 18%,
38% and 36% respectively, of the volume coming from community hospitals. During the year ended December 31, 2015, one Biopharma client accounted for approximately
19% of our revenue. During the year ended December 31, 2014, two Biopharma clients accounted for approximately 23% and 12%, respectively, of our revenue. During the
year ended December 31, 2013 there was one Biopharma client that accounted for approximately 40% of our revenue.
We expect to continue to incur significant expenses to develop and market our diagnostic tests, which could make it difficult for us to achieve and sustain profitability.
In recent years, we have incurred significant costs in connection with the development of our diagnostic tests. For the year ended December 31, 2015, our research and
development expenses were $5.5 million, which was 30% of our revenue and our sales and marketing expenses were $5.3 million, which was 29% of revenue. For the year
ended December 31, 2014, our research and development expenses were $4.6 million, which was 45% of our net revenue and our sales and marketing expenses were $4.0
million, which was 39% of revenue. For the year ended December 31, 2013, our research and development expenses were $2.2 million, which was 33% of our revenue, and
our sales and marketing expenses were $1.8 million, which was 28% of revenue. We expect our expenses to continue to increase, in absolute dollars, for the foreseeable future
as we seek to expand the clinical utility of our diagnostic tests, drive adoption of and reimbursement for our diagnostic tests and develop new tests. As a result, we will need to
generate significant revenues in order to achieve sustained profitability.
We depend on certain collaborations with third parties for the supply of certain tissue samples and biological materials that we use in our research and development
efforts. If the costs of such collaborations increase or our third party collaborators terminate their relationship with us, our business may be materially harmed.
Under standard clinical practice in the United States, tumor biopsies removed from patients are chemically preserved, embedded in paraffin wax and stored. Our clinical
development relies on our ability to access these archived tumor biopsy samples, as well as information pertaining to their associated clinical outcomes. Other companies often
compete with us for access. Additionally, the process of negotiating access to archived samples is lengthy, because it typically involves numerous parties and approvals to
resolve complex issues such as usage rights, institutional review board approval, privacy rights, publication rights, intellectual property ownership and research parameters.
We have collaborative relationships with Memorial Sloan-Kettering Cancer Center, Mayo, North Shore-Long Island Jewish Health System, the National Cancer Institute, the
Cleveland Clinic and other institutions who provide us with tissue samples and other biological materials that we use in developing and validating our tests. We do not have
any written arrangement with certain third party collaborators, and in many of the cases in which the arrangements are in writing, our collaborative relationships are terminable
on 30 days' notice or less. If one or more collaborators terminate their relationship with us, we will need to identify other third parties to provide us with tissue samples and
biological materials, which could result in a delay in our research and development activities and negatively affect our business.
We currently rely on a single third-party to produce our microarrays and any problems experienced by this vendor could result in a delay or interruption in the supply of
our microarrays to us until the problem is cured by such vendor or until we locate and qualify an alternative source of supply.
The design of our microarrays is currently optimized on a family of instruments referred to as the Agilent Microarray Platform, which is currently produced solely by Agilent
Technologies Inc. (“Agilent”). We currently purchase these components from Agilent under purchase orders and do not have a long-term contract with Agilent. If Agilent were
to delay or stop producing our microarrays, or if the prices Agilent charges us were to increase significantly, we would need to identify another supplier and optimize our
microarrays on a new technology platform. We could experience delays in manufacturing the microarrays while finding another acceptable supplier, which could impact our
results of operations. The changes could also result in increased costs associated with migrating to the new technology platform and in increased manufacturing costs. Further,
any prolonged disruption in Agilent's operations could have a significant negative impact on the supply of our microarrays.
If we were sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.
37
Table of Contents
The marketing, sale and use of our tests could lead to the filing of product liability claims were someone to allege that our tests failed to perform as designed. We may also be
subject to liability for errors in the test results we provide to pathologists and oncologists or for a misunderstanding of, or inappropriate reliance upon, the information we
provide. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend.
Although we believe that our existing product and professional liability insurance is adequate, our insurance may not fully protect us from the financial impact of defending
against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our
insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could damage our reputation, result in the recall of our
tests, or cause current clinical partners to terminate existing agreements and potential clinical partners to seek other partners, any of which could impact our results of
operations.
If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.
Our activities currently require the controlled use of potentially harmful biological materials and hazardous materials and chemicals. We cannot eliminate the risk of accidental
contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held
liable for any resulting damages, and any liability could exceed our resources or any applicable insurance coverage we may have. Additionally, we are subject to, on an
ongoing basis, federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of
compliance with these laws and regulations may become significant and could have a material adverse effect on our financial condition, results of operations and cash flows. In
the event of an accident or if we otherwise fail to comply with applicable regulations, we could lose our permits or approvals or be held liable for damages or penalized with
fines.
If we cannot support demand for our tests, including successfully managing the evolution of our technology and manufacturing platforms, our business could suffer.
As our test volume grows, we will need to increase our testing capacity, implement increases in scale and related processing, customer service, billing, collection and systems
process improvements and expand our internal quality assurance program and technology to support testing on a larger scale. We will also need additional certified laboratory
scientists and other scientific and technical personnel to process these additional tests. Any increases in scale, related improvements and quality assurance may not be
successfully implemented and appropriate personnel may not be available. As additional tests are commercialized, we will need to bring new equipment on line, implement
new systems, technology, controls and procedures and hire personnel with different qualifications. Failure to implement necessary procedures or to hire the necessary
personnel could result in a higher cost of processing or an inability to meet market demand. We cannot assure you that we will be able to perform tests on a timely basis at a
level consistent with demand, that our efforts to scale our commercial operations will not negatively affect the quality of our test results or that we will respond successfully to
the growing complexity of our testing operations. If we encounter difficulty meeting market demand or quality standards for our tests, our reputation could be harmed and our
future prospects and business could suffer, which may have a material adverse effect on our financial condition, results of operations and cash flows.
We depend on our information technology and telecommunications systems, and any failure of these systems could harm our business.
We depend on information technology and telecommunications systems for significant aspects of our operations. In addition, our third-party billing and collections provider
depends upon telecommunications and data systems provided by outside vendors and information we provide on a regular basis. These information technology and
telecommunications systems support a variety of functions, including test processing, sample tracking, quality control, customer service and support, billing and
reimbursement, research and development activities and our general and administrative activities. Information technology and telecommunications systems are vulnerable to
damage from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters. Moreover, despite network security and back-
up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary
measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of
our information technology or telecommunications systems or those used by our third-party service providers could prevent us from processing tests, providing test results to
pathologists, oncologists, billing payors, processing reimbursement appeals, handling patient or physician inquiries, conducting research and development activities and
managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our
operations depend could have an adverse effect on our business.
38
Table of Contents
Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and
expose us to fines, penalties, liability, and adverse effects to our business and our reputation.
In the ordinary course of our business, we and our third-party billing and collections provider collect and store sensitive data, including legally protected health information,
personally identifiable information, intellectual property, and proprietary business information owned or controlled by ourselves or our customers, payors, and
biopharmaceutical partners. The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy, and we
devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our
information technology and infrastructure, and that of our third-party billing and collections provider, may be vulnerable to attacks by hackers or viruses or breached due to
employee error, malfeasance, or other disruptions. Any such breach or interruption could compromise our networks, and the information stored there could be accessed by
unauthorized parties, publicly disclosed, lost, or stolen. Any such improper access or disclosure, or loss of information could require us to provide notice to the affected
individuals, the press, and regulatory bodies, result in legal claims or proceedings, liability, fines and penalties under laws that protect the privacy of personal information, such
as the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), the Health Information Technology for Economic and Clinical Health Act (“HITECH”), their
implementing regulations, and similar state laws. Unauthorized access, loss, or dissemination could also disrupt our operations, including our ability to conduct our analyses,
provide test results, bill payors or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process, and
prepare company financial information, provide information about our products and other patient and physician education and outreach efforts through our website, manage
the administrative aspects of our business, and damage our reputation, any of which could adversely affect our business.
The U.S. Department of Health and Human Services Office for Civil Rights (“OCR”) may impose penalties on a covered entity, such as us, for a failure to comply with a
requirement of HIPAA. Penalties will vary significantly depending on factors such as the date of the violation, whether the covered entity knew or should have known of the
failure to comply, or whether the covered entity's failure to comply was due to willful neglect. These penalties include civil monetary penalties of $100 to $50,000 per
violation, up to an annual, per violation cap of $1,500,000. A single breach incident can result in violations of multiple standards, resulting in possible penalties potentially in
excess of $1,500,000. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face a criminal penalty of up to
$50,000 and up to one year imprisonment. The criminal penalties increase to $100,000 and up to five years imprisonment if the wrongful conduct involves false pretenses, and
to $250,000 and up to 10 years imprisonment if the wrongful conduct involves the intent to sell, transfer, or use identifiable health information for commercial advantage,
personal gain, or malicious harm. The U.S. Department of Justice is responsible for criminal prosecutions under HIPAA.
HIPAA authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys' fees related to violations of
HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as
the basis for a duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of Protected Health Information.
In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities for compliance with the HIPAA privacy and security
regulations. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured Protected Health Information may
receive a percentage of the Civil Monetary Penalty fine paid by the violator.
HIPAA further requires covered entities to notify affected individuals "without unreasonable delay and in no case later than 60 calendar days after discovery of the breach" if
their unsecured Protected Health Information is subject to an unauthorized access, use or disclosure. If a breach affects 500 patients or more, it must be reported to HHS and
local media without unreasonable delay, and HHS will post the name of the breaching entity on its public website. If a breach affects fewer than 500 individuals, the covered
entity must log it and notify HHS at least annually.
In addition, the interpretation and application of consumer, health-related, and data protection laws in the United States, Europe, and elsewhere are often uncertain,
contradictory, and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-
imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition, these privacy regulations may differ from country to
country, and may vary based on whether testing is performed in the United States or in the local country. Complying with these various laws could cause us to incur
substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business.
39
Table of Contents
Regulatory Risks Relating to Our Business
Health care policy changes, including recently enacted legislation reforming the U.S. health care system, may have a material adverse effect on our financial condition,
results of operations and cash flows.
In March 2010, U.S. President Barack Obama signed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
(collectively, “PPACA”), which makes a number of substantial changes in the way health care is financed by both governmental and private insurers. Among other things, the
PPACA:
•
Requires each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices, beginning in 2013. This
tax may apply to some or all of our current products and products which are in development.
• Mandates a reduction in payments for clinical laboratory services paid under the Medicare Clinical Laboratory Fee Schedule (“CLFS”) of 1.75% for the years 2011
through 2015. In addition, a productivity adjustment is made to the fee schedule payment amount. These changes in payments apply to some or all of the clinical
laboratory test services we furnish to Medicare beneficiaries.
Establishes an Independent Payment Advisory Board to reduce the per capita rate of growth in Medicare spending. The Independent Payment Advisory Board has
broad discretion to propose policies, which may have a negative impact on payment rates for services, including clinical laboratory services, beginning in 2016, and
for hospital services beginning in 2020.
•
Although some of these provisions may negatively impact payment rates for clinical laboratory services, the PPACA also extends coverage to approximately 32 million
previously uninsured people, which may result in an increase in the demand for our tests and services. The mandatory purchase of insurance has been strenuously opposed by a
number of state governors, resulting in lawsuits challenging the constitutionality of certain provisions of the PPACA. On June 28, 2012, the Supreme Court upheld the
constitutionality of the health care reform law, with the exception of certain provisions dealing with the expansion of Medicaid coverage under the law. While most of the law's
provisions went into effect in 2013 and 2014, Congress has proposed a number of legislative initiatives, including possible repeal of the PPACA. On June 25, 2015, the
Supreme Court affirmed the Fourth Circuit Court of Appeals in King v. Burwell, which allows the federal government to continue to extend tax subsidies to those individuals
who purchased coverage through federal exchanges, in addition to the exchanges established by individual states.
In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. Recently, on August 2, 2011, the President signed into law the Budget
Control Act of 2011, which, among other things, creates the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The
Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation's automatic reduction to
several government programs. This includes aggregate reductions to Medicare payments to providers of 2% per fiscal year, starting in 2013. This 2% sequester was recently
extended through 2024.
The full impact on our business of the PPACA and the new law is uncertain. In addition, on February 22, 2012, the President signed the Middle Class Tax Relief and Job
Creation Act of 2012 (“MCTRJCA”), which, among other things, mandated an additional change in Medicare reimbursement for clinical laboratory services. This legislation
requires a rebasing of the Medicare CLFS to effect a 2% reduction in payment rates otherwise determined for 2013. This will serve as a base for 2014 and subsequent years. As
a result of the changes mandated by PPACA and MCTRJCA, the Centers for Medicare & Medicaid Services (“CMS”) projects laboratory services for 2015 will be reduced by
approximately 0.25%.
Further, in 2014, Congress passed the Protecting Access to Medicare Act or PAMA which also makes significant changes in the way the Medicare will pay for laboratory
services. Under PAMA, laboratories were required to report the amount that they are paid by third party payors for each test beginning in January 2016. CMS will use this
data to calculate a weighted median for each test. That new price is supposed to effective on January 1, 2017, although any resulting reductions will be phased in over time.
This data reporting process will be repeated every three years for most tests, although certain advanced diagnostic tests will have to report every year. It is possible that some
of our tests may qualify as Advanced Diagnostic Laboratory Tests, which will require us to submit pricing annually. In addition, under PAMA, we will also be required to
obtain new codes from CMS or any entity it designates, for our tests that do not currently have codes. Although CMS was also required to issue a Final Rule implementing
PAMA by June 30, 2016, it failed to do so. It did issue a Proposed Rule, however, on October 1, 2015. As a result of this delay, many of the statutory deadlines will likely not
be met. If PAMA results in a significant reduction in the prices for our tests, it could have a significant impact on our revenues and it is not known at this time how the
implementation of PAMA will affect our reimbursement.
40
Table of Contents
Certain of our laboratory services are paid under the Medicare Physician Fee Schedule and, under the current statutory formula, the rates for these services are updated
annually. For the past several years, the application of the statutory formula would have resulted in substantial payment reductions if Congress failed to intervene. In the past,
Congress passed interim legislation to prevent the decreases. On April 16, 2015, President Obama signed the Medicare and CHIP Reauthorization Act (“MACRA”), which had
previously been passed by both houses of Congress. MACRA repealed the provisions related to the Medicare SGR formula and implements a new physician payment system
that is designed to reward the quality of care. In addition, it extends the current Medicare Physician Fee Schedule rates through June 2015, and then increases them by 0.5%t
for the remainder of 2015. Beginning on January 1, 2016, the rates will be increased annually by 0.5%, through 2019. For 2020 through 2025 payments will be frozen,
although payment will be adjusted to account for performance on certain quality metrics under the Merit-Based Incentive Payment Systems (“MIPS”) or to reflect physician
participation in alternative payment models (“APMs”). For 2026 and subsequent years, qualified APM participants receive an annual 0.75% update on Medicare physician
payment rates, while those not participating receive a 0.25% annual payment update, plus any applicable MIPS-based payment adjustments. At this time, it is too early to
determine how these changes may impact our business beyond 2015. It is unclear what impact, if any, MACRA will have on our business and operating results, but any
resulting decrease in payment may result in reduced demand for our services, which could adversely impact our revenues and results of operations.
On October 30, 2015, CMS issued its Final Physician Fee Schedule Rule for 2016, which set out policies that will be effective January 2016. Among those policy changes are
reductions in the payments for flow cytometry and immunohistochemistry, two types of tests that we frequently perform. CMS has also stated that certain of these same tests
may be considered "misvalued" which means they could be subject to additional scrutiny in the future. At this time, we are still assessing the potential impact of these
changes.
In addition, many of the Current Procedure Terminology (“CPT”) procedure codes that we use to bill our tests were revised by the AMA, effective January 1, 2013. In the
Final Physician Fee Schedule Rule for 2013, CMS announced that it has decided to keep the new molecular codes on the CLFS, rather than move them to the Medicare
Physician Fee Schedule as some stakeholders had urged. CMS also announced that for 2013 it would price the new codes using a "gapfilling" process by which it will refer the
codes to the Medicare contractors to allow them to determine an appropriate price. Those prices were determined and became effective January 1, 2014. In addition, CMS also
stated that it would not recognize certain of the new codes for Multi-Analyte Assays with Algorithmic Assays (“MAAAs”) because it does not believe they qualify as clinical
laboratory tests. However, more recently, it has determined that the individual contractors may determine whether to pay for MAAA tests on a case by case basis. On
September 25, 2015, CMS released its Preliminary Determinations for new CPT codes effective in 2016, including several new MAAA CPT codes. CMS had proposed
"crosswalking" these codes to an unrelated test, resulting in a significant cut in their reimbursement. However, on November 17, 2015, CMS reversed its policy and directed
that the tests be gapfilled by the local contracts. It is expected that when PAMA is fully implemented, many of the MAAA codes will be considered and reimbursed as
Advanced Diagnostic Laboratory Tests (“ADLTs”). There can be no guarantees that Medicare and other payors will establish positive or adequate coverage policies or
reimbursement rates.
We cannot predict whether future health care initiatives will be implemented at the federal or state level, or how any future legislation or regulation may affect us. The taxes
imposed by the new federal legislation and the expansion of government's role in the U.S. health care industry as well as changes to the reimbursement amounts paid by
payors for our products or our medical procedure volumes may reduce our profits and have a materially adverse effect on our business, financial condition, results of
operations and cash flows. Moreover, Congress has proposed on several occasions to impose a 20% coinsurance on patients for clinical laboratory tests reimbursed under the
CLFS, which would require us to bill patients for these amounts. Because of the relatively low reimbursement for many clinical laboratory tests, in the event that Congress
were to ever enact such legislation, the cost of billing and collecting for these services would often exceed the amount actually received from the patient and effectively
increase our costs of billing and collecting.
We depend on Medicare and a limited number of private payors for a significant portion of our revenues and if these or other payors stop providing reimbursement or
decrease the amount of reimbursement for our tests, our revenues could decline.
For the year ended December 31, 2015, we derived approximately 12% of our total revenue from private insurance, including managed care organizations and other health care
insurance providers, 10% from Medicare and 9% from other health care facilities billed directly. Medicare and other third-party payors may withdraw their coverage policies or
cancel their contracts with us at any time, review and adjust the rate of reimbursement or stop paying for our tests altogether, which would reduce our total revenues.
41
Table of Contents
Payors have increased their efforts to control the cost, utilization and delivery of health care services. In the past, measures have been undertaken to reduce payment rates for
and decrease utilization of the clinical laboratory industry generally. Because of the cost-trimming trends, third-party payors that currently cover and provide reimbursement
for our tests may suspend, revoke or discontinue coverage at any time, or may reduce the reimbursement rates payable to us. Any such action could have a negative impact on
our revenues, which may have a material adverse effect on our financial condition, results of operations and cash flows.
In addition, we are currently considered a “non-contracting provider” by a number of private third-party payors because we have not entered into a specific contract to provide
our specialized diagnostic services to their insured patients at specified rates of reimbursement. If we were to become a contracting provider in the future, the amount of overall
reimbursement we receive is likely to decrease because we will be reimbursed less money per test performed at a contracted rate than at a non-contracted rate, which could
have a negative impact on our revenues. Further, we typically are unable to collect payments from patients beyond that which is paid by their insurance and will continue to
experience lost revenue as a result.
Because of certain Medicare billing rules, we may not receive reimbursement for all tests provided to Medicare patients.
Under current Medicare billing rules, claims for our tests performed on Medicare beneficiaries who were hospital inpatients when the tumor tissue samples were obtained and
whose tests were ordered less than 14 days from discharge must be incorporated in the payment that the hospital receives for the inpatient services provided. Accordingly, we
must bill individual hospitals for tests performed on Medicare beneficiaries during these timeframes in order to receive payment for our tests. Because we generally do not
have a written agreement in place with these hospitals that purchase these tests, we may not be paid for our tests or may have to pursue payment from the hospital on a case-
by-case basis. In addition, until 2012, we were permitted to bill globally for certain anatomic pathology services we furnished to certain hospitals, i.e. we billed both the
technical component and the professional component to Medicare. As part of the Middle Class Tax Relief and Job Creation Act of 2012, Congress terminated the special
provision for "grandfathered" hospitals as of July 1, 2012. Therefore, as of that date we were required to bill all hospitals for the technical component of all anatomic pathology
services we furnish to their patients, which may be difficult and/or costly for us.
Further, the Medicare Administrative Contractors who process claims for Medicare also can impose their own rules related to coverage and payment for laboratory services
provided in their jurisdiction. Recently, Palmetto GBA, the Medicare Administrative Contractor for North Carolina, South Carolina, Virginia and West Virginia, announced a
comprehensive new billing policy and a coverage policy applicable to molecular diagnostic tests, such as ours. Under coverage policy, Palmetto will deny payment for
molecular diagnostic tests, unless it has issued a positive coverage determination for the test. Other Medicare contractors are also adopting policies similar to Palmetto's. If any
of our tests are subject to the Palmetto policy and/or the Palmetto policy is adopted by other contractors that process claims with hospitals or laboratories that purchase and bill
for our tests, our business could be adversely impacted.
Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial
penalties.
We are subject to CLIA, a federal law regulating clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the
diagnosis, prevention or treatment of disease. Our clinical laboratory must be certified under CLIA in order for us to perform testing on human specimens. In addition, our
proprietary tests must also be recognized as part of our accredited programs under CLIA so that we can offer them in our laboratory. CLIA is intended to ensure the quality and
reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiency
testing, patient test management, quality control, quality assurance and inspections. We have a current certificate under CLIA to perform high complexity testing and our
laboratory is accredited by CAP, one of six CLIA-approved accreditation organizations. To renew this certificate, we are subject to survey and inspection every two years.
Moreover, CLIA inspectors may make periodic inspections of our clinical reference laboratory outside of the renewal process.
The law also requires us to maintain a state laboratory license to conduct testing in that state. Our laboratory is located in New Jersey and must have a New Jersey state license;
as we expand our geographic focus, we may need to obtain laboratory licenses from additional states. New Jersey laws establish standards for day-to-day operation of our
clinical reference laboratory, including the training and skills required of personnel and quality control. In addition, several other states require that we hold licenses to test
specimens from patients in those states. Other states may have similar requirements or may adopt similar requirements in the future. Finally, we may be subject to regulation in
foreign jurisdictions as we seek to expand international distribution of our tests.
42
Table of Contents
If we were to lose our CLIA certification, CAP accreditation or New Jersey laboratory license, whether as a result of a revocation, suspension or limitation, we would no
longer be able to offer our tests, which would limit our revenues and harm our business. If we were to lose our license in other states where we are required to hold licenses, we
would not be able to test specimens from those states.
If FDA were to begin requiring approval or clearance of our tests, we could incur substantial costs and time delays associated with meeting requirements for pre-market
clearance or approval or we could experience decreased demand for, or reimbursement of, our tests.
Although FDA maintains that it has authority to regulate the development and use of LDTs, such as ours, as medical devices, it has not exercised its authority with respect to
most LDTs as a matter of enforcement discretion. FDA does not generally extend its enforcement discretion to reagents or software provided by third parties and used to
perform LDTs, and therefore these products must typically comply with FDA medical device regulations, which are wide-ranging and govern, among other things: product
design and development, product testing, product labeling, product storage, pre-market clearance or approval, advertising and promotion and product sales and distribution.
We believe that our proprietary tests, as utilized in our laboratory testing, are LDTs. As a result, we believe that pursuant to FDA's current policies and guidance that FDA does
not require that we obtain regulatory clearances or approvals for our LDTs. The container we provide for collection and transport of tumor samples from a pathology
laboratory to our clinical reference laboratory may be a medical device subject to FDA's enforcement of its medical device regulations but we believe it is currently exempt
from pre-market review by FDA. While we believe that we are currently in material compliance with applicable laws and regulations, we cannot assure you that FDA or other
regulatory agencies would agree with our determination, and a determination that we have violated these laws, or a public announcement that we are being investigated for
possible violations of these laws, could adversely affect our business, prospects, results of operations or financial condition.
Moreover, FDA guidance and policy pertaining to diagnostic testing is continuing to evolve and is subject to ongoing review and revision. A significant change in any of the
laws, regulations or policies may require us to change our business model in order to maintain regulatory compliance. At various times since 2006, FDA has issued guidance
documents or announced draft guidance regarding initiatives that may require varying levels of FDA oversight of our tests. For example, in June 2010, FDA announced a
public meeting to discuss the agency's oversight of LDTs prompted by the increased complexity of LDTs and their increasingly important role in clinical decision-making and
disease management, particularly in the context of personalized medicine. FDA indicated that it was considering a risk-based application of oversight to LDTs and that,
following public input and discussion, it might issue separate draft guidance on the regulation of LDTs, which ultimately could require that we seek and obtain either pre-
market clearance or approval of LDTs, depending upon the risk-based approach FDA adopts. The public meeting was held in July 2010 and further public comments were
submitted to FDA through September 2010. Section 1143 of the Food and Drug Administration Safety and Innovation Act, signed by the U.S. President on July 9, 2012,
required FDA to notify U.S. Congress at least 60 days prior to issuing a draft or final guidance regulating LDTs and provide details of the anticipated action.
On July 31, 2014, FDA notified Congress pursuant to the FDASIA that it intended to issue draft Guidances that would modify its policy of enforcement discretion with respect
to LDTs and begin to enforce the applicable medical device regulations with respect to such products and tests. On October 3, 2014, the FDA issued two separate draft
guidances: “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)” (“The Framework Draft Guidance”) and “FDA Notification and Medical Device
Reporting for Laboratory Developed Tests” (the “Notification Draft Guidance”). In the Framework Draft Guidance, FDA states that after the Guidances are finalized, it will
no longer exercise enforcement discretion with respect to LDTs and will, instead, regulate them in a risk-based manner consistent with the existing classification of medical
devices. Thus, the FDA plans to begin to enforce its medical device requirements, including premarket submission requirements, on LDTs that have historically been marketed
without FDA premarket review and oversight. Comments on the Draft Guidances were due on February 2 and those comments are now being considered by the FDA. It is not
known when the FDA may issue final Guidances or what form those Guidances may take.
The Framework Draft Guidance states that within six months after the Guidances are finalized, all laboratories will be required to give notice to the FDA and provide basic
information concerning the nature of the LDTs offered. The FDA will then begin a phased review of the LDTs available, based on the risk associated with the test. For the
highest risk LDTs, which the FDA classifies as Class III devices, the Framework Draft Guidance states that the FDA will begin to require premarket review within 12 months
after the Guidance is finalized. Other high risk LDTs will be reviewed over the next four years and then lower risk tests, which will be classified as Class II, will be reviewed in
the following four to nine years. The Framework Draft Guidance states that FDA expects to issue a separate Guidance describing the criteria for its risk-based classification 18-
24 months after the Guidances are finalized. At this time, we cannot predict how our tests would be classified.
43
Table of Contents
If the FDA regulates LDTs as proposed, then it would classify LDTs according to the current system used to regulate medical devices. Under that system, there are three
different classes of medical devices, with the requirements becoming more stringent depending on the Class.
If and when the Guidances are finalized, and the FDA begins to actively enforce its premarket submission regulations with respect to LDTs, we will be required to obtain
premarket clearance for our tests under Section 510(k) of the FDCA or approval of a PMA, unless an exemption applies. The premarket review process may require that we
conduct clinical trials in support of a 510(k) submission or PMA application. These trials generally require an effective Investigational Device Exemption, or IDE, from FDA
for a specified number of patients, unless the product is exempt from IDE requirements or deemed a non-significant risk device eligible for more abbreviated IDE
requirements. The IDE application must be supported by appropriate data, such as animal and laboratory testing results. Clinical trials may begin 30 days after the submission
of the IDE application unless FDA or the appropriate institutional review boards at the clinical trial sites place the trial on clinical hold.
The process for submitting a 510(k) premarket notification and receiving FDA clearance usually takes from three to twelve months, but it can take significantly longer and
clearance is never guaranteed. The process for submitting and obtaining FDA approval of a PMA is much more costly, lengthy and uncertain. It generally takes from one to
three years or even longer and approval is not guaranteed. PMA approval typically requires extensive clinical data and can be significantly longer, more expensive and more
uncertain than the 510(k) clearance process. Despite the time, effort and expense expended, there can be no assurance that a particular test ultimately will be cleared or
approved by the FDA through either the 510(k) clearance process or the PMA process on a timely basis, or at all.
Under the Guidances, we could also for the first time be subject to enforcement of other regulatory requirements applicable to medical devices. For example, our currently-
marketed LDTs would be subject to the above pre-market requirements, as well as significant post-market requirements. After a device is placed on the market, regardless of
the classification or pre-market pathway, it remains subject to significant regulatory requirements. Even if regulatory approval or clearance of a medical device is granted, FDA
may impose limitations or restrictions on the uses and indications for which the device may be labeled and promoted. Medical devices may be marketed only for the uses and
indications for which they are cleared or approved.
Device manufacturers must also comply with the FDA's registration and device listing requirements. A medical device manufacturer's manufacturing processes and those of its
suppliers are required to comply with the applicable portions of the Quality Systems Regulation, which covers the methods and documentation of the design, testing,
production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to
periodic unscheduled inspections by FDA. FDA also may inspect foreign facilities that export products to the United States.
Failure to comply with applicable regulatory requirements can result in enforcement action by FDA, which may include any of the following sanctions: warning letters, fines,
injunctions, civil or criminal penalties, recall or seizure of current or future products, operating restrictions, partial suspension or total shutdown of production, denial of 510(k)
clearance or PMA applications for new products, or challenges to or withdrawal of existing 510(k) clearances or PMA applications. In addition, FDA could publicly issue a
safety notice related to our test or request updates to our product labeling, including the addition of warnings, precautions or contraindications.
We cannot provide any assurance that FDA regulation, including pre-market review, will not be required in the future for our tests, whether through additional guidance issued
by FDA, new enforcement policies adopted by FDA or new legislation enacted by Congress. We believe it is possible that legislation will be enacted into law or guidance
could be issued by FDA, which may result in increased regulatory burdens for us to continue to offer our tests or to develop and introduce new tests. Given the attention
Congress continues to give to these issues, legislation affecting this area may be enacted into law and may result in increased regulatory burdens on us as we continue to offer
our tests and to develop and introduce new tests.
In addition, the Secretary of the Department of Health and Human Services requested that its Advisory Committee on Genetics, Health and Society make recommendations
about the oversight of genetic testing. A final report was published in April 2008. If the report's recommendations for increased oversight of genetic testing were to result in
further regulatory burdens, they could negatively affect our business and delay the commercialization of tests in development.
The requirement of pre-market review could negatively affect our business until such review is completed and clearance or approval to market is obtained. FDA could require
that we stop selling our tests pending pre-market clearance or approval. If FDA allows our tests to remain on the market but there is uncertainty about our tests, if they are
labeled investigational by FDA or if labeling claims FDA allows us to make are very limited, orders or reimbursement may decline. The regulatory approval
44
Table of Contents
process may involve, among other things, successfully completing additional clinical trials and making a 510(k) submission, or filing a PMA application with FDA. If FDA
requires pre-market review, our tests may not be cleared or approved on a timely basis, if at all. We may also decide voluntarily to pursue FDA pre-market review of our tests
if we determine that doing so would be appropriate.
Additionally, should future regulatory actions affect any of the reagents we obtain from vendors and use in conducting our tests, our business could be adversely affected in the
form of increased costs of testing or delays, limits or prohibitions on the purchase of reagents necessary to perform our testing.
If we were required to conduct additional clinical trials prior to continuing to offer our proprietary tests or any other tests that we may develop as LDTs, those trials could
lead to delays or failure to obtain necessary regulatory approval, which could cause significant delays in commercializing any future products and harm our ability to
achieve sustained profitability.
If FDA decides to require that we obtain clearance or approvals to commercialize our proprietary tests, we may be required to conduct additional clinical testing prior to
submitting a 510(k) premarket notification or PMA application for commercial sales. In addition, as part of our long-term strategy we plan to seek FDA clearance or approval
so we can sell our proprietary tests outside our laboratory; however, we need to conduct additional clinical validation activities on our proprietary tests before we can submit
an application for FDA approval or clearance. Clinical trials must be conducted in compliance with FDA regulations or FDA may take enforcement action or reject the data.
The data collected from these clinical trials may ultimately be used to support market clearance or approval for our tests. Once commenced, we believe it would likely take two
years or more to conduct the studies and trials necessary to obtain clearance or approval from FDA to commercially launch any of our proprietary microarrays outside of our
clinical laboratory. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our test claims or that FDA or foreign authorities
will agree with our conclusions regarding our test results. Success in early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that
the later trials will replicate the results of prior trials and studies. If we are required to conduct clinical trials, whether using prospectively acquired samples or archival
samples, delays in the commencement or completion of clinical testing could significantly increase our test development costs, delay commercialization, and interrupt sales of
our current products and tests. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or
denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors,
including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial. Moreover, the
clinical trial process may fail to demonstrate that our tests are effective for the proposed indicated uses, which could cause us to abandon a test candidate and may delay
development of other tests.
We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the
cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials properly. If these
parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated. Many of
these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are delays
in testing or approvals as a result of the failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory
clearance or approval for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes
would harm our ability to market our tests or to achieve sustained profitability.
We are subject to federal and state health care fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.
We are subject to health care fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business. These health care
laws and regulations include, for example:
•
•
the federal Anti-kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or
indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may
be made under a federal health care program such as the Medicare and Medicaid programs;
the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to
providers of "designated health services" with whom the physician or a
45
Table of Contents
•
•
•
•
member of the physician's immediate family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies;
HIPAA, which established federal crimes for knowingly and willfully executing a scheme to defraud any health care benefit program or making false statements in
connection with the delivery of or payment for health care benefits, items or services;
the federal civil monetary penalties law, which prohibits, among other things, offering or transferring remuneration, including waivers of co-payments and deductible
amounts (or any part thereof), to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary's decision to order or
receive items or services reimbursable by the government from a particular provider or supplier;
federal false claims laws, which, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from
Medicare, Medicaid, or other third-party payors that are false or fraudulent; and
state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-
party payor, including commercial insurers.
Further, the PPACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes. A person or entity no longer needs
to have actual knowledge of this statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation
of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the false claims statutes.
The PPACA, among other things, also imposed new reporting requirements on manufacturers of certain devices, drugs and biologics for certain payments and transfers of
value by them and in some cases their distributors to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate
family members. Failure to submit required information timely, completely and accurately for all payments, transfers of value and ownership or investment interests may result
in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1.0 million per year for “knowing failures”). Manufacturers must submit
reports by the 90th day of each calendar year. Any failure to comply with these reporting requirements could result in significant fines and penalties. Because we manufacture
our own LDTs solely for use by or within our own laboratory, we believe that we are exempt from these reporting requirements. We cannot assure you, however, that the
government will agree with our determination, and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated
for possible violations, could adversely affect our business, prospects, results of operations or financial condition.
We have adopted policies and procedures designed to comply with these laws, including policies and procedures relating to financial arrangements between us and physicians
who refer patients to us. In the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance is also subject to governmental
review. The government alleged that we engaged in improper billing practices in the past and we may be the subject of such allegations in the future as the growth of our
business and sales organization may increase the potential of violating these laws or our internal policies and procedures. The risk of our being found in violation of these laws
and regulations is further increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a
variety of interpretations.
Any action brought against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert
our management's attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any
applicable penalty associated with the violation, including civil and criminal penalties, damages and fines, and/or exclusion from participation in Medicare, Medi-Cal or other
state or federal health care programs, we could be required to refund payments received by us, and we could be required to curtail or cease our operations. Any of the
foregoing consequences could seriously harm our business and our financial results.
We are required to comply with laws governing the transmission, security and privacy of health information that require significant compliance costs, and any failure to
comply with these laws could result in material criminal and civil penalties.
Under the administrative simplification provisions of HIPAA, the U.S. Department of Health and Human Services has issued regulations which establish uniform standards
governing the conduct of certain electronic health care transactions and protecting the privacy and security of Protected Health Information used or disclosed by health care
providers and other covered entities. Three principal regulations with which we are currently required to comply have been issued in final form under HIPAA: privacy
regulations, security regulations and standards for electronic transactions.
46
Table of Contents
The privacy regulations cover the use and disclosure of Protected Health Information by health care providers. It also sets forth certain rights that an individual has with respect
to his or her Protected Health Information maintained by a health care provider, including the right to access or amend certain records containing Protected Health Information
or to request restrictions on the use or disclosure of Protected Health Information. We have implemented policies, procedures and standards in an effort to comply
appropriately with the final HIPAA security regulations, which establish requirements for safeguarding the confidentiality, integrity and availability of Protected Health
Information, which is electronically transmitted or electronically stored. The HIPAA privacy and security regulations establish a uniform federal "floor" and do not supersede
state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing Protected Health
Information. As a result, we are required to comply with both HIPAA privacy regulations and varying state privacy and security laws. Moreover, HITECH, among other
things, established certain health information security breach notification requirements. Under HIPAA, a covered entity must notify any individual "without unreasonable
delay and in no case later than 60 calendar days after discovery of the breach" if their unsecured Protected Health Information is subject to an unauthorized access, use or
disclosure. If a breach affects 500 patients or more, it must be reported to HHS and local media without unreasonable delay, and HHS will post the name of the breaching
entity on its public website. If a breach affects fewer than 500 individuals, the covered entity must log it and notify HHS at least annually.
These laws contain significant fines and other penalties for wrongful use or disclosure of Protected Health Information. We have implemented practices and procedures to
meet the requirements of the HIPAA privacy regulations and state privacy laws. In addition, we are in the process of taking necessary steps to comply with HIPAA's standards
for electronic transactions, which establish standards for common health care transactions. Given the complexity of the HIPAA, HITECH and state privacy restrictions, the
possibility that the regulations may change, and the fact that the regulations are subject to changing and potentially conflicting interpretation, our ability to comply with the
HIPAA, HITECH and state privacy requirements is uncertain and the costs of compliance are significant. To the extent that we submit electronic health care claims and
payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied.
Additionally, the costs of complying with any changes to the HIPAA, HITECH and state privacy restrictions may have a negative impact on our operations. We could be
subject to criminal penalties and civil sanctions for failing to comply with the HIPAA, HITECH and state privacy restrictions, which could result in the incurrence of
significant monetary penalties. For further discussion of HIPAA and the impact on our business, see the section entitled "Risk Factors-Risks Related to Our Business and
Strategy-Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical
information and expose us to fines, penalties, liability, and adverse effects to our business and our reputation."
Intellectual Property Risks Related to Our Business
Our rights to use technologies licensed from third parties are not within our control, and we may not be able to sell our products if we lose our existing rights or cannot
obtain new rights on reasonable terms.
Our ability to market certain of our tests and services, domestically and/or internationally, is in part derived from licenses to intellectual property which is owned by third
parties. As such, we may not be able to continue selling our tests and services if we lose our existing licensed rights or sell new tests and services if we cannot obtain such
licensed rights on reasonable terms. In particular, we currently in-license a biomarker from the National Cancer Institute used in our FHACT probe. Further, we may also need
to license other technologies to commercialize future products. As may be expected, our business may suffer if (i) these licenses terminate; (ii) if the licensors fail to abide by
the terms of the license, properly maintain the licensed intellectual property or fail to prevent infringement of such intellectual property by third parties; (iii) if the licensed
patents or other intellectual property rights are found to be invalid or (iv) if we are unable to enter into necessary licenses on reasonable terms or at all. In return for the use of
a third-party's technology, we may agree to pay the licensor royalties based on sales of our products as well as other fees. Such royalties and fees are a component of cost of
product revenues and will impact the margins on our tests.
Our collaborators may assert ownership or commercial rights to inventions we develop from our use of the biological materials they provide to us.
We rely on certain collaborators to provide us with tissue samples and biological materials that we use to develop our tests. In some cases we have written agreements with
collaborators that may require us to negotiate ownership and commercial rights with the collaborator if our use of such collaborator's materials results in an invention. Other
agreements may limit our use of those materials to research/not for profit use. In other cases, we may not have written agreements, or the written agreements we have may not
clearly deal with intellectual property rights. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a
collaborator's materials where required, or if disputes
47
Table of Contents
otherwise arise with respect to the intellectual property developed with the use of a collaborator's samples, we may be limited in our ability to capitalize on the market potential
of these inventions.
The U.S. government may have "march-in rights" to certain of our probe related intellectual property.
Because federal grant monies were used in support of the research and development activities that resulted in our two issued U.S. patents, the federal government retains what
are referred to as "march-in rights" to these patents. In particular, the National Cancer Institute and the National Institutes of Health, each of which administered grant monies
to us, technically retain the right to require us, under certain specific circumstances, to grant the U.S. government either a nonexclusive, partially exclusive, or exclusive license
to the patented invention in any field of use, upon terms that are reasonable for a particular situation. Circumstances that trigger march-in rights include, for example, failure to
take, within a reasonable time, effective steps to achieve practical application of the invention in a field of use, failure to satisfy the health and safety needs of the public, and
failure to meet requirements of public use specified by federal regulations. The National Cancer Institute and the National Institutes of Health can elect to exercise these march-
in rights on their own initiative or at the request of a third-party.
If we are unable to maintain intellectual property protection, our competitive position could be harmed.
Our ability to protect our proprietary discoveries and technologies affects our ability to compete and to achieve sustained profitability. Currently, we rely on a combination of
U.S. and foreign patents and patent applications, copyrights, trademarks and trademark applications, confidentiality or non-disclosure agreements, material transfer
agreements, licenses, work-for-hire agreements and invention assignment agreements to protect our intellectual property rights. We also maintain as trade secrets certain
company know-how and technological innovations designed to provide us with a competitive advantage in the marketplace. Currently, including both U.S. and foreign patent
applications, we have only two issued U.S. patents and twelve pending patent applications relating to various aspects of our technology. While we intend to pursue additional
patent applications, it is possible that our pending patent applications and any future applications may not result in issued patents. Even if patents are issued, third parties may
independently develop similar or competing technology that avoids our patents. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of
our trade secrets and other confidential information and technology, particularly in foreign countries where we do not have intellectual property rights.
From time to time the U.S. Supreme Court, other federal courts, the U.S. Congress or the U.S. Patent and Trademark Office (“USPTO”) may change the standards of
patentability. Any such changes could have a negative impact on our business. For instance, on October 30, 2008, the Court of Appeals for the Federal Circuit issued a
decision that methods or processes cannot be patented unless they are tied to a machine or involve a physical transformation. The U.S. Supreme Court later reversed that
decision in Bilski v. Kappos, finding that the "machine-or-transformation" test is not the only test for determining patent eligibility. The Court, however, declined to specify
how and when processes are patentable. Most recently, on March 20, 2012, in the case Mayo v. Prometheus, the U.S. Supreme Court reversed the Federal Circuit's application
of Bilski and invalidated a patent focused on a diagnostic process because the patent claim embodied a law of nature. On July 3, 2012, the USPTO issued its Interim Guidelines
for Subject Matter Eligibility Analysis of Process Claims Involving Laws of Nature in view of the Prometheus decision. It remains to be seen how these guidelines play out in
the actual prosecution of diagnostic claims. Similarly, it remains to be seen lower courts will interpret the Prometheus decision. Some aspects of our technology involve
processes that may be subject to this evolving standard, and we cannot guarantee that any of our pending process claims will be patentable as a result of such evolving
standards.
The U.S. Supreme Court's June 14, 2013 decision in Association for Molecular Pathology v. Myriad will likely have an impact on the entire biotechnology industry.
Specifically, the case involved certain of Myriad Genetics, Inc.'s U.S. patents related to the breast cancer susceptibility genes BRCA1 and BRCA2. Plaintiffs asserted that the
breast cancer genes were not patentable subject matter. The Supreme Court unanimously held that the isolated form of naturally occurring DNA molecules does not rise to the
level of patent-eligible subject matter. But the Court also held that claims directed to complementary DNA (cDNA) molecules were patent-eligible because cDNA is not
naturally occurring. The Supreme Court focused on the informational content of the isolated DNA and determined that the information contained in the isolated DNA
molecule was not markedly different from that naturally found in the human chromosome. Yet, in holding isolated cDNA molecules patent-eligible, the Court recognized the
differences between human chromosomal DNA and the corresponding cDNA. Because the non-coding regions of naturally occurring chromosomal DNA have been removed
in cDNA, the Court accepted that cDNA is not a product of nature and, therefore, is patent-eligible subject matter.
It does not appear that the Supreme Court's ruling in Myriad will adversely affect our current patent portfolio which, unlike the claims at issue in Myriad, centers on
algorithmic methods associating chromosomal markers to specific clinical end-points. Nevertheless, we of course need to remain mindful that this is an evolving area of law.
48
Table of Contents
In addition, on February 5, 2010, the Secretary's Advisory Committee on Genetics, Health and Society voted to approve a report entitled “Gene Patents and Licensing Practices
and Their Impact on Patient Access to Genetic Tests.” That report defines "patent claims on genes" broadly to include claims to isolated nucleic acid molecules as well as
methods of detecting particular sequences or mutations. The report also contains six recommendations, including the creation of an exemption from liability for infringement
of patent claims on genes for anyone making, using, ordering, offering for sale or selling a test developed under the patent for patient care purposes, or for anyone using the
patent-protected genes in the pursuit of research. The report also recommended that the Secretary should explore, identify and implement mechanisms that will encourage more
voluntary adherence to current guidelines that promote nonexclusive in-licensing of diagnostic genetic and genomic technologies. It is unclear whether the U.S. Department of
Health and Human Services will act upon these recommendations, or if the recommendations would result in a change in law or process that could negatively impact our patent
portfolio or future research and development efforts.
We may become involved in lawsuits or other proceedings to protect or enforce our patents or other intellectual property rights, which could be time-consuming and costly
to defend, and could result in our loss of significant rights and the assessment of treble damages.
From time to time we may face intellectual property infringement (or misappropriation) claims from third parties. Some of these claims may lead to litigation. The outcome of
any such litigation can never be guaranteed, and an adverse outcome could affect us negatively. For example, were a third-party to succeed on an infringement claim against
us, we may be required to pay substantial damages (including up to treble damages if such infringement were found to be willful). In addition, we could face an injunction,
barring us from conducting the allegedly infringing activity. The outcome of the litigation could require us to enter into a license agreement which may not be pursuant to
acceptable or commercially reasonable or practical terms or which may not be available at all. It is also possible that an adverse finding of infringement against us may require
us to dedicate substantial resources and time in developing non-infringing alternatives, which may or may not be possible. In the case of diagnostic tests, we would also need to
include non-infringing technologies which would require us to re-validate our tests. Any such re-validation, in addition to being costly and time consuming, may be
unsuccessful.
Furthermore, we may initiate claims to assert or defend our own intellectual property against third parties. Any intellectual property litigation, irrespective of whether we are
the plaintiff or the defendant, and regardless of the outcome, is expensive and time-consuming, and could divert our management's attention from our business and negatively
affect our operating results or financial condition. We may not be able to prevent, alone or with our collaborators, misappropriation of our proprietary rights, particularly in
countries where the laws may not protect those rights as fully as in the United States. In addition, interference proceedings brought by the USPTO may be necessary to
determine the priority of inventions with respect to our patents and patent applications or those of our current or future collaborators.
Finally, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential and proprietary
information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our financial
condition.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on our technologies in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in
some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual
property rights to the same extent as federal and state laws in the United States. For example, many foreign countries have compulsory licensing laws under which a patent
owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise
infringing products to territories where we have patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our
technologies in jurisdictions where we do not have any issued patents and our patent claims or other intellectual rights may not be effective or sufficient to prevent them from
so competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries
do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents generally.
Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could
put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
49
Table of Contents
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may
not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license.
Risks Relating to our International Operations
International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of
the United States.
Our business strategy incorporates international expansion, including our recent acquisitions which have provided us with facilities in India and China, and the possibility of
establishing and maintaining clinician marketing and education capabilities in other locations outside of the United States and expanding our relationships with distributors and
manufacturers. Doing business internationally involves a number of risks, including:
• multiple, conflicting and changing laws and regulations such as tax and transfer pricing laws, export and import restrictions, employment laws, regulatory
•
•
•
•
•
•
•
•
•
requirements and other governmental approvals, permits and licenses;
failure by us or our distributors to obtain regulatory approvals for the sale or use of our tests in various countries, including failure to achieve "CE Marking", a
conformity mark which is required to market in vitro diagnostic medical devices in the European Economic Area and which is broadly accepted in other international
markets;
difficulties in managing foreign
operations;
complexities associated with managing multiple payor-reimbursement regimes or self-pay
systems;
logistics and regulations associated with shipping tissue samples, including infrastructure conditions and transportation
delays;
limits on our ability to penetrate international markets if our diagnostic tests cannot be processed by an appropriately qualified local
laboratory;
financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to foreign currency exchange rate
fluctuations;
reduced protection for intellectual property
rights;
natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other
business restrictions; and
failure to comply with the Foreign Corrupt Practices Act, including its books and records provisions and its anti-bribery provisions, by maintaining accurate
information and control over sales and distributors' activities.
Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, have a material adverse effect on our
financial condition, results of operations and cash flows.
Our operations are subject to risks associated with emerging markets, including China and India.
Emerging markets are a significant focus of our growth strategy. The developing nature of these markets presents several risks, including deterioration of social, political,
labor, or economic conditions in a country or region, and difficulties in staffing and managing foreign operations. Perceived risks associated with investing in emerging
markets such as China and India, or a general disruption in the development of such markets could materially and adversely affect our business, operating results and financial
condition.
With the completion of the Gentris acquisition, a portion of our assets and operations are located in China and we are subject to regulatory, economic, political and other
uncertainties in China.
The Chinese government has the ability to exercise significant influence and control over our operations in China. In recent years, the Chinese government has implemented
measures for economic reform, the reduction of state ownership of productive assets and the establishment of corporate governance practices in business enterprises. However,
many productive assets in China are still owned by the Chinese government. In addition, the government continues to play a significant role in regulating industrial
development by imposing business regulations. It also exercises significant control over the country's economic growth through the allocation of resources, controlling
payment of foreign currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies.
There can be no assurance that China's economic, political or legal systems will not develop in a way that becomes detrimental to our business, results of operations and
financial condition. Our activities may be materially and adversely affected by changes
50
Table of Contents
in China's economic and social conditions and by changes in the policies of the government, such as measures to control inflation, changes in the rates or method of taxation
and the imposition of additional restrictions on currency conversion.
Additional factors that we may experience in connection with having operations in China or other foreign countries that may adversely affect our business and results of
operations include:
•
•
•
•
•
•
our inability to enforce or obtain a remedy under any material
agreements;
Chinese restrictions on foreign investment that could impair our ability to conduct our business or acquire or contract with other entities in the
future;
restrictions on currency exchange that may limit our ability to use cash flow most effectively or to repatriate our
investment;
fluctuations
values;
cultural, language and managerial differences that may reduce our overall performance;
and
political
instability.
currency
in
With the completion of the BioServe acquisition a portion of our assets and operations are located in India and we are subject to regulatory, economic, political and other
uncertainties in India.
In August 2014 we acquired BioServe a leading genomic service and next-generation sequencing company founded in 2002 serving both the research and clinical markets and
based in Hyderabad, India. In the past, the Indian economy has experienced many of the problems that commonly confront the economies of developing countries, including
high inflation, erratic gross domestic product growth and shortages of foreign exchange. The Indian government has exercised, and continues to exercise, significant influence
over many aspects of the Indian economy through the allocation of resources, controlling payment of foreign currency-denominated obligations, setting monetary policy and
providing preferential treatment to particular industries, and Indian government actions concerning the economy could have a material adverse effect on private sector entities
like us.
India has experienced significant economic growth over the last several years, but faces major challenges in sustaining that growth in the years ahead. These challenges
include the need for substantial infrastructure development. India has also recently experienced civil unrest and terrorism and has been involved in conflicts with neighboring
countries. In recent years, there have been military confrontations between India and Pakistan that have occurred in the region of Kashmir and along the India-Pakistan border.
If India becomes engaged in armed hostilities, particularly if these hostilities are protracted or involve the threat of or use of weapons of mass destruction, it is likely that our
operations would be materially adversely affected.
Our financial performance may be adversely affected by general economic conditions and economic and fiscal policy in India, including changes in exchange rates and
controls, interest rates and taxation policies, as well as social stability and political, economic or diplomatic developments affecting India in the future.
Some of our contract manufacturers and distributors are located outside of the United States, which may subject us to increased complexity and costs.
We rely on manufacturing facilities located outside the United States for our FHACT probes, particularly in India. We also utilize distributors to sell FHACT probes outside
the United States. Our FHACT probe manufacturing and international sales may be subject to certain risks, including:
•
•
•
•
•
•
•
•
•
•
difficulty in obtaining, maintaining or enforcing intellectual property rights in some
countries;
local business and cultural factors that differ from our normal standards and
practices;
foreign currency exchange
fluctuations;
different regulatory
requirements;
impediments to the flow of foreign exchange capital payments and receipts due to exchange controls instituted by certain foreign governments and the fact that local
currencies of some countries are not freely convertible;
geopolitical and economic instability and military
conflicts;
difficulties in managing international
distributors;
burdens of complying with a variety of foreign laws and treaties and changes in local laws and regulations, including tax and transfer pricing
laws;
difficulty in enforcing agreements, judgments and arbitration awards in foreign jurisdictions;
and
adverse economic conditions in any
jurisdiction.
Our operating results may be adversely affected by fluctuations in foreign currency exchange rates and restrictions on the deployment of cash across our global
operations.
51
Table of Contents
Although we report our operating results in U.S. dollars, a portion of our revenues and expenses are or will be denominated in currencies other than the U.S. dollar.
Fluctuations in foreign currency exchange rates can have a number of adverse effects on us. Because our consolidated financial statements are presented in U.S. dollars, we
must translate revenues, expenses and income, as well as assets and liabilities, into U.S. dollars at exchange rates in effect during or at the end of each reporting period.
Therefore, changes in the value of the U.S. dollar against other currencies will affect our revenues, income from operations, other income (expense), net and the value of
balance sheet items originally denominated in other currencies. There is no guarantee that our financial results will not be adversely affected by currency exchange rate
fluctuations. In addition, in some countries we could be subject to strict restrictions on the movement of cash and the exchange of foreign currencies, which could limit our
ability to use these funds across our global operations.
We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and other worldwide anti-bribery laws.
The FCPA and anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or
retaining business or other commercial advantage. Our policies mandate compliance with these anti-bribery laws, which often carry substantial penalties, including criminal
and civil fines, potential loss of export licenses, possible suspension of the ability to do business with the federal government, denial of government reimbursement for
products and exclusion from participation in government health care programs. We operate in jurisdictions such as India and China that have experienced governmental and
private sector corruption to some degree, and, in certain circumstances, strict compliance with anti-bribery laws may conflict with certain local customs and practices. We
cannot assure that our internal control policies and procedures always will protect us from reckless or other inappropriate acts committed by our affiliates, employees or
agents. Violations of these laws, or allegations of such violations, could have a material adverse effect on our business, financial position and results of operations.
Risks Relating to Our Common Stock
There has been a limited trading market for our common stock.
We received approval to list our common stock on The NASDAQ Capital Market in August 2013. No assurance can be given that an active trading market will be sustained.
A lack of an active market may impair the ability of our stockholders to sell shares at the time they wish to sell them or at a price that they consider reasonable. The lack of an
active market may also reduce the fair market value of our shares. An inactive market may also impair our ability to raise capital by selling shares of capital stock and may
impair our ability to acquire other companies or technologies by using our common stock as consideration.
The price of our common stock may be volatile, and the market price of our common stock may decrease.
Our stock price per share may vary from time to time. Even if an active market for our stock continues, our stock price nevertheless may be volatile. Market prices for
securities of early-stage life sciences companies have historically been particularly volatile. The factors that may cause the market price of our common stock to fluctuate
include, but are not limited to:
•
•
•
•
•
•
•
•
•
•
•
•
progress, or lack of progress, in developing and commercializing our proprietary
tests;
favorable or unfavorable decisions about our tests or services from government regulators, insurance companies or other third-party
payors;
our ability to recruit and retain qualified regulatory and research and development
personnel;
changes in investors' and securities analysts' perception of the business risks and conditions of our
business;
changes in our relationship with key
collaborators;
changes in the market valuation or earnings of our competitors or companies viewed as similar to
us;
changes in key
personnel;
depth of the trading market in our common
stock;
changes in our capital structure, such as future issuances of securities or the incurrence of additional
debt;
the granting or exercise of employee stock options or other equity
awards;
realization of any of the risks described under this section titled “Risk Factors”;
and
general market and economic
conditions.
In addition, the equity markets have experienced significant price and volume fluctuations that have affected the market prices for the securities of newly public companies for
a number of reasons, including reasons that may be unrelated to our business or operating performance. These broad market fluctuations may result in a material decline in the
market price of our common
52
Table of Contents
stock and you may not be able to sell your shares at prices you deem acceptable. In the past, following periods of volatility in the equity markets, securities class action
lawsuits have been instituted against public companies. Such litigation, if instituted against us, could result in substantial cost and the diversion of management attention.
Our stockholders may be diluted by exercises of outstanding options and warrants.
As of December 31, 2015, we had outstanding options to purchase an aggregate of 1,960,929 shares of our common stock at a weighted average exercise price of $10.55 per
share and warrants to purchase an aggregate of 4,431,925 shares of our common stock at a weighted average exercise price of $6.78 per share. The exercise of such outstanding
options and warrants will result in dilution of the value of our shares.
Reports published by securities or industry analysts, including projections in those reports that exceed our actual results, could adversely affect our common stock price
and trading volume.
Securities research analysts, including those affiliated with our underwriters, establish and publish their own periodic projections for our business. These projections may vary
widely from one another and may not accurately predict the results we actually achieve. Our stock price may decline if our actual results do not match securities research
analysts' projections. Similarly, if one or more of the analysts who writes reports on us downgrades our stock or publishes inaccurate or unfavorable research about our
business, our stock price could decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, our stock price or trading
volume could decline. While we expect securities research analyst coverage, if no securities or industry analysts begin to cover us, the trading price for our stock and the
trading volume could be adversely affected.
Our directors and executive officers have substantial influence over us and could delay or prevent a change in corporate control.
Our directors and executive officers, together with their affiliates, in the aggregate beneficially own approximately 25.2% of our outstanding common stock, based on the
number of shares outstanding on December 31, 2015. These stockholders, acting together, have significant influence over the outcome of matters submitted to our stockholders
for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. In addition, these stockholders, acting together,
have significant influence over our management and affairs. Accordingly, this concentration of ownership might harm the market price of our common stock by:
•
•
•
delaying, deferring or preventing a change in
control;
impeding a merger, consolidation, takeover or other business combination involving us;
or
discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of
us.
We are an “emerging growth company,” and any decision on our part to comply only with certain reduced disclosure requirements applicable to “emerging growth
companies” could make our common stock less attractive to investors.
We are an “emerging growth company,” as defined in the JOBS Act, and, for as long as we continue to be an “emerging growth company,” we intend to take advantage of
exemptions from various reporting requirements applicable to other public companies but not to “emerging growth companies,” including, but not limited to, not being required
to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as discussed below, reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earliest of (i) the last day of the fiscal
year in which we have total annual gross revenue of $1.0 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our
initial public offering; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; and (iv) the date on which we are
deemed to be a large accelerated filer under the rules of the SEC. We have irrevocably chosen to "opt out" of the extended transition periods available under the JOBS Act for
complying with new or revised accounting standards. We intend to take advantage of certain exemptions from various reporting requirements including, but not limited to,
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved, and if we do take advantage of these
exemptions, we cannot predict if investors will find our common stock less attractive as a result. If some investors find our common stock less attractive as a result of any
choices to take advantage of these reduced disclosure obligations, there may be a less active trading market for our common stock and our stock price may be more volatile.
53
Table of Contents
We are incurring significantly increased costs and devote substantial management time as a result of operating as a public company particularly after we are no longer an
“emerging growth company.”
As a public company and particularly after we cease to be an “emerging growth company,” we are incurring significant legal, accounting and other expenses that we did not
incur as a private company and which may increase after we are no longer an "emerging growth company." For example, in addition to being required to comply with certain
requirements of the Sarbanes-Oxley Act of 2002, we will be required to comply with certain requirements of the Dodd Frank Wall Street Reform and Consumer Protection
Act, as well as rules and regulations subsequently implemented by the SEC, including the establishment and maintenance of effective disclosure and financial controls and
changes in corporate governance practices. We expect that compliance with these requirements will increase our legal and financial compliance costs and will make some
activities more time consuming and costly. In addition, we expect that our management and other personnel will need to divert attention from operational and other business
matters to devote substantial time to these public company requirements.
The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular,
we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal
control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. In addition, after we are no longer an “emerging growth company,” we will be required
to have our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting. Our compliance with Section 404 of the
Sarbanes-Oxley Act, as applicable, requires us to incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit
group, and we will need to continue to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. If we or
our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market
price of our stock could decline and we could be subject to sanctions or investigations by the NASDAQ, the SEC or other regulatory authorities, which would require
additional financial and management resources.
Our ability to successfully implement our business plan and comply with Section 404, as applicable, requires us to be able to prepare timely and accurate financial statements.
We expect that we will need to continue to improve existing, and implement new operational and financial systems, procedures and controls to manage our business
effectively. Any delay in the implementation of, or disruption in the transition to, new or enhanced systems, procedures or controls, may cause our operations to suffer and we
may be unable to conclude that our internal control over financial reporting is effective and to obtain an unqualified report on internal controls from our auditors as required
under Section 404 of the Sarbanes-Oxley Act. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our
financial results, and current and potential stockholders may lose confidence in our financial reporting. This, in turn, could have an adverse impact on trading prices for our
common stock, and could adversely affect our ability to access the capital markets.
Anti-takeover provisions of our certificate of incorporation, our bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board and management.
Certain provisions of our amended and restated certificate of incorporation and bylaws could discourage, delay or prevent a merger, acquisition or other change of control that
stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Furthermore, these provisions could prevent or
frustrate attempts by our stockholders to replace or remove members of our board of directors. These provisions also could limit the price that investors might be willing to pay
in the future for our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the
opportunity to do so. These provisions, among other things:
•
•
•
•
allow the authorized number of directors to be changed only by resolution of our board of
directors;
authorize our board of directors to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of the board of
directors and that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our board of
directors does not approve;
establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings;
and
limit who may call a stockholder
meeting.
54
Table of Contents
In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which may, unless certain criteria are met, prohibit large
stockholders, in particular those owning 15% or more of the voting rights on our common stock, from merging or combining with us for a prescribed period of time.
Because we do not expect to pay cash dividends for the foreseeable future, you must rely on appreciation of our common stock price for any return on your investment.
Even if we change that policy, we may be restricted from paying dividends on our common stock.
We do not intend to pay cash dividends on shares of our common stock for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of
our board of directors and will depend upon results of operations, financial performance, contractual restrictions, restrictions imposed by applicable law and other factors our
board of directors deems relevant. Accordingly, you will have to rely on capital appreciation, if any, to earn a return on your investment in our common stock. Investors
seeking cash dividends in the foreseeable future should not purchase our common stock.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
Our ability to utilize our federal net operating loss, carryforwards and federal tax credits are limited under Sections 382 and 383 of the Internal Revenue Code of 1986, as
amended. The limitations apply since we have experienced an “ownership change,” as defined by Section 382, as a result of the Company's securities offerings. Generally, an
ownership change occurs if the percentage of the value of the stock that is owned by one or more direct or indirect “five percent shareholders” changes by more than
50 percentage points over their lowest ownership percentage at any time during the applicable testing period (typically three years). Since we have experienced an “ownership
change”, our NOL carryforwards and federal tax credits are subject to limitations as to our ability to utilize them to offset taxable income and related income taxes. In addition,
future changes in our stock ownership, which may be outside of our control, may trigger further “ownership changes” which would further limit their utilization. As a result, if
we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and other tax attributes to offset United States federal taxable income and
related income taxes are subject to limitations, which could potentially result in increased future tax liability to us.
Our failure to meet the continued listing requirements of The NASDAQ Capital Market could result in a de-listing of our common stock.
If we fail to satisfy the continued listing requirements of The NASDAQ Capital Market, such as the corporate governance requirements or the minimum closing bid price
requirement, NASDAQ may take steps to de-list our common stock. Such a de-listing would likely have a negative effect on the price of our common stock and would impair
your ability to sell or purchase our common stock when you wish to do so. In the event of a de-listing, we would take actions to restore our compliance with NASDAQ's listing
requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve
the liquidity of our common stock, prevent our common stock from dropping below the NASDAQ minimum bid price requirement or prevent future non-compliance with
NASDAQ listing requirements.
Item 1B.
Unresolved Staff Comments
None.
Item 2.
Properties
As of December 31, 2015, we had a lease for approximately 17,900 square feet of office and laboratory space in Rutherford, New Jersey, 24,900 square feet of laboratory space
located in Research Triangle Park (RTP) in Morrisville, North Carolina, 10,000 square feet of laboratory space in Hyderabad, India, 2,700 square feet of laboratory space in
Shanghai, China and approximately 27,000 square feet of laboratory space in Los Angeles, California. We have escalating lease agreements for both our New Jersey and North
Carolina spaces which expire February 2018 and May 2020 respectively. We also have a lease agreement for our California space which expires on June 30, 2016. We
currently are negotiating an extension of our California lease.
55
Table of Contents
Item 3.
Legal Proceedings
In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. We are not party to any legal proceedings or aware of
any threatened legal proceedings which are expected to have a material adverse effect on our financial condition, results of operations or liquidity.
Item 4.
Mine Safety Disclosures
Not applicable.
56
Table of Contents
PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
The following table sets forth, for the periods indicated, the reported high and low sales prices of our common stock on The NASDAQ Capital Market.
4th Quarter 2015
3rd Quarter 2015
2nd Quarter 2015
1st Quarter 2015
4th Quarter 2014
3rd Quarter 2014
2nd Quarter 2014
1st Quarter 2014
Holders
$
$
$
$
$
$
$
$
High
Low
8.51 $
12.75 $
12.22 $
9.76 $
8.95 $
11.35 $
16.55 $
20.00 $
2.75
7.57
7.57
6.55
4.83
8.36
8.54
13.50
As of December 31, 2015, we had approximately 105 holders of record of our common stock. The number of record holders was determined from the records of our transfer
agent and does not include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies. The
transfer agent of our common stock is Continental Stock Transfer & Trust, 17 Battery Place, 8th Floor, New York, New York, 10004.
Dividends
We have never declared dividends on our equity securities, and currently do not plan to declare dividends on shares of our common stock in the foreseeable future. We expect
to retain our future earnings, if any, for use in the operation and expansion of our business. Subject to the foregoing, the payment of cash dividends in the future, if any, will be
at the discretion of our board of directors and will depend upon such factors as earnings levels, capital requirements, our overall financial condition and any other factors
deemed relevant by our board of directors.
Stock Performance Graph
This graph is not "soliciting material," is not deemed "filed" with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act or the
Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
The following graph shows the total stockholder return of an investment of $100 in cash on April 5, 2013 (the first day of trading on our common stock), through December
31, 2015 for (i) our common stock, (ii) the NASDAQ Composite Index (U.S.), and (iii) NASDAQ Biotechnology Index. Pursuant to applicable SEC rules, all values assume
reinvestment of the full amount of all dividends; however, no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is
not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.
57
Table of Contents
Equity Compensation Plan Information
The following table provides information as of December 31, 2015 regarding shares of our common stock that may be issued under our existing equity compensation plans,
including our 2008 Stock Option Plan (the “2008 Plan”) and our 2011 Equity Incentive Plan (the “2011 Plan”) as well as shares issued outside of these plans.
Equity Compensation Plan Information
(a)
Number of securities
to be issued upon exercise
of outstanding options
and rights(1)
(b)
Weighted Average
exercise price of
outstanding options
and rights
(c)
Number of securities
remaining available for
future issuance under equity
compensation plan
(excluding securities
referenced in column (a))
1,924,929 $
36,000 $
1,960,929 $
10.56
10.00
10.55
964,253
(3)
—
964,253
Plan Category
Equity compensation plans approved by
security holders (2)
Equity compensation plans not approved
by security holders (4)
Total
__________________________________
(1)
(2)
(3)
(4)
Does not include any restricted stock as such shares are already reflected in our outstanding shares.
Consists of the 2008 Plan and the 2011 Plan.
Includes securities available for future issuance under the 2008 Plan and the 2011 Plan.
These options were issued to one of our current board members in connection with consulting
services.
Item 6.
Selected Financial Data.
The selected financial data set forth below as of December 31, 2015 and 2014, and for each of the years ended December 31, 2015, 2014, and 2013 has been derived from the
audited consolidated financial statements of the Company, which are included elsewhere in this Annual Report on Form 10-K. We derived the consolidated financial data for
the years ended December 31,
58
Table of Contents
2012 and 2011, and as of December 31, 2013, 2012 and 2011 from our audited consolidated financial statements that are not included elsewhere in this Annual Report on Form
10-K.
The information set forth below should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the audited
consolidated financial statements, and the notes thereto, and other financial information included herein. Our historical results are not necessarily indicative of our future
results.
Consolidated Statements of Operations Data:
Revenue
$
Cost of revenues
Gross profit (loss)
Operating expenses:
Research and development
General and administrative
Sales and marketing
Total operating expenses
Loss from operations
Other income (expense):
Interest expense
Interest income
Change in fair value of warrant liability
Change in fair value of acquisition note
payable
Loss on debt and warrant restructuring
Debt conversion costs
Total other income (expense)
Loss before income taxes
Income tax (benefit)
Net (loss)
Basic net (loss) per share
Diluted net (loss) per share
Basic weighted average shares outstanding
Diluted weighted average shares outstanding
Consolidated Balance Sheet Data:
Cash and cash equivalents
Working capital (deficit)
Total assets
Debt, excluding current portion
Accumulated deficit
Total stockholders' equity (deficit)
$
$
$
$
$
Year Ended December 31,
2015
2014
2013
2012
2011
(in thousands, expect per share data)
18,040 $
14,098
3,942
10,199 $
8,453
1,746
6,610 $
4,925
1,685
4,302 $
3,929
373
5,483
14,567
5,269
25,319
(21,377 )
(344)
49
35
269
—
—
9
(21,368 )
(1,184 )
(20,184 ) $
(1.96 ) $
(1.96 ) $
10,298
10,299
4,622
12,369
3,964
20,955
(19,209 )
(473)
74
417
198
—
—
216
(18,993 )
(2,350 )
(16,643 ) $
(1.76 ) $
(1.80 ) $
9,449
9,462
2,190
6,115
1,842
10,147
(8,462 )
(2,388 )
30
4,633
—
—
(6,850 )
(4,575 )
(13,037 )
(664)
(12,373 ) $
(2.65 ) $
(3.64 ) $
4,665
4,676
2,112
4,503
1,399
8,014
(7,641 )
(4,701 )
—
7,538
—
(1,862 )
—
975
(6,666 )
—
(6,666 ) $
(4.97 ) $
(10.55 ) $
1,342
1,346
3,019
3,117
(98)
2,074
4,439
1,574
8,087
(8,185 )
(1,314 )
—
(10,388 )
—
—
—
(11,702 )
(19,887 )
—
(19,887 )
(15.61 )
(15.61 )
1,274
1,274
2015
2014
2013
2012
2011
Year Ended December 31,
19,459 $
18,333
48,884
4,642
(98,151 )
33,017 $
(in thousands)
25,554 $
27,389
47,105
6,000
(77,967 )
34,554 $
49,460 $
43,272
55,157
—
(61,325 )
45,463 $
820 $
(9,612 )
8,952
8,441
(48,935 )
(23,981 ) $
2,417
(1,078 )
7,031
10,350
(42,269 )
(19,065 )
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
59
Table of Contents
As used herein, the “Company,” “we,” “us,” “our” or similar terms, refer to Cancer Genetics, Inc. and its wholly owned subsidiaries: Cancer Genetics Italia, S.r.l., Gentris,
LLC and BioServe Biotechnologies (India) Private Limited, except as expressly indicated or unless the context otherwise requires. The following Management’s Discussion
and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help facilitate an understanding of our financial condition and our historical results of
operations for the periods presented. This MD&A should be read in conjunction with the audited consolidated financial statements and notes thereto included in this annual
report Form10-K. This MD&A may contain forward-looking statements that involve risks and uncertainties. For a discussion on forward-looking statements, see the
information set forth in the Introductory Note to this Annual Report under the caption “Forward Looking Statements”, which information is incorporated herein by reference.
Overview
We are an emerging leader in the field of personalized medicine, enabling precision medicine in the field of oncology through our diagnostic products and services and
molecular markers. We develop, commercialize and provide molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management
of each individual patient by providing genomic information to better diagnose, monitor and inform cancer treatment and that enable biopharmaceutical companies engaged in
oncology trials to better select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to
therapeutics. We have a comprehensive, disease-focused oncology testing portfolio. Our tests and techniques target a wide range of cancers, covering eight of the top ten
cancers in prevalence in the United States, with additional unique capabilities offered by our Tissue of Origin® test for identifying difficult to diagnose tumor types or poorly
differentiated metastatic disease.
Our vision is to become the oncology diagnostics partner for biopharmaceutical companies and clinicians by participating in the entire care continuum from bench to bedside.
We believe the diagnostics industry is undergoing a rapid evolution in its approach to oncology testing, embracing precision medicine and individualized testing as a means to
drive higher standards of patient treatment and disease management. Similarly, biopharmaceutical companies are increasingly engaging companies such as ours to provide
information on clinical trial participants' molecular profiles in order to identify biomarker and genomic variations that may be responsible for differing responses to
pharmaceuticals, and particularly to oncology drugs, thereby increasing the efficiency of trials while lowering related costs. We believe tailored therapeutics can revolutionize
oncology medicine through molecular- and biomarker-based testing services, enabling physicians and researchers to target the factors that make each patient and disease
unique. We have created a unique position in the industry by providing targeted somatic analysis of tumor sample cells alongside germline analysis of an individual's non-
cancerous cells' molecular profile as we attempt to reach the next milestone in personalized medicine. Individuals are born with germline mutations, and somatic mutations
arise in tissues over the course of a lifetime.
Our services are performed at our state-of-the-art laboratories located in New Jersey, North Carolina, California, Shanghai (China), and Hyderabad, India. Our laboratories
comply with the highest regulatory standards as appropriate for the services they deliver including CLIA, CAP, NY State, California State and NABL (India). We have two
advisory boards to counsel our scientific and clinical direction. Our Scientific Advisory Board is comprised of preeminent scientists and physicians from the fields of cancer
biology, cancer pathology, cancer medicine and molecular genetics. Our Clinical Advisory Board is comprised of clinicians and scientists focused on clinical implementation
of our proprietary tests and services and mapping those tests and services to patient needs. Our services are built on a foundation of world-class scientific knowledge and
intellectual property in solid and blood-borne cancers, as well as strong academic relationships with major cancer centers such as Memorial Sloan-Kettering, Mayo Clinic, and
the National Cancer Institute.
Our clinical offerings include our portfolio of proprietary tests targeting hematological, urogenital and HPV-associated cancers, in conjunction with ancillary non-proprietary
tests. Our proprietary tests target cancers that are difficult to prognose and predict treatment outcomes through currently available mainstream techniques. We provide our
proprietary tests and services, along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services, to oncologists and pathologists at hospitals,
cancer centers, and physician offices, as well as biotech and pharmaceutical companies to support their clinical trials. Our proprietary tests are based principally on our
expertise in specific cancer types, test development methodologies and proprietary algorithms correlating genetic events with disease specific information. Our portfolio
primarily includes comparative genomic hybridization (CGH) microarrays and next generation sequencing (NGS) panels, and DNA fluorescent in situ hybridization (FISH)
probes.
The non-proprietary testing services we offer are focused in part on specific oncology categories where we are developing our proprietary tests. We believe that there is
significant synergy in developing and marketing a complete set of tests and services that are disease focused and delivering those tests and services in a comprehensive manner
to help with treatment decisions.
60
Table of Contents
The insight that we develop in delivering the non-proprietary services are often leveraged in the development of our proprietary programs and now increasingly in the
validation of our proprietary programs, such as MatBA and Focus::NGS.
We expect to continue to incur significant losses for the near future. We incurred losses of $20.2 million, $16.6 million and $12.4 million for fiscal years ended December 31,
2015, 2014 and 2013, respectively. As of December 31, 2015, we had an accumulated deficit of $98.2 million.
Acquisitions
On July 16, 2014, we purchased substantially all of the assets of Gentris Corporation, a Delaware corporation (“Gentris”), with its principal place of business in North
Carolina, for aggregate consideration of approximately $4.8 million.
On August 18, 2014, we acquired BioServe Biotechnologies (India) Private Limited, an Indian corporation (“BioServe”) for an aggregate purchase price of approximately $1.1
million.
On October 9, 2015, we acquired substantially all of the assets of Response Genetics, Inc. (“Response Genetics”) with its principal place of business in California, for
aggregate consideration of approximately $12.9 million.
Key Factors Affecting our Results of Operations and Financial Condition
Our overall long-term growth plan is predicated on our ability to develop and commercialize our proprietary tests, penetrate the Biopharma community to achieve more
revenue supporting clinical trials and develop and penetrate the Indian market. Our proprietary tests include CGH microarrays, NGS panels, and DNA FISH probes.We
continue to develop additional proprietary tests. To facilitate market adoption of our proprietary tests, we anticipate having to successfully complete additional studies with
clinical samples and publish our results in peer-reviewed scientific journals. Our ability to complete such studies is dependent upon our ability to leverage our collaborative
relationships with leading institutions to facilitate our research and obtain data for our quality assurance and test validation efforts.
We believe that the factors discussed in the following paragraphs have had and are expected to continue to have a material impact on our results of operations and financial
condition.
Revenues
Our revenue is primarily generated through our Clinical Services and Biopharma Services. Clinical Services can be billed to Medicare, another third party insurer or the
referring community hospital or other healthcare facility in accordance with state and federal law. Biopharma Services are billed to the customer directly. While we have
agreements with our Biopharma clients, volumes from these clients are subject to the progression and continuation of the trials which can impact testing volume. We also
derive limited revenue from Discovery Services, which are services provided in the development of new testing assays and methods. Discovery Services are billed directly to
the customer.
We have historically derived a significant portion of our revenue from a limited number of test ordering sites, although the test ordering sites that generate a significant portion
of our revenue have changed from period to period. Test ordering sites account for all of our Clinical Services revenue along with a portion of the Biopharma Services
revenue. Our test ordering sites are hospitals, cancer centers, reference laboratories, physician offices and biopharmaceutical companies. Oncologists and pathologists at these
sites order the tests on behalf of the needs of their oncology patients or as part of a clinical trial sponsored by a biopharmaceutical company in which the patient is being
enrolled.
The top five test ordering clients during 2015 and 2014 accounted for 49% and 56%, respectively, of our testing volumes, with 18% and 38%, respectively, of the test volume
coming from community hospitals. During the year ended December 31, 2015, one Biopharma client accounted for approximately 19% of our revenue. During the year ended
December 31, 2014 there were two Biopharma clients that accounted for approximately 23% and 12%, respectively, of our revenue. The loss of our largest client would
materially adversely affect our results of operations, however the loss of any other test ordering client would not materially adversely affect our results of operations.
We receive revenue for our Clinical Services from Medicare, other insurance carriers and other healthcare facilities. Some of our customers choose, generally at the beginning
of our relationship, to pay for laboratory services directly as opposed to having patients (or their insurers) pay for those services and providing us with the patients’ insurance
information. A hospital may elect to be a direct bill customer and pay our bills directly, or may provide us with patient information so that their patients pay our bills, in which
case we generally expect payment from their private insurance carrier or Medicare. In a few instances,
61
Table of Contents
we have arrangements where a hospital may have two accounts with us, so that certain tests are billed directly to the hospital, and certain tests are billed to and paid by a
patient’s insurer. The billing arrangements generally are dictated by our customers and in accordance with state and federal law.
For the year ended December 31, 2015, Medicare accounted for approximately 10% of our total revenue, other insurance accounted for approximately 12% of our total
revenue and other healthcare facilities accounted for 9% of our total revenue. On average, we generate less revenue per test from other healthcare facilities billed directly, than
from other insurance payors.
Cost of Revenues
Our cost of revenues consists principally of internal personnel costs, including stock-based compensation, laboratory consumables, shipping costs, overhead and other direct
expenses, such as specimen procurement and third party validation studies. We are pursuing various strategies to reduce and control our cost of revenues, including automating
our processes through more efficient technology and attempting to negotiate improved terms with our suppliers. We completed two acquisitions in 2014; Gentris in North
Carolina and BioServe in India. In 2015, we acquired substantially all of the assets of Response Genetics in California. With these three acquisitions, we have made significant
process with integrating our resources and services in an effort to reduce costs. We will continue to assess how geographic advantage can help us improve our cost structure.
Operating Expenses
We classify our operating expenses into three categories: research and development, sales and marketing, and general and administrative. Our operating expenses principally
consist of personnel costs, including stock-based compensation, outside services, laboratory consumables and overhead, development costs, marketing program costs and legal
and accounting fees.
Research and Development Expenses. We incur research and development expenses principally in connection with our efforts to develop our proprietary tests. Our primary
research and development expenses consist of direct personnel costs, laboratory equipment and consumables and overhead expenses. In 2013, we entered into a joint venture
with the Mayo Foundation for Medical Education and Research, with a focus on developing oncology diagnostic services and tests utilizing next generation sequencing. All
research and development expenses are charged to operations in the periods they are incurred.
General and Administrative Expenses. General and administrative expenses consist principally of personnel-related expenses, professional fees, such as legal, accounting and
business consultants, occupancy costs, bad debt and other general expenses. We have incurred increases in our general and administrative expenses and anticipate further
increases as we expand our business operations.
Sales and Marketing Expenses. Our sales and marketing expenses consist principally of personnel and related overhead costs for our sales team and their support personnel,
travel and entertainment expenses, and other selling costs including sales collaterals and trade shows. We expect our sales and marketing expenses to increase as we expand
into new geographies and add new clinical tests and services.
Seasonality
Our business experiences decreased demand during spring vacation season, summer months and the December holiday season when patients are less likely to visit their health
care providers. We expect this trend in seasonality to continue for the foreseeable future.
Results of Operations
Years Ended December 31, 2015 and 2014
The following table sets forth certain information concerning our results of operations for the periods shown:
62
Table of Contents
(dollars in thousands)
Revenue
Cost of revenues
Research and development expenses
General and administrative expenses
Sales and marketing expenses
Total operating loss
Interest income (expense)
Change in fair value of warrant liability
Change in fair value of acquisition note payable
Loss before income taxes
Income tax benefit (expense)
Net loss
Revenue
The breakdown of our revenue is as follows:
Year Ended December 31,
Change
2015
2014
$
%
$
$
$
18,040 $
14,098
5,483
14,567
5,269
(21,377) $
(295)
35
269
(21,368)
1,184
(20,184) $
10,199 $
8,453
4,622
12,369
3,964
(19,209) $
(399)
417
198
(18,993)
2,350
(16,643) $
7,841
5,645
861
2,198
1,305
(2,168)
104
(382)
71
(2,375)
(1,166)
(3,541)
77 %
67 %
19 %
18 %
33 %
11 %
-26 %
-92 %
36 %
13 %
-50 %
21 %
(dollars in thousands)
Biopharma Services
Clinical Services
Discovery Services
Total Revenue
Year Ended December 31,
Change
2015
2014
$
11,564
5,651
825
18,040
%
$
%
$
%
64%
31%
5%
100%
5,606
4,432
161
10,199
55%
43%
2%
100%
5,958
1,219
664
7,841
106%
28%
412%
77%
Revenue increased 77%, or $7.8 million, to $18.0 million for the year ended December 31, 2015, from $10.2 million for the year ended December 31, 2014, principally due to
the acquisitions of Gentris, BioServe and Response Genetics, whose revenue accounted for $5.5 million of the increase. The increase of $2.4 million was driven by additional
clinical trial studies performed by our New Jersey location. Our average revenue (excluding probe revenue) per test decreased to $532 per test for the year ended December 31,
2015 from $550 per test for the year ended December 31, 2014, principally due to lower revenue per test at the newly acquired West Coast location. Overall test volumes
increased by 68% from 11,912 tests for the year ended December 31, 2014 to 19,996 tests for the year ended December 31, 2015.
Revenue from Biopharma Services increased 106%, or $6.0 million, to $11.6 million for the year ended December 31, 2015, from $5.6 million for the year ended
December 31, 2014, principally due to the acquisition of Gentris whose revenue accounted for a $3.1 million increase; additional clinical trial studies performed at our New
Jersey location which accounted for $2.4 million of the increase; and the acquisition of Response Genetics, which accounted for $0.5 million of the increase. Revenue from
Clinical Services customers increased 28%, or $1.2 million, to $5.7 million for the year ended December 31, 2015, from $4.4 million for the year ended December 31, 2014,
principally due to the acquisition of Response Genetics, which accounted for $1.2 million of the increase. Revenue from Discovery Services, our new line of business in 2014,
increased $0.7 million, to $0.8 million for the year ended December 31, 2015, representing 5% of total revenue.
Cost of Revenues
Cost of revenues increased 67%, or $5.6 million, to $14.1 million for the year ended December 31, 2015, from $8.5 million for the year ended December 31, 2014, principally
due to the following: costs of revenue from the acquired businesses of $4.8 million, lab supplies expenses increased by $0.4 million or 27% as a result of higher test volumes,
and compensation costs increased by $0.2 million or 9% as a result of us securing the expertise needed to continue to deliver high quality test results. Overall the cost of
revenue as a percentage of revenue decreased in comparison to 2014 as a result of us implementing cost transformation programs to reduce shipping, consulting and direct
labor costs.
63
Table of Contents
Operating Expenses
Research and Development Expenses. Research and development expenses increased 19%, or $0.9 million, to $5.5 million for the year ended December 31, 2015, from $4.6
million for the year ended December 31, 2014, principally due to the following: compensation increased by $0.4 million or 24% due to key additions to the R&D team;
supplies costs increased by $0.3 million or 45% as a result of us accelerating the development of proprietary tests; costs associated with the acquired businesses of $0.2
million; and collaboration costs increased by $0.2 million or 65% as we teamed up with other research labs to capitalize on R&D efforts. These increases were partially offset
by a decrease in our share of the loss from Oncospire, our joint venture with Mayo Clinic, of $0.2 million or 25%.
General and Administrative Expenses. General and administrative expenses increased 18%, or $2.2 million to $14.6 million for the year ended December 31, 2015, from $12.4
million for the year ended December 31, 2014, principally due to the following: $0.9 million of costs from the acquisition of Response Genetics; costs from the acquired
businesses of $2.2 million; increased compensation costs of $0.2 million or 8% as a result of increased headcount; and increased bad debt allowance of $0.2 million or 92% as
a result of establishing a reserve for potential uncollectible amounts in our Clinical Services businesses. These increases were partially off-set by a decrease in stock-based
compensation of $0.9 million or 32%; a reduction in Delaware corporate taxes of $0.1 million or 41%; a reduction of Medical Billing third-party expenses of $0.1 million or
17% as a result of bringing part of the function in-house; a reduction of $0.1 million in recruiting fees or 35% as a result of stabilizing our staff; and a reduction of $41,000 or
19% in printing costs as a result of our cost transformation initiatives.
Sales and Marketing Expenses. Sales and marketing expenses increased 33%, or $1.3 million, to $5.3 million for the year ended December 31, 2015, from $4.0 million for the
year ended December 31, 2014, principally due to the following: costs from the acquired businesses of $1.0 million, and compensation costs increased by $0.3 million, or
11%, as a result of increased commissions resulting from increased revenue and us building and developing our team.
Interest Income and Expense
Interest expense decreased 26%, or $0.1 million, to $0.3 million for the year ended December 31, 2015, from $0.4 million for the year ended December 31, 2014, principally
due to the decrease in amortization of loan guarantee and financing fees, offset by the higher interest rate related to debt that was refinanced in May 2015.
Change in Fair Value of Warrant Liability
The change in the fair market value of our warrant liability resulted in $35,000 in non-cash income for the year ended December 31, 2015, as compared to non-cash income of
$0.4 million for the year ended December 31, 2014. The fair market value of these common stock warrants decreased as a consequence of a decrease in our stock price and the
expiration 15,000 warrants in 2015.
Change in Fair Value of Acquisition Note Payable
The change in fair value of the acquisition note payable resulted in $ 0.3 million in non-cash income for the year ended December 31, 2015, as compared to $0.2 million for the
year ended December 31, 2014. The fair value of the note, representing part of the purchase price for BioServe, decreased as a consequence of a decrease in our stock price.
Income Taxes
In November 2015, we received $1.2 million from sales of state NOL's and research and development tax credits. During the year ended December 31, 2014, we received two
payments totaling $2.4 million from sales of state NOL’s.
Year Ended December 31, 2014 and 2013
The following table sets forth certain information concerning our results of operations for the periods shown:
64
Table of Contents
(dollars in thousands)
Revenue
Cost of revenues
Research and development expenses
General and administrative expenses
Sales and marketing expenses
Total operating loss
Interest income (expense)
Change in fair value of warrant liability
Change in fair value of acquisition note payable
Debt conversion costs
Loss before income taxes
Income tax benefit (expense)
Net loss
Revenue
The breakdown of our revenue is as follows:
Year Ended December 31,
2014
2013
Change
$
%
$
$
$
10,199 $
8,453
4,622
12,369
3,964
(19,209) $
(399)
417
198
—
(18,993)
2,350
(16,643) $
6,610 $
4,925
2,190
6,115
1,842
(8,462) $
(2,358)
4,633
—
(6,850)
(13,037)
664
(12,373) $
3,589
3,528
2,432
6,254
2,122
(10,747)
1,959
(4,216)
198
6,850
(5,956)
1,686
(4,270)
54 %
72 %
111 %
102 %
115 %
127 %
-83 %
-91 %
n/a
100 %
46 %
254 %
35 %
(dollars in thousands)
Biopharma Services
Clinical Services
Discovery Services
Grants
Total Revenue
Year Ended December 31,
Change
2014
2013
$
5,606
4,432
161
—
10,199
%
$
%
$
%
55%
43%
2%
—%
100%
2,650
3,663
—
297
6,610
40%
55%
—%
5%
100%
2,956
769
161
(297)
3,589
112 %
21 %
n/a
(100)%
54 %
Revenue increased 54%, or $3.6 million, to $10.2 million for the year ended December 31, 2014, from $6.6 million for the year ended December 31, 2013, principally due to
the acquisitions of Gentris and BioServe, whose revenue accounted for $3.3 million of the increase. Our average revenue (excluding grant revenue and probe revenue) per test
decreased to $550 per test for the year ended December 31, 2014 from $566 per test for the year ended December 31, 2013, principally due to a decrease in the average
revenue per test from private insurance carriers and other non-Medicare payors. This was offset by an 11% increase in test volume from 10,771 tests for the year ended
December 31, 2013, to 11,912 tests for the year ended December 31, 2014.
Revenue from Biopharma Services increased 112%, or $3.0 million, to $5.6 million for the year ended December 31, 2014, from $2.7 million for the year ended December 31,
2013, principally due to the acquisition of Gentris whose revenue accounted for a $3.1 million increase offset by an $0.2 million decrease in legacy Biopharma Services.
Revenue from Clinical Services customers increased 21%, or $0.8 million, to $4.4 million for the year ended December 31, 2014, from $3.7 million for the year ended
December 31, 2013, principally due to an increase in test volume. This increase in volume was partially offset by a decrease in average revenue per test. Revenue from
Discovery Services, our new line of business, increased $0.2 million for the year ended December 31, 2014 representing 2% of total revenue. Revenue from Grants decreased
100%, or $0.3 million, for the year ended December 31, 2014, due to the completion of all grant activities in the year ended December 31, 2013.
Cost of Revenues
Cost of revenues increased 72%, or $3.5 million, to $8.4 million for the year ended December 31, 2014, from $4.9 million for the year ended December 31, 2013, principally
due to the following: Costs of revenue from the acquired businesses of $2.2 million, lab supplies expenses increased by $0.5 million or 40% as a result of higher test volumes,
shipping costs increased by $0.3 million or 130% as a result of higher test volume, outsourcing services increased by $0.2 million or 257% as a result of us
65
Table of Contents
contracting with select labs to perform some of our tests, and compensation costs increased by $0.2 million or 9% as a result of us securing the expertise needed to continue to
deliver high quality test results. Overall the cost of revenue did not increase proportionately with revenue, due to the cost of revenue in 2013 being lower in proportion as a
result of us performing a large number of tests for a clinical trials client in 2013 and in 2013 there was $0.3 million in grant revenues that carried minimal costs, whereas in
2014 there were no grant revenues.
Operating Expenses
Research and Development Expenses. Research and development expenses increased 111%, or $2.4 million, to $4.6 million for the year ended December 31, 2014, from $2.2
million for the year ended December 31, 2013, principally due to the following: Our share of the loss from Oncospire, our joint venture with Mayo Clinic, increased $0.9
million, as it incurred a full year of research expenses related to the pursuit of developing new clinical tests. (In 2013, the costs associated with our joint venture was $12,000).
Compensation costs increased by $0.8 million or 88% as a result of us building up our R&D team, and supplies costs increased by $0.3 million or 64% as a result of us
accelerating the development of our proprietary tests.
General and Administrative Expenses. General and administrative expenses increased 102%, or $6.3 million to $12.4 million for the year ended December 31, 2014, from $6.1
million for the year ended December 31, 2013, principally due to the following: Costs from the acquired businesses of $1.4 million, stock-based compensation increased by
$2.5 million, costs associated with being a public company increased by $1.5 million due to higher consulting, legal and insurance expenses, compensation costs increased by
$0.6 million primarily due to a severance agreement for a former officer, allowance for doubtful accounts increased by $0.2 million as we established a reserve for potential
uncollectable amounts in our Clinical Services business, professional and consulting fees increased by $0.1 million, recruiting fee costs increased by $0.1 million, and travel
costs increased by $0.1 million as a result of the increased travel related to the acquisitions and our expanded customer base, partially off-set by $0.6 million in IPO costs
incurred in 2013, which did not recur in 2014.
Sales and Marketing Expenses. Sales and marketing expenses increased 115%, or $2.1 million, to $3.9 million for the year ended December 31, 2014, from $1.8 million for
the year ended December 31, 2013, principally due to the following: Costs from the acquired businesses of $0.5 million, compensation costs increased by $1.1 million or 86%
as a result of us building and developing our team, marketing costs increased by $0.2 million or 163% as a result of a concentrated effort to expand our customer base, travel
costs increased by $0.1 million, and stock-based compensation increased by $0.1 million due to increases in the number of sales personnel.
Interest Income and Expense
Interest expense decreased 83%, or $2.0 million, to $0.4 million for the year ended December 31, 2014, from $2.4 million for the year ended December 31, 2013. The
decrease is attributable to the conversion of $9.6 million of debt into common stock which occurred concurrently with the closing of our IPO on April 10, 2013 and the
repayment of $3.5 million in indebtedness in August 2013.
Debt Conversion Costs
On April 10, 2013, we completed our IPO. In connection with the IPO, $9.6 million of debt was converted into common stock at the IPO price of $10.00 per share. In
connection with the conversion of debt into common stock, we expensed the applicable remaining debt discounts of $3.5 million, financing fees of $0.4 million and a
contingently recognizable beneficial conversion feature in the converted debt of $3.0 million, the total of which resulted in a $6.9 million write-off. There were no comparable
costs in 2014.
Change in Fair Value of Warrant Liability
The change in the fair market value of our warrant liability resulted in $0.4 million in non-cash income for the year ended December 31, 2014, as compared to non-cash
income of $4.6 million for the year ended December 31, 2013. The fair market value of these common stock warrants decreased as a consequence of a decrease in our stock
price.
Income Taxes
During the year ended December 31, 2014, we received two payments totaling $2.4 million from sales of state NOL’s. During January 2013, we received $0.7 million from
the sale of state NOL’s.
Liquidity and Capital Resources
66
Table of Contents
Sources of Liquidity
Our primary sources of liquidity have been funds generated from our debt financings and equity financings. In addition, we have generated funds from the following sources:
(i) cash collections from customers and (ii) cash received from sale of state NOL’s.
During November 2015, we received $1.2 million from sales of state NOL’s and research and development tax credits. During the year ended December 31, 2014, we received
two payments totaling $2.4 million from sales of state NOL’s. During January 2013, we received $0.7 million from the sale of state NOL’s.
In general, our primary uses of cash are providing for operating expenses, working capital purposes and servicing debt. As of December 31, 2015, we have not borrowed on
our line of credit, which allows for borrowings of up to $4.0 million. Our largest source of operating cash flow is cash collections from our customers.
Offerings
On April 10, 2013, we sold 690,000 shares of common stock at a public offering price of $10.00 per share and completed our initial public offering, or IPO, with net proceeds
of $5.2 million. Upon the closing of the IPO, all shares of our then-outstanding Series A and Series B convertible preferred stock automatically converted into an aggregate of
1,287,325 shares of common stock. Concurrent with the IPO, certain derivative warrants with a fair value of $7.2 million were reclassified into equity due to the lapsing of
anti-dilution provisions in the warrants. Also concurrent with the IPO, $9.6 million of debt converted into 963,430 shares of common stock. Refer to Notes 1, 6 and 11 in the
Notes to Consolidated Financial Statements included in Item 8 of this Annual Report.
On August 19, 2013 in our Secondary Offering, or our Secondary Offering, we sold 1,500,000 shares of common stock at a public offering price of $10.00 per share which
resulted in gross proceeds of $15.0 million ($13.3 million of net proceeds after offering expenses and underwriting discounts). On September 5, 2013, we sold 105,000
additional common shares pursuant to the underwriter’s partial exercise of the over-allotment option which resulted in gross proceeds of $1.1 million ($0.9 million of net
proceeds after offering expenses and underwriting discounts). Upon completion of the Secondary Offering we repaid indebtedness in the aggregate principal amount of $3.5
million plus accrued interest to DAM and to one of our directors, Andrew Pecora, and an affiliated company NJCCA, all of which indebtedness was due on August 15, 2013.
On October 28, 2013 in a follow-on public offering, or our Follow-On Offering, we sold 3,286,700 shares of common stock (including the underwriter’s overallotment of
428,700 shares), at a public offering price of $14.00 per share resulting in gross proceeds of $46.0 million (net proceeds of $42.3 million).
In July 2015, we sold 2,800 shares of common stock that resulted in net proceeds to the Company of $34,000 through our sales agreement with Cantor Fitzgerald & Co. See
Note 19 in the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report.
On November 12, 2015, we sold 3,000,000 shares of common stock with warrants to purchase an aggregate of 3,000,000 shares of common stock at a combined public
offering price of $4.00 per share and warrant resulting in gross proceeds of $12.0 million ($10.3 million of net proceeds after offering expenses and underwriting discounts).
The underwriters also received 450,000 warrants pursuant to the partial exercise of the over-allotment option. The warrants have an exercise price of $5.00, became fully-
exercisable at issuance and expire on November 12, 2020.
Credit Facility
On May 7, 2015, we entered into a new debt financing facility with Silicon Valley Bank (“SVB”) to refinance the Company’s cash collateralized loan from Wells Fargo and to
provide an additional working capital line of credit. The SVB credit facility provides for a $6.0 million term note (“Term Note”) and a revolving line of credit (“Line of
Credit”) for an amount not to exceed the lesser of (i) $4.0 million or (ii) an amount equal to 80% of eligible accounts receivable. The Term Note requires interest-only
payments through April 30, 2016 and beginning May 1, 2016, monthly principal payments of approximately$167,000 will be required plus interest through maturity on
April 1, 2019. The interest rate of the Term Note is the Wall Street Journal prime rate plus 2%, with a floor of 5.25% (5.50% at December 31, 2015) and an additional deferred
interest payment of $180,000 will be due upon maturity. The Line of Credit requires monthly interest-only payments of the Wall Street Journal prime rate plus 1.5% (5.00% at
December 31, 2015) and matures on May 7, 2017. The new loan agreement requires maintenance of certain financial ratios and grants SVB a first security interest in
substantially all Company assets (other than
67
Table of Contents
our intellectual property). Pursuant to the new loan agreement, we are no longer required to maintain restricted cash accounts. At December 31, 2015, the principal balance of
the Term Note was $6,000,000 and the principal balance of the Line of Credit was $0. Pursuant to the amendment dated January 28, 2016, we are restricted from using the
Line of Credit until $13 million of additional equity is raised.
Cash Flows
Our net cash flow from operating, investing and financing activities for the periods below were as follows:
(in thousands)
Cash provided by (used in):
Operating activities
Investing activities
Financing activities
Net increase (decrease) in cash and cash equivalents
2015
Year Ended
December 31,
2014
2013
$
$
(13,599 ) $
(2,640 )
10,144
(6,095 ) $
(12,338 ) $
(11,373 )
(195 )
(23,906 ) $
(8,075 )
(1,399 )
58,114
48,640
We had cash and cash equivalents of $19.5 million at December 31, 2015, $25.6 million at December 31, 2014, and $49.5 million at December 31, 2013.
The $6.1 million decrease in cash and cash equivalents for the year ended December 31, 2015 was principally the result of the use of $ 13.6 million of net cash in operations,
purchasing substantially all of assets of Response Genetics for $7.5 million (plus stock), and investing $1.0 million in fixed assets, offset by the $6.0 million decrease in
restricted cash and the $10.3 million in net proceeds from the 2015 Offering.
The $23.9 million decrease in cash and cash equivalents for the year ended December 31, 2014 was principally the result of the use of $12.3 million of net cash in operations,
restricting $6.0 million to secure a line of credit with Wells Fargo of $6.0 million, payments of $2.9 million for the acquisitions of Gentris and BioServe, payment of $1.0
million to invest in our joint venture with Mayo and the purchase of fixed assets of $1.4 million.
The $48.6 million increase in cash and cash equivalents for the year ended December 31, 2013 was principally the result of the receipt of $5.0 million in proceeds received in
our IPO, the receipt of $14.2 in net proceeds from our Secondary Offering, and the receipt of $42.3 million in net proceeds from our Follow-On Offering, all of which were
offset by $1.0 million paid to invest in our joint venture with Mayo, the repayment of $3.6 million in indebtedness and the use of $8.1 million of net cash in operations.
Cash Used in Operating Activities
Net cash used in operating activities was $13.6 million for the year ended December 31, 2015. We used $15.7 million in net cash to run our core operations, which included
$0.2 million in cash paid for interest. We incurred additional uses of cash when adjusting for working capital items as follows: a net increase in accounts receivable of $1.7
million; an increase in other current assets of $0.4 million and an increase in other assets of $0.1 million. All of these uses of cash were partially offset by a net increase in
accounts payable, accrued expenses and deferred revenue of $3.1 million and the receipt of $1.2 million from the sale of state NOL carryforwards and research and
development credits in November 2015.
Net cash used in operating activities was $12.3 million for the year ended December 31, 2014. We used $13.5 million in net cash to run our core operations, which included
$0.1 million in cash paid for interest. We incurred additional uses of cash when adjusting for working capital items as follows: a net increase in accounts receivable of $1.7
million; an increase in other current assets of $0.2 million which included prepayments for our insurance policies. All of these uses of cash were partially offset by a net
increase in accounts payable, accrued expenses and deferred revenue of $0.7 million and the receipt of $2.4 million from the sale of certain state NOL carryforwards in January
2014 and December 2014.
Net cash used in operating activities was $8.1 million for the year ended December 31, 2013. We used $7.1 million in net cash to run our core operations, which included $0.6
million in cash paid for interest. We incurred additional uses of cash as follows: $0.7 million for a net decrease in accounts payable, accrued expenses and deferred revenue;
$0.4 million to increase other
68
Table of Contents
current assets which included prepayments for consumables and other supplies used to run our operations as well as prepayments for our insurance policies, and; accounts
receivable increased by $0.7 million. All of these uses of cash were partially offset by the receipt of $0.7 million from the sale of certain state NOL carryforwards in January
2013.
Cash Used in Investing Activities
Net cash used in investing activities was $2.6 million for the year ended December 31, 2015 and principally resulted from the purchase of substantially all assets of Response
Genetics for $7.5 million, plus stock, and the purchase of fixed assets for $1.0 million, offset by the $6.0 million decrease in restricted cash resulting from refinancing our debt
in May 2015.
Net cash used in investing activities was $11.4 million for the year ended December 31, 2014 and principally resulted from an increase in our restricted cash of $6.0 million
related to the collateralization of our line of credit with Wells Fargo; cash paid of $2.9 million in the acquisitions of Gentris and BioServe; investment of $1.0 million in our
Joint Venture with the Mayo Foundation and purchase of fixed assets of $1.4 million.
Net cash used in investing activities was $1.4 million for the year ended December 31, 2013 and principally resulted from: a $1.0 million payment to Mayo to fund our joint
venture; purchases of fixed assets of $0.3 million; patent application costs of $0.1 million, and; an increase in our restricted cash related to a $0.1 million increase in the Letter
of Credit related to our lease. Pursuant to the terms of our lease for our Rutherford facility, we were required to maintain a letter of credit in the amount of $0.3 million to use
as a guarantee for the security deposit.
Cash Used/Provided by Financing Activities
Net cash provided by financing activities was $10.1 million for the year ended December 31, 2015 principally due to the 2015 Offering, which resulted in $10.3 million in net
proceeds, offset by capital lease payments of $0.1 million and equity issuance costs of $0.1 million.
Net cash used in financing activities was $0.2 million for the year ended December 31, 2014, and primarily resulted from payments on notes payable of $0.4 million; partially
off-set by proceeds received from warrant and option exercises of $0.3 million.
Net cash provided by financing activities was $58.1 million for the year ended December 31, 2013, and primarily consisted of receipt of $61.5 million in net proceeds raised in
our IPO, Secondary Offering and Follow-On Offering offset by the repayment of $3.6 million in indebtedness.
Capital Resources, Acquisitions and Expenditure Requirements
We expect to continue to incur substantial operating losses in the future. It may take several years, if ever, to achieve positive operational cash flow. Until we can generate a
sufficient amount of revenue to finance our cash requirements, which we may never do, we will need to continue to raise additional capital to fund our operations.
We also expect to use significant cash to fund acquisitions. On July 16, 2014, we purchased substantially all of the assets of Gentris, with its principal place of business in
North Carolina for approximately $4.8 million. On August 18, 2014, we acquired BioServe, an Indian corporation, for an aggregate purchase price of approximately $1.1
million. On October 9, 2015, we acquired substantially all of the assets of Response Genetics, Inc. for aggregate consideration of approximately $12.9 million consisting of
$7.5 million in cash and our common stock valued at approximately $5.4 million.
In May 2015, we entered into a line of credit with Silicon Valley Bank. Pursuant to the amendment dated January 28, 2016, the Company agreed not to draw on the line of
credit until $13 million of additional equity is raised. See Note 6 in the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report.
On July 15, 2015, the Company entered into a Controlled Equity OfferingSM Sales Agreement (“Sales Agreement”) with Cantor Fitzgerald & Co., (“Cantor”) as sales agent,
pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $20.0 million.
We believe that our current cash will support operations for the next 15 to 24 months. We can provide no assurances that any additional sources of financing will be available
to us on favorable terms, if at all, when needed. Our forecast of the period of time through which our current financial resources will be adequate to support our operations and
the costs to support our
69
Table of Contents
general and administrative, sales and marketing and research and development activities are forward-looking statements and involve risks and uncertainties.
We expect our operating expenses to increase as we continue investing in sales and marketing, research and development and other general and administrative expenses.
Our forecast of the period of time through which our current financial resources will be adequate to support our operations and our expected operating expenses are forward-
looking statements and involve risks and uncertainties. Actual results could vary materially and negatively as a result of a number of factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
our ability to achieve revenue growth and
profitability;
the costs for funding the operations we recently acquired, including Response Genetics, and our ability to successfully integrate those operations with and into
our own;
our ability to obtain approvals for our new diagnostic
tests;
our ability to execute on our marketing and sales strategy for our genomic tests and gain acceptance of our tests in the
market;
our ability to obtain adequate reimbursement from governmental and other third-party payors for our tests and
services;
the costs, scope, progress, results, timing and outcomes of the clinical trials of our diagnostic
tests;
the costs of operating and enhancing our laboratory
facilities;
our ability to succeed with our cost control
initiative;
the timing of and the costs involved in regulatory compliance, particularly if the regulations
change;
the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and
liabilities;
our ability to manage the costs of manufacturing our
tests;
our rate of progress in, and cost of research and development activities associated with, products in research and early
development;
the effect of competing technological and market
developments;
costs related to
expansion;
our ability to secure financing and the amount thereof;
and
other risks discussed in the section entitled “Risk
Factors.”
We expect that our operating expenses and capital expenditures will increase in the future as we expand our business and integrate our recent acquisitions. We plan to increase
our sales and marketing headcount to promote our new clinical tests and services and to expand into new geographies and to increase our research and development
expenditures associated with performing work with research collaborators, to expand our pipeline and to perform work associated with our research collaborations. For
example, in 2011 we entered into an affiliation agreement to form a joint venture with the Mayo Foundation for Medical Education and Research pursuant to which we made
an initial $1.0 million capital contribution in October 2013 and $1.0 million in the third quarter of 2014. We currently anticipate that we will make capital contributions of $1.0
million in the second quarter of 2016 and expect to make additional capital contributions of up to $3.0 million, subject to the joint venture entity’s achievement of certain
operational milestones. Until we can generate a sufficient amount of revenues to finance our cash requirements, which we may never do, we may need to raise additional
capital to fund our operations.
We need to raise additional capital to fund our current operations, to repay certain outstanding indebtedness and to fund expansion of our business to meet our long-term
business objectives through public or private equity offerings, debt financings, borrowings or strategic partnerships coupled with an investment in our company or a
combination thereof. If we raise additional funds through the issuance of convertible debt securities, or other debt securities, these securities could be secured and could have
rights senior to those of our common stock. In addition, any new debt incurred by the Company could impose covenants that restrict our operations and increase our interest
expense. The issuance of any new equity securities will also dilute the interest of our current stockholders. Given the risks associated with our business, including our
unprofitable operating history and our ability to develop additional proprietary tests, additional capital may not be available when needed on acceptable terms, or at all. If
adequate funds are not available, we will need to curb our expansion plans or limit our research and development activities, which would have a material adverse impact on
our business prospects and results of operations.
Future Contractual Obligations
The following table reflects a summary of our estimates of future contractual obligations as of December 31, 2015. The information in the table reflects future unconditional
payments and is based on the terms of the relevant agreements, appropriate classification of items under U.S. GAAP as currently in effect and certain assumptions, such as the
interest rate on
70
Table of Contents
our variable debt that was in effect as of December 31, 2015. Future events could cause actual payments to differ from these amounts.
Contractual Obligations
Total
Less than 1 Year
1-3 Years
3-5 Years
More than 5 years
Payments Due by Period
(dollars in thousands)
Principal and interest under notes payable and lines of credit
Capital Lease obligations, including interest, for equipment
Operating lease obligations relating to corporate headquarters
and clinical laboratories
Total
Income Taxes
$
$
$
6,771
449
3,206
10,426 $
1,629 $
143
1,396
3,168 $
4,288 $
153
1,333
5,774 $
854 $
129
477
1,460 $
—
24
—
24
Over the past several years we have generated operating losses in all jurisdictions in which we may be subject to income taxes. As a result, we have accumulated significant
net operating losses and other deferred tax assets. Because of our history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation
allowance has been recognized. We do not expect to report a benefit related to the deferred tax assets until we have a history of earnings, if ever, that would support the
realization of our deferred tax assets.
Off-Balance Sheet Arrangements
Since inception, we have not engaged in any off balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.
Critical Accounting Policies and Significant Judgment and Estimates
Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in
accordance with U.S. GAAP. The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenue and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates based on historical experience and
make various assumptions, which management believes to be reasonable under the circumstances, which form the basis for judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Section 107 of the JOBS Act provides that an “emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. However, we have chosen to “opt out” of such extended transition period, and as a result, we will comply with
new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act
provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.
The notes to our audited consolidated financial statements contain a summary of our significant accounting policies. We consider the following accounting policies critical to
the understanding of the results of our operations:
•
•
Revenue
recognition;
Accounts receivable and bad
debts;
Stock-based compensation;
and
• Warrant
liability.
•
Item 7A.
Qualitative and Quantitative Disclosures about Market Risk
We have exposure to financial market risks, including changes in foreign currency exchange rates and interest rates, and risk associated with how we invest our cash.
71
Table of Contents
Foreign Exchange Risk
We conduct business in foreign markets through our subsidiary in India (BioServe Biotechnologies (India) Private Limited) and in Italy through our subsidiary (Cancer
Genetics Italia, S.r.l.). For the years ended December 31, 2015, 2014 and 2013 approximately 5%, 4% and 3%, respectively, of our revenues were earned outside the United
States and collected in local currency. We are subject to risk for exchange rate fluctuations between such local currencies and the United States dollar and the subsequent
translation of the Indian Rupee or Euro to United States dollars. We currently do not hedge currency risk. The translation adjustments for the years ended December 31, 2015,
2014 and 2013 were not significant.
Interest Rate Risk
At December 31, 2015, we had interest rate risk primarily related to borrowings of $6.0 million on the term note with Silicon Valley Bank (“Silicon Valley Line”). Borrowings
under the Silicon Valley term note bear interest at the Wall Street Journal prime rate plus 2%, with a floor of 5.25% (5.50% at December 31, 2015). If interest rates increased
by 1.0%, interest expense in 2016 on our current borrowings would increase by approximately $60,000.
Investment of Cash
We invest our cash primarily in money market funds. Because of the short-term nature of these investments, we do not believe we have material exposure due to market risk.
The impact to our financial position and results of operations from likely changes in interest rates is not material.
72
Table of Contents
Item 8.
Financial Statements and Supplementary Data
INDEX TO FINANCIAL STATEMENTS
Cancer Genetics, Inc. and Subsidiaries
Consolidated Financial Report December 31, 2015
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
73
74
75
76
77
79
80
Table of Contents
To the Board of Directors and Stockholders
Cancer Genetics, Inc. and Subsidiaries
Report of Independent Registered Public Accounting Firm
We have audited the accompanying consolidated balance sheets of Cancer Genetics, Inc. and subsidiaries as of December 31, 2015 and 2014, and the related consolidated
statements of operations, changes in stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2015. These financial
statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we
engaged to perform an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing
audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over
financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cancer Genetics, Inc. and subsidiaries as
of December 31, 2015 and 2014, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2015 in conformity with
U.S. generally accepted accounting principles.
/s/ RSM US LLP
New York, New York
March 10, 2016
74
Table of Contents
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(in thousands, except par value)
ASSETS
CURRENT ASSETS
Cash and cash equivalents
Accounts receivable, net of allowance for doubtful accounts of 2015 $664; 2014 $251
Other current assets
Total current assets
FIXED ASSETS, net of accumulated depreciation
OTHER ASSETS
Restricted cash
Patents and other intangible assets, net of accumulated amortization
Investment in joint venture
Goodwill
Other
Total other assets
Total Assets
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued expenses
Obligations under capital leases, current portion
Deferred revenue
Bank term note, current portion
Total current liabilities
Obligations under capital leases
Deferred rent payable and other
Line of credit
Warrant liability
Acquisition note payable
Deferred revenue, long-term
Bank term note
Total Liabilities
STOCKHOLDERS’ EQUITY
Preferred stock, authorized 9,764 shares $0.0001 par value, none issued
Common stock, authorized 100,000 shares, $0.0001 par value, 13,652 and 9,821 shares issued and outstanding as of
December 31, 2015 and 2014, respectively
Additional paid-in capital
Accumulated deficit
Total Stockholders’ Equity
Total Liabilities and Stockholders’ Equity
See Notes to Consolidated Financial Statements.
75
December 31,
2015
2014
19,459 $
6,621
2,118
28,198
6,069
300
1,727
341
12,029
220
14,617
48,884 $
7,579 $
122
831
1,333
9,865
276
315
—
17
—
752
4,642
15,867
—
1
131,167
(98,151 )
33,017
48,884 $
25,554
5,028
1,173
31,755
4,310
6,300
503
1,048
3,187
2
11,040
47,105
3,763
59
544
—
4,366
300
348
6,000
52
560
925
—
12,551
—
1
112,520
(77,967 )
34,554
47,105
$
$
$
$
Table of Contents
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(in thousands, except per share amounts)
Revenue
Cost of revenues
Gross profit
Operating expenses:
Research and development
General and administrative
Sales and marketing
Total operating expenses
Loss from operations
Other income (expense):
Interest expense
Interest income
Change in fair value of warrant liability
Change in fair value of acquisition note payable
Debt conversion costs
Total other income (expense)
Loss before income taxes
Income tax (benefit)
Net (loss)
Basic net (loss) per share
Diluted net (loss) per share
Basic weighted average shares outstanding
Diluted weighted average shares outstanding
See Notes to Consolidated Financial Statements.
Years Ended December 31,
2015
2014
2013
$
18,040
14,098
3,942
5,483
14,567
5,269
25,319
(21,377 )
(344 )
49
35
269
—
9
(21,368 )
(1,184 )
(20,184 ) $
(1.96 ) $
(1.96 ) $
10,298
10,299
10,199 $
8,453
1,746
4,622
12,369
3,964
20,955
(19,209 )
(473 )
74
417
198
—
216
(18,993 )
(2,350 )
(16,643 ) $
(1.76 ) $
(1.80 ) $
9,449
9,462
6,610
4,925
1,685
2,190
6,115
1,842
10,147
(8,462 )
(2,388 )
30
4,633
—
(6,850 )
(4,575 )
(13,037 )
(664 )
(12,373 )
(2.65 )
(3.64 )
4,665
4,676
$
$
$
$
76
Table of Contents
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
Years Ended December 31, 2015, 2014 and 2013
(in thousands)
77
Table of Contents
Balance, December 31, 2012
Stock based compensation - employees
Stock based compensation - non-
employees
Vesting of common pursuant to joint
venture agreement
Conversion of preferred stock into
common stock
Conversion of debt into common stock
Issuance of common stock in IPO, net of
offering costs
Issuance of common stock in Secondary
Offering, net of offering costs
Issuance of common stock in Follow-On
Offering, net of offering costs
Issuance of common stock pursuant to
license agreement
Issuance of common stock pursuant to joint
venture agreement
Reclassification of derivative warrants
Exercise of warrants
Exercise of options
Retirement of treasury stock
Net loss
Balance, December 31, 2013
Stock based compensation - employees
Stock based compensation - non-
employees
Exercise of warrants
Exercise of options
Issuance of stock - acquisition of Gentris
Corporation
Issuance of stock - acquisition of BioServe
Net loss
Balance, December 31, 2014
Stock based compensation—employees
Stock based compensation—non-
employees
Exercise of warrants
Exercise of options
Issuance of stock - Cantor Sales
Agreement
Issuance of stock - acquisition of Response
Genetics
Issuance of stock with warrants in 2015
Offering
Net loss
Balance, December 31, 2015
Preferred Stock
Series A
Preferred Stock
Series B
Common Stock
Shares Amount Shares
Amount
Shares
Amount
Additional
Paid-in
Capital
Treasury
Stock
Accumulated
Deficit
(48,934 ) $
(17) $
—
588 $ —
—
—
1,822 $
—
—
—
(588)
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(1,822 )
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1,350 $
3
— $
—
24,970 $
647
—
—
1,287
963
—
—
—
—
88
232
—
12,596
—
690
—
3,743
—
1,605
—
14,230
—
3,287
1
42,302
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
2
10
—
78
—
—
—
9,275
208
5
135
19
148
31
—
9,821
35
—
—
4
3
—
—
—
—
—
—
—
1
—
—
—
—
—
—
—
1
—
—
—
—
—
20
175
7,170
612
2
—
—
106,787
3,462
373
303
79
1,272
244
—
112,520
2,558
276
1
23
34
—
789
—
5,436
—
—
—
—
—
—
—
—
—
—
—
—
—
(17)
(12,373 )
(61,324 )
—
—
—
—
—
—
(16,643 )
(77,967 )
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
17
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
— $ —
—
—
— $
—
—
—
3,000
—
13,652 $
10,319
—
—
—
1 $ 131,167 $
—
—
— $
—
(20,184 )
(98,151 ) $
Total
(23,981 )
647
88
232
—
12,596
3,743
14,230
42,303
20
175
7,170
612
2
—
(12,373 )
45,464
3,462
373
303
79
1,272
244
(16,643 )
34,554
2,558
276
1
23
34
5,436
10,319
(20,184 )
33,017
See Notes to Consolidated Financial Statements
78
Table of Contents
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(in thousands)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization
Provision for bad debts
Stock-based compensation
Stock-based research and development/general and administrative expenses
Change in fair value of acquisition note payable
Change in fair value of Gentris contingent consideration
Change in fair value of warrant liability
Amortization of loan guarantee, financing fees and debt issuance costs
Accretion of discount on debt
Loss in equity-method investment
Loss on conversion of debt to equity
Deferred initial public offering costs expensed
Change in working capital components:
Accounts receivable
Other current assets
Other non-current assets
Accounts payable, accrued expenses and deferred revenue
Deferred rent and other
Net cash (used in) operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets
(Increase) decrease in restricted cash
Patent costs
Investment in joint venture
Cash used in acquisition of Gentris, net of cash received
Cash from acquisition of BioServe
Cash used in acquisition of Response Genetics
Net cash (used in) investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on capital lease obligations
Payment of equity issuance costs
Proceeds from public offerings of common stock, net of offering costs
Proceeds from warrant exercises
Proceeds from option exercises
Payment of debt issuance costs
Principal payments on notes payable
Net cash provided by (used in) financing activities
Net increase (decrease) in cash and cash equivalents
CASH AND CASH EQUIVALENTS
Beginning
Ending
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest
SUPPLEMENTAL DISCLOSURE OF NONCASH
INVESTING AND FINANCING ACTIVITIES
Fixed assets acquired through capital lease arrangements
Warrants issued for financing fees
Retirement of treasury stock
Conversion of notes payable and lines of credit to common stock
Value of shares issued as partial consideration to purchase Gentris and BioServe
Value of shares issued as partial consideration to purchase Response Genetics
Reclassification of derivative warrants
Cashless exercise of derivative warrants
Offering costs discounted
Net tangible assets acquired via acquisition
Accrued expenses reclassified as derivative warrant liability
See Notes to Consolidated Financial Statements.
Years Ended December 31,
2015
2014
2013
$
(20,184 )
$
(16,643 ) $
(12,373 )
1,503
159
413
2,834
—
269
(207)
(35)
8
—
707
—
—
(1,662 )
(384)
(101)
3,114
(33)
(13,599 )
(1,008 )
6,000
(137)
—
—
—
(7,495 )
(2,640 )
(83)
(117)
10,353
1
23
(33)
—
10,144
(6,095 )
810
28
215
3,835
—
(198)
—
(417)
311
—
940
—
—
(1,657 )
(199)
—
675
(38)
(12,338 )
(1,374 )
(6,000 )
(130)
(1,000 )
(3,181 )
312
—
(11,373 )
(44)
—
—
178
79
—
(408)
(195)
(23,906 )
$
$
$
25,554
19,459
$
49,460
25,554
$
240
$
128
$
— $
—
—
—
—
5,436
—
—
—
2,843
—
$
42
—
—
—
1,516
—
—
125
—
1,255
—
79
311
15
—
735
427
—
—
(4,633 )
1,195
585
12
6,850
618
(717)
(375)
—
(731)
6
(8,075 )
(257)
(50)
(92)
(1,000 )
—
—
—
(1,399 )
(17)
—
61,517
192
2
—
(3,580 )
58,114
48,640
820
49,460
608
354
47
17
9,634
—
—
7,170
420
733
—
221
Table of Contents
Notes to Consolidated Financial Statements
Note 1. Organization, Acquisitions, Description of Business, Reverse Stock Split and Charter Amendment
CANCER GENETICS, INC. AND SUBSIDIARIES
We are an emerging leader in the field of personalized medicine, enabling precision medicine in the field of oncology through our diagnostic products and services and
molecular markers. We develop, commercialize and provide molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management
of each individual patient by providing genomic information to better diagnose, monitor and inform cancer treatment and that enable biopharmaceutical companies engaged in
oncology trials to better select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to
therapeutics. We have a comprehensive, disease-focused oncology testing portfolio. Our tests and techniques target a wide range of cancers, covering eight of the top ten
cancers in prevalence in the United States, with additional unique capabilities offered by our Tissue of Origin® test for identifying difficult to diagnose tumor types or poorly
differentiated metastatic disease.
We were incorporated in the State of Delaware on April 8, 1999 and have offices and state-of-the-art laboratories located in California, New Jersey, North Carolina, Shanghai
(China), and Hyderabad (India). Our laboratories comply with the highest regulatory standards as appropriate for the services they deliver including CLIA, CAP, NY State,
California State and NABL (India).We have two advisory boards to counsel our scientific and clinical direction. Our Scientific Advisory Board is comprised of preeminent
scientists and physicians from the fields of cancer biology, cancer pathology, cancer medicine and molecular genetics. Our Clinical Advisory Board is comprised of clinicians
and scientists focused on clinical implementation of our proprietary tests and services and mapping those tests and services to patient needs. Our services are built on a
foundation of world-class scientific knowledge and intellectual property in solid and blood-borne cancers, as well as strong academic relationships with major cancer centers
such as Memorial Sloan-Kettering, Mayo Clinic, and the National Cancer Institute.
Acquisition of Gentris Corporation
On July 16, 2014, we purchased substantially all of the assets of Gentris Corporation ("Gentris"), a laboratory specializing in pharmacogenomics profiling for therapeutic
development, companion diagnostics and clinical trials. Gentris’ laboratory is located in Morrisville, North Carolina and the company has a CLIA and FDA-compliant
laboratory facility in Shanghai, China. Upon closing of the acquisition transaction, Gentris Corporation was re-named Gentris, LLC and is now a wholly-owned subsidiary of
Cancer Genetics, Inc. The acquisition allows us to expand our biopharma services.
The assets and liabilities of Gentris were recorded in our consolidated financial statements at their estimated fair values as of the acquisition date. The excess value of the
consideration paid over the fair value of assets acquired and liabilities assumed was recorded as goodwill. Goodwill arising from the acquisition consists largely from a trained
workforce in place and expected synergies with existing operations. Goodwill recorded in conjunction with the acquisition is deductible for income tax purposes. The total
consideration for the Gentris acquisition is as follows (in thousands except share amounts):
Cash paid at closing
Issuance of 147,843 common shares
Estimated fair value of contingent consideration
Total purchase price
$
$
Amount
3,250
1,272
293
4,815
During the year ended December 31, 2015, we recognized a gain of $207,000 due to settling the contingent consideration for $86,400.
We incurred a finder's fee of $147,500 related to the transaction.
The following table summarizes the final valuation of the assets acquired and liabilities assumed as of July 16, 2014 (in thousands):
80
Table of Contents
Accounts receivable
Other current assets
Current liabilities
Deferred revenue, long-term
Fixed assets
Goodwill
Total purchase price
Amount
1,869
266
(785)
(938)
1,951
2,452
4,815
$
$
Acquisition of BioServe Biotechnologies (India) Pvt. Ltd.
On August 18, 2014 we entered into two agreements by which we acquired BioServe Biotechnologies (India) Pvt. Ltd. ( “BioServe”), a premier genomics services provider
serving both the research and clinical markets in India. This transaction was completed through a newly formed subsidiary, Cancer Genetics (India) Pvt. Ltd.
BioServe is a leading genomic service and next-generation sequencing company serving both the research and clinical markets based in Hyderabad, India. With the BioServe
acquisition we believe we will be able to access the Indian healthcare market. The acquisition provides us with an infrastructure in India for developing lower cost
manufacturing of probes and kits including probes and kits used for our proprietary FHACT test and access to one of the fastest-growing molecular and clinical diagnostic
markets in the world. BioServe will continue to serve biotechnology and biopharmaceutical companies, diagnostic companies and research hospitals, including those owned or
operated by the Indian government, as well as seek to expand its customer base.
The assets and liabilities of BioServe were recorded in the Company's consolidated financial statements at their estimated fair values as of the acquisition date. The excess
value of the consideration paid over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Goodwill arising from the acquisition consists largely
from a trained workforce in place and expected synergies from new lines of business. Goodwill recorded in conjunction with the acquisition is not deductible for income tax
purposes. The aggregate purchase price is as follows (in thousands except share amounts):
Cash paid at closing
Notes payable
Notes payable (value of 84,278 common shares)
Issuance of 31,370 common shares
Total purchase price
$
$
Amount
73
24
733
244
1,074
The final payment for BioServe will be a cash payment equal to the value of 84,278 shares of our common stock in November 2016. This liability is subject to future
adjustment based upon changes to our stock price. During the year ended December 31, 2015 and 2014, we recognized a gain of $269,000 and $198,000, respectively, due to
the decrease in value of this note. The amounts used in computing the purchase price differ from the amounts in the purchase agreements due to fair value measurement
conventions prescribed in accounting standards.
During 2015, the Company made revisions to the preliminary valuation of certain assets acquired which increased goodwill by approximately $193,000, reduced fixed assets
by approximately $136,000, reduced other assets by approximately $38,000 and reduced other current assets by approximately $19,000.
The following table summarizes the final valuation of the assets acquired and liabilities assumed as of August 18, 2014 (in thousands):
81
Table of Contents
Accounts receivable
Other current assets
Fixed assets
Other assets
Goodwill
Current liabilities
Other liabilities
Total purchase price
Amount
151
102
489
378
735
(759)
(22)
1,074
$
$
Acquisition of Response Genetics, Inc.
On October 9, 2015, we acquired substantially all the assets and assumed certain liabilities of Response Genetics, Inc. (“Response Genetics”), with its principal place of
business in California, in a transaction valued at approximately $12.9 million, comprised of $7,495,193 in cash and 788,584 shares of the Company’s common stock, with the
common stock being valued at $5,436,104.
Response Genetics was a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. Response Genetics generated revenues
primarily from sales of its ResponseDX® diagnostic tests, which Response Genetics launched in 2008, and by providing clinical trial testing services to pharmaceutical
companies.
The transaction is being accounted for using the acquisition method of accounting for business combinations in accordance with GAAP. Under this method, the total
consideration transferred to consummate the acquisition is being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their
respective fair values as of the closing date of the acquisition. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the
consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed.
Goodwill arising from the acquisition consists largely from a trained workforce in place and expected synergies from new lines of business. Goodwill recorded in conjunction
with the acquisition is deductible for income tax purposes. Business transactions expense of approximately $890,000 incurred in connection with the acquisition was expensed
as incurred.
The final allocation of the purchase price of the fair value of the assets acquired and the liabilities assumed as of October 9, 2015 is as follows (in thousands):
Accounts receivable
Prepaid expenses and other current assets
Fixed assets
Intangible assets
Goodwill
Current liabilities
Obligations under capital lease
Total purchase price
Amount
344
561
2,254
1,246
8,842
(194)
(122)
12,931
$
$
Acquisitions Pro Forma Financial Information
The following table provides certain pro forma financial information for the Company as if the acquisitions of Response Genetics, Gentris and Bioserve discussed above
occurred on January 1, 2013 (in thousands except per share amounts):
82
Table of Contents
Revenue
Net loss
Basic net loss per share
Dilutive net loss per share
$
$
Unaudited
Year Ended December 31,
2014
2015
28,528 $
(33,237)
34,167 $
(26,427)
2013
32,488
(26,712)
(3.05) $
(3.05)
(2.56) $
(2.59)
(4.74)
(5.55)
The pro forma numbers above are derived from historical numbers of the Company, Response Genetics, Gentris and Bioserve. Over time the operations of Response Genetics
will be integrated into the operations of the Company. This integration may change how certain tests are coded and submitted to payers (including Medicare) and,
consequently, may result in differences in the future in which revenues and bad debt expenses are recorded when compared with the historical methods of Response Genetics.
At the current time, we do not have enough information to prepare a reliable estimate of any possible changes.
The results of operations for the year ended December 31, 2015 include the operations of Response Genetics from October 9, 2015 and twelve months of operations of Gentris
and Bioserve with combined revenues of $8,771,000. The net loss of Response Genetics, Gentris and Bioserve cannot be determined, as their operations are integrated with
Cancer Genetics. The results of operations for the year ended December 31, 2014 include the the operations of Gentris from July 16, 2014 and BioServe from August 18, 2014
and include combined revenues of $3,296,465.
Reverse Stock Splits
On February 8, 2013, we filed a charter amendment with the Secretary of State for the State of Delaware and effected a 1-for-2 reverse stock split of our common stock. On
March 1, 2013, we filed another charter amendment with the Secretary of State for the State of Delaware and effected a 1-for-2.5 reverse stock split of our common stock. All
shares and per share information referenced throughout the consolidated financial statements have been retroactively adjusted to reflect both reverse stock splits.
Public Offerings
On April 10, 2013, we sold 690,000 shares of common stock at a public offering price of $10.00 per share and completed our initial public offering (“IPO”) with gross
proceeds of $6.9 million (net proceeds of $5 million). Upon the closing of the IPO, all shares of our then-outstanding Series A and Series B convertible preferred stock
automatically converted into an aggregate of 1,287,325 shares of common stock. Concurrent with the IPO, certain derivative warrants with a fair value of $7.2 million were
reclassified into equity due to the lapsing of anti-dilution provisions in the warrants. Also concurrent with the IPO, $9.6 million of debt converted into 963,430 shares of
common stock. All references to our Series A convertible preferred stock refer collectively to the Series A and Series A-1 convertible preferred shares.
On August 19, 2013, we sold 1,500,000 shares of common stock at a public offering price of $10.00 per share resulting in gross proceeds of $15.0 million (net proceeds of
$13.3 million). We used $3.5 million of the proceeds to repay certain indebtedness which was due on August 15, 2013 (see Note 6 for further discussion of the Company’s
debt). On September 5, 2013, we sold 105,000 additional common shares pursuant to partial exercise of the underwriter’s over-allotment option which resulted in gross
proceeds of $1.1 million (net proceeds of $947,000). All references to the sales of common stock mentioned in this paragraph are referred to as the “Secondary Offering.”
On October 28, 2013, we sold 3,286,700 shares of common stock, (including the underwriter’s overallotment of 428,700 shares), at a public offering price of $14.00 per share
resulting in gross proceeds of $46.0 million (net proceeds of $42.3 million). All references to the sales of common stock mentioned in this paragraph are referred to as the
“Follow-On Offering.”
On November 12, 2015, we sold 3,000,000 shares of common stock with warrants to purchase an aggregate of 3,000,000 shares of common stock at a combined public
offering price of $4.00 per share and warrant resulting in gross proceeds of $12.0 million ($10.3 million of net proceeds after offering expenses and underwriting discounts).
The underwriters also received 450,000 warrants pursuant to the partial exercise of the over-allotment option. The warrants have an exercise price of $5.00, became fully-
exercisable at issuance and expire on November 12, 2020. All references to the sales of common stock with warrants mentioned in this paragraph are referred to as the “2015
Offering.”
83
Table of Contents
Note 2. Significant Accounting Policies
Basis of presentation: We prepare our financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States
of America.
Segment reporting: Operating segments are defined as components of an enterprise about which separate discrete information is used by the chief operating decision maker, or
decision-making group, in deciding how to allocate resources and in assessing performance. We view our operations and manage our business in one operating segment, which
is the business of developing and selling diagnostic tests.
Liquidity: Our primary sources of liquidity have been funds generated from our debt financings and equity financings. In addition, we have generated funds from the
following sources: (i) cash collections from our customers; (ii) grants from the National Institutes of Health and (iii) the sale of State of New Jersey net operating loss
carryforwards.
Principles of consolidation: The accompanying consolidated financial statements include the accounts of Cancer Genetics, Inc. and our wholly owned subsidiaries, Cancer
Genetics Italia S.r.l (“CGI Italia”), Gentris LLC (from July 16, 2014), Bioserve Biotechnologies (India) Private Limited (from August 18, 2014).
All significant intercompany account balances and transactions have been eliminated in consolidation.
Use of estimates and assumptions: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date
of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include, among others,
realization of amounts billed, realization of long-lived assets, realization of intangible assets, accruals for litigation and registration payments, assumptions used to value stock
options, warrants and goodwill and the valuation of assets acquired and liabilities assumed from acquisitions. Actual results could differ from those estimates.
Risks and uncertainties: We operate in an industry that is subject to intense competition, government regulation and rapid technological change. Our operations are subject to
significant risk and uncertainties including financial, operational, technological, regulatory, foreign operations, and other risks, including the potential risk of business failure.
Cash and cash equivalents: Highly liquid investments with original maturities of three months or less when purchased are considered to be cash equivalents. Financial
instruments which potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents. We maintain cash and cash equivalents with high-credit
quality financial institutions. At times, such amounts may exceed insured limits. We have not experienced any losses in such accounts and believe we are not exposed to any
significant credit risk on our cash and cash equivalents.
Restricted cash: Represents cash held at financial institutions which we may not withdraw and which collateralizes certain of our financial commitments. All of our restricted
cash is invested in interest bearing certificates of deposit. Our restricted cash collateralizes a $300,000 letter of credit in favor of our landlord, pursuant to the terms of the lease
for our Rutherford facility.
Revenue recognition: Revenue is recognized in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue
Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized:
(1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the customer or services
have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. In determining whether the price is fixed or determinable, we consider
payment limits imposed by insurance carriers and Medicare and the amount of revenue recorded takes into account the historical percentage of revenue we have collected for
each type of test for each payor category. Periodically, an adjustment is made to revenue to record differences between our anticipated cash receipts from insurance carriers and
Medicare and actual receipts from such payors. For the periods presented, such adjustments were not significant. For some Clinical Service and Biopharma customers billed
directly, revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, we consider whether we have sufficient payment history to
reliably estimate a payor’s individual payment patterns. For new tests where there is no evidence of payment history at the time the tests are completed, we only recognize
revenues once reimbursement experience can be established. We then recognize revenue equal to the amount of cash received. We do not bill customers for shipping and
handling fees and do not collect any sales or other taxes.
84
Table of Contents
Revenues from grants to support product development are recognized when costs and expenses under the terms of the grant have been incurred and payments under the grants
become contractually due.
Accounts receivable: Accounts receivable are carried at original invoice amount less an estimate for contractual adjustments and doubtful receivables, the amounts of which are
determined by an analysis of individual accounts. Our policy for assessing the collectability of receivables is dependent upon the major payor source of the underlying
revenue. For direct bill clients, an assessment of credit worthiness is performed prior to initial engagement and is reassessed periodically. If deemed necessary, an allowance is
established on receivables from direct bill clients. For insurance carriers where there is not an established pattern of collection, revenue is not recorded until cash is received.
For receivables where insurance carriers have made payments to patients instead of directing payments to the Company, an allowance is established for a portion of such
receivables. After reasonable collection efforts are exhausted, amounts deemed to be uncollectible are written off against the allowance for doubtful accounts. Since the
Company only recognizes revenue to the extent it expects to collect such amounts, bad debt expense related to receivables from patient service revenue is recorded in general
and administrative expense in the consolidated statement of operations. Recoveries of accounts receivable previously written off are recorded when received.
Deferred revenue: Payments received in advance of services rendered are recorded as deferred revenue and are subsequently recognized as revenue in the period in which the
services are performed.
Fixed assets: Fixed assets consist of diagnostic equipment, furniture and fixtures and leasehold improvements. Fixed assets are carried at cost and are depreciated using the
straight-line method over the estimated useful lives of the assets, which generally range from five to seven years. Leasehold improvements are depreciated over the lesser of
the lease term or the estimated useful lives of the improvements using the straight-line method. Repairs and maintenance are charged to expense as incurred while
improvements are capitalized. Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or
loss recorded to the consolidated statement of operations.
Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize
judgments and assumptions inherent in our estimate of future cash flows to determine recoverability of these assets. If our assumptions about these assets were to change as a
result of events or circumstances, we may be required to record an impairment loss.
Goodwill: Goodwill resulted from the purchases of Gentris and BioServe in 2014 and the purchase of Response Genetics in 2015, as described in Note 1. In accordance with
ASC 350, Intangibles - Goodwill and Other, we are required to test goodwill for impairment and adjust for impairment losses, if any, at least annually and on an interim basis if
an event or circumstance indicates that it is likely impairment has occurred. Our annual goodwill impairment testing date is October 1 of each year. No such losses were
incurred during the years ended December 31, 2015 and 2014.
Goodwill (in thousands)
Balance, December 31, 2013
Purchased through acquisitions of Gentris and BioServe
Balance, December 31, 2014
Purchased through acquisition of Response Genetics
Balance, December 31, 2015
$
$
—
3,187
3,187
8,842
12,029
Loan guarantee and financing fees: Loan guarantee fees are amortized on a straight-line basis over the term of the guarantee. Financing fees are amortized using the effective
interest method over the term of the related debt.
Warrant liability: We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than
the exercise price of the warrant. The warrants are described herein as derivative warrants. We account for these derivative warrants as liabilities. These common stock
purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the binomial lattice valuation pricing model with
the assumptions as follows: The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve. The expected life of the
warrants is based upon the contractual life of the warrants. Volatility is estimated based on an average of the historical volatilities of the common stock of four entities with
characteristics similar to those of the Company. Prior to our IPO, the measurement date fair value of the underlying common shares was based upon an external valuation of
our shares. (See Notes 13 and 14). Subsequent to the IPO and Secondary Offering, we used the closing price of our shares on the OTC Bulletin Board and the NASDAQ
Capital Market, respectively.
85
Table of Contents
We compute the fair value of the warrant liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key
component in the value of the warrant liability is our stock price, which is subject to significant fluctuation and is not under our control. The resulting effect on our net income
(loss) is therefore subject to significant fluctuation and will continue to be so until the warrants are exercised, amended or expire. Assuming all other fair value inputs remain
constant, we will record non-cash expense when the stock price increases and non-cash income when the stock price decreases.
Income taxes: Income taxes are provided for the tax effects of transactions reported in the consolidated financial statements and consist of taxes currently due plus deferred
income taxes. Deferred income taxes are recognized for temporary differences between the financial statement and tax bases of assets and liabilities that will result in taxable
or deductible amounts in the future. Deferred income taxes are also recognized for net operating loss carryforwards that are available to offset future taxable income and
research and development credits.
Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. We have established a full valuation allowance on
our deferred tax assets as of December 31, 2015 and 2014, therefore we have not recognized any tax benefit or expense in the periods presented.
ASC 740, Income Taxes, clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax
positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation
processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides
guidance on measurement, de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. At December 31, 2015 and 2014 we
had no uncertain tax positions.
Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. There is no accrual for interest or penalties on our consolidated
balance sheets at December 31, 2015 or 2014, and we have not recognized interest and/or penalties in the consolidated statements of operations for the years ended
December 31, 2015, 2014 or 2013.
Patents and other intangible assets: We account for intangible assets under ASC 350-30. Patents consisting of legal fees incurred are initially recorded at cost. We have also
acquired patents that are initially recorded at fair value. Patents are amortized over the useful lives of the assets, using the straight-line method. Certain patents are in the legal
application process and therefore are not currently being amortized. We review the carrying value of patents at the end of each reporting period. Based upon our review, there
were no patent impairments in 2015, 2014 or 2013.
Other intangible assets consist of software acquired with Response Genetics, which are amortized using the straight-line method over the estimated useful lives of the assets,
which range from three to five years.
Research and development: Research and development costs associated with service and product development include direct costs of payroll, employee benefits, stock-based
compensation and supplies and an allocation of indirect costs including rent, utilities, depreciation and repairs and maintenance. All research and development costs are
expensed as they are incurred.
Registration payment arrangements: We account for our obligations under registration payment arrangements in accordance with ASC 825-20, Registration Payment
Arrangements. ASC 825-20 requires us to record a liability if we determine a registration payment is probable and if it can reasonably be estimated. As of both December 31,
2015 and 2014, we have an accrued liability of $300,000.
Stock-based compensation: Stock-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation, which requires the
measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We
estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model. The value of the portion of the award that is ultimately
expected to vest is recognized as expense over the requisite service periods using the straight-line method. See additional information in Note 12.
All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value
of the equity instrument issued.
We account for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity Based Payments to Non-Employees. Under ASC 505-50, we
determine the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity
instruments issued, whichever is
86
Table of Contents
more reliably measurable. Stock-based compensation awards issued to non-employees are recorded in expense and additional paid-in capital in stockholders’ equity (deficit)
over the applicable service periods based on the fair value of the awards or consideration received at the vesting date.
Fair value of financial instruments: The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses,
approximate their estimated fair values due to the short term maturities of those financial instruments. The fair value of warrants recorded as derivative liabilities, contingent
consideration and note payable to VenturEast are described in Notes 14 and 15.
Joint venture accounted for under the equity method: The Company records its joint venture investment following the equity method of accounting, reflecting its initial
investment in the joint venture and its share of the joint venture’s net earnings or losses and distributions. The Company’s share of the joint venture’s net loss was
approximately $707,000 in 2015, $940,000 in 2014 and $12,000 in 2013 (the first year of the joint venture’s operations) and is included in research and development expense
on the Consolidated Statement of Operations. The Company has a net receivable due from the joint venture of approximately $10,000 and $10,000 at December 31, 2015 and
2014, respectively, which is included in other assets in the Consolidated Balance Sheet. See additional information in Note 17.
Subsequent events: We have evaluated potential subsequent events through the date the financial statements were issued.
Recent Accounting Pronouncements: In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842),” which provides guidance for accounting for leases. Under ASU
2016-02, the Company will be required to recognize the assets and liabilities for the rights and obligations created by leased assets. ASU 2016-02 will take effect for public
companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the effect this standard will
have on the consolidated financial statements.
In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805) “Simplifying the Accounting for Measurement-Period Adjustments,” which
eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under this ASU, acquirers must recognize
measurement-period adjustments in the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous
periods if the accounting had been completed at the acquisition date. The amendments in this update should be applied prospectively. This guidance is effective for fiscal years
beginning after December 15, 2015, with early adoption permitted for financial statements that have not been issued.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects
to be entitled for the transfer of promised goods or services to customers. As issued and amended, ASU 2014-9 will replace most existing revenue recognition guidance in U.S.
GAAP when it becomes effective and permits the use of either a full retrospective or retrospective with cumulative effect transition method. The updated standard becomes
effective for the Company in the first quarter of fiscal year 2018. Early adoption is permitted in the first quarter of fiscal year 2017. The Company has not yet selected a
transition method and is currently evaluating the effect that the updated standard will have on the consolidated financial statements.
During the second quarter of 2015, the Company adopted ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30) “Simplifying the Presentation of Debt Issuance
Costs” and ASU 2015-15, Interest-Imputation of Interest (Subtopic 835-30) “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-
Credit Arrangements.” Previously, debt issuance costs were recorded as assets on the balance sheet. ASU 2015-03 requires that debt issuance costs related to a debt liability be
presented on the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. ASU 2015-03 does not change the
recognition and measurement of debt issuance costs and requires retrospective adoption. ASU 2015-15 expands on the treatment of debt issuance costs related to line-of-credit
arrangements. Under ASU 2015-15, an entity is allowed to defer and present debt issuance costs related to line-of-credit arrangements as an asset and to amortize these costs
ratably over the term of the debt, regardless of whether there is any outstanding borrowings on the line-of-credit. The Company did not have debt issuance costs in the
December 31, 2014 Consolidated Balance Sheet.
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) “Disclosure of Uncertainties about an Entity's
Ability to Continue as a Going Concern.” The objective of the guidance is to require management to explicitly assess an entity's ability to continue as a going concern, and to
provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an
entity's ability to continue as a going concern within one year after the issuance date of an entity’s financial statements. The new standard defines substantial doubt and
provides examples of indicators thereof. The definition of
87
Table of Contents
substantial doubt incorporates a likelihood threshold of "probable" similar to the current use of that term in U.S. GAAP for loss contingencies. The new standard will be
effective for all entities in the first annual period ending after December 15, 2016. Earlier application is permitted. The Company is currently assessing this standard for its
impact on future reporting periods.
Earnings (loss) per share: Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of
common shares assumed to be outstanding during the period of computation. Diluted earnings per share is computed similar to basic earnings per share except that the
numerator is adjusted for the change in fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of dilutive potential common
shares outstanding during the period using the treasury stock method.
Basic net loss and diluted net loss per share data were computed as follows (in thousands, except per share amounts):
Numerator:
Net (loss) for basic earnings per share
Less change in fair value of warrant liability
Net (loss) for diluted earnings per share
Denominator:
Weighted-average basic common shares outstanding
Assumed conversion of dilutive securities:
Common stock purchase warrants
Potentially dilutive common shares
Denominator for diluted earnings per share—adjusted weighted-average shares
Basic net loss per share
Diluted net loss per share
2015
2014
2013
(20,184 ) $
35
(20,219 ) $
10,298
1
1
10,299
(1.96 ) $
(1.96 ) $
(16,643 ) $
417
(17,060 ) $
9,449
13
13
9,462
(1.76 ) $
(1.80 ) $
(12,373 )
4,633
(17,006 )
4,665
11
11
4,676
(2.65 )
(3.64 )
$
$
$
$
The following table summarizes potentially dilutive adjustments to the weighted average number of common shares which were excluded from the calculation (in thousands):
Common stock purchase warrants
Stock options
Restricted shares of common stock
Note 3. Revenue and Accounts Receivable
2015
2014
2013
4,372
1,961
121
6,454
1,061
1,839
133
3,033
Revenue by service type for each of the years ended December 31 is comprised of the following (in thousands):
Biopharma Services
Clinical Services
Discovery Services
Grants
2015
2014
2013
$
$
11,564 $
5,651
825
—
18,040 $
5,606 $
4,432
161
—
10,199 $
1,702
874
7
2,583
2,650
3,663
—
297
6,610
The table above includes approximately $486,000 of biopharma services revenue and approximately $1,265,000 of clinical services revenue from our acquisition of Response
Genetics for the period October 9, 2015 through December 31, 2015.
Accounts receivable by service type at December 31, 2015 and 2014 consists of the following (in thousands):
88
Table of Contents
Biopharma Services
Clinical Services
Discovery Services
Allowance for doubtful accounts
$
$
2015
2014
3,238 $
3,733
314
(664 )
6,621 $
3,203
1,925
151
(251 )
5,028
Allowance for Doubtful Accounts (in thousands)
Balance, December 31, 2013
Additions to allowance for doubtful accounts
Balance, December 31, 2014
Additions to allowance for doubtful accounts
Balance, December 31, 2015
$
$
36
215
251
413
664
Revenue for Biopharma Services are customized solutions for patient stratification and treatment selection through an extensive suite of DNA-based testing services. Clinical
Services are tests performed to provide information on diagnosis, prognosis and theranosis of cancers to guide patient management. These tests can be billed to Medicare,
another third party insurer or the referring community hospital or other healthcare facility. Discovery Services are services that provide the tools and testing methods for
companies and researchers seeking to identify new DNA-based biomarkers for disease. Grants includes revenue from grants. The breakdown of our Clinical Services revenue
(as a percent of total revenue) is as follows:
Medicare
Other insurers
Other healthcare facilities
Total Clinical Services
2015
2014
2013
10 %
12 %
9 %
31 %
11 %
16 %
16 %
43 %
13 %
25 %
18 %
56 %
We have historically derived a significant portion of our revenue from a limited number of test ordering sites. Test ordering sites account for all of our Clinical Services and
Biopharma Services revenue. Our test ordering sites are largely hospitals, cancer centers, reference laboratories, physician offices and biopharmaceutical companies.
Oncologists and pathologists at these sites order the tests on behalf of the needs of their oncology patients or as part of a clinical trial sponsored by a biopharmaceutical
company in which the patient is being enrolled. We generally do not have formal, long-term written agreements with such test ordering sites, and, as a result, we may lose a
significant test ordering site at any time.
The top five test ordering clients during 2015, 2014 and 2013 accounted for 49%, 56% and 69% respectively, of our testing volumes, with 18%, 38% and 36% respectively, of
the test volume coming from community hospitals. During the year ended December 31, 2015, one Biopharma client accounted for approximately 19% of our revenue. During
the year ended December 31, 2014 there were two Biopharma clients that accounted for approximately 23% and 12%, respectively, of our revenue. During 2013, there was one
client that accounted for approximately 40% of our revenue.
89
Table of Contents
Note 4. Other Current Assets
At December 31, 2015 and 2014, other current assets consisted of the following (in thousands):
Inventory
Prepaid expenses
2015
2014
$
$
133 $
1,985
2,118 $
280
893
1,173
Note 5. Lease Commitments
We lease our laboratory, research facility and administrative office space under various operating leases. We have approximately 17,900 square feet of office and laboratory
space in Rutherford, New Jersey, 24,900 square feet in Morrisville, North Carolina, 27,400 square feet in Los Angeles, California, 10,000 square feet in Hyderabad, India and
2,700 square feet in Shanghai, China. We have escalating lease agreements for both our New Jersey and North Carolina spaces which expire January 2018 and May 2020,
respectively. These leases require monthly rent with periodic rent increases that vary from $1 to $2 per square foot of the rented premises per year. The difference between
minimum rent and straight-line rent is recorded as deferred rent payable. The terms of our New Jersey lease require that a $300,000 security deposit for the facility be held in a
stand by letter of credit in favor of the landlord (see Note 7). The California lease expires June 30, 2016.
We acquired office and scientific equipment under long term leases which have been capitalized at the present value of the minimum lease payments. The equipment under
these capital leases had a cost of $706,154 and accumulated depreciation of $311,855, as of December 31, 2015.
Minimum future lease payments under all capital and operating leases as of December 31, 2015 are as follows (in thousands):
December 31,
2016
2017
2018
2019
2020
Thereafter
Total minimum lease payments
Less amount representing interest
Present value of net minimum obligations
Less current obligation under capital lease
Long-term obligation under capital lease
Capital
Leases
Operating
Leases
Total
$
$
$
143 $
78
75
70
59
24
449 $
51
398
122
276
1,396 $
936
397
342
135
—
3,206 $
1,539
1,014
472
412
194
24
3,655
Rent expense for the years ended December 31, 2015, 2014 and 2013 was $1,136,778, $692,324, and $550,882, respectively.
Note 6. Debt
Term Note - Silicon Valley Bank
On May 7, 2015, we entered into a new debt financing facility with Silicon Valley Bank (“SVB”) to refinance the Company’s cash collateralized loan from Wells Fargo and to
provide an additional working capital line of credit. The SVB credit facility provides for a $6.0 million term note (“Term Note”) and a revolving line of credit (“Line of
Credit”) for an amount not to exceed the lesser of (i) $4.0 million or (ii) an amount equal to 80% of eligible accounts receivable. The Term Note requires interest-only
payments through April 30, 2016 and beginning May 1, 2016, monthly principal payments of approximately$167,000 will be required plus interest through maturity on
April 1, 2019. The interest rate of the Term Note is the Wall Street
90
Table of Contents
Journal prime rate plus 2%, with a floor of 5.25% (5.50% at December 31, 2015) and an additional deferred interest payment of $180,000 will be due upon maturity. The Line
of Credit requires monthly interest-only payments of the Wall Street Journal prime rate plus 1.5% (5.00% at December 31, 2015) and matures on May 7, 2017. The new loan
agreement requires maintenance of certain financial ratios and grants SVB a first security interest in substantially all Company assets (other than our intellectual property).
Pursuant to the new loan agreement, the Company is no longer required to maintain restricted cash accounts. At December 31, 2015, the principal balance of the Term Note
was $6,000,000 and the principal balance of the Line of Credit was $0. On January 28, 2016, the Line of Credit was amended with SVB and we are no longer able to draw on
the Line of Credit until we raise approximately $13 million of additional equity.
The following is a summary of long-term debt as of December 31, 2015 (in thousands):
Term Note, principal balance
Less unamortized debt issuance costs
Term Note, net
Less current maturities
Long-term portion
$
$
$
6,000
25
5,975
1,333
4,642
Principal maturities of the Term Note as of December 31, 2015 are as follows: 2016 - $1,333,333; 2017 - $2,000,000; 2018 - $2,000,000; 2019 - $666,667.
Business Line of Credit - Wells Fargo
At December 31, 2014, we had a long-term, fully-utilized line of credit with Wells Fargo Bank, which provided for maximum borrowings of $6 million. The line of credit had
a maturity date of April 1, 2016 and required monthly interest payments equal to the Daily One Month LIBOR rate plus 1.75%. The line of credit was collateralized with $6
million in restricted cash and was refinanced by the SVB Term Note in May 2015.
Conversion of Debt concurrent with IPO
On April 10, 2013, we completed our IPO and converted the following indebtedness into shares of common stock at the IPO price of $10.00 per share (in thousands):
December 2011 Financing Transaction
2012 Convertible Debt Financing Transaction
December 2012 Bridge Financing Transaction
Business Lines of Credit (DAM)
Other Note Payable and accrued interest
Converted Amount
Common Shares
$
$
4,500
3,000
1,000
1,000
134
9,634
450
300
100
100
13
963
In connection with the conversion of debt into common stock, we expensed the applicable remaining debt discounts of $3.5 million, financing fees of $419,000 and a
contingently recognizable beneficial conversion feature in the converted debt of $3 million.
December 2011 Financing Transaction
The December 2011 Credit Agreement was with John Pappajohn and Andrew Pecora (indirectly through an investment company), both then members of our board of
directors, and NNJCA Capital, LLC (“NNJCA”), a limited liability company of which Dr. Pecora is a member. Mr. Pappajohn originally provided $4.0 million of financing,
NNJCA originally provided $1.5 million of financing and Dr. Pecora provided $500,000 of financing under the Credit Agreement. On April 10, 2013, Mr. Pappajohn
converted $4.0 million and Dr. Pecora converted $500,000 into 450,000 shares of our common stock at the IPO price of $10.00 per share concurrent with our IPO. The
remaining outstanding balance of $1.5 million was repaid on August 19, 2013 using a portion of the proceeds from our Secondary Offering.
91
Table of Contents
2012 Convertible Debt Financing Transaction
On April 10, 2013, the entire $3 million outstanding under a Restated Credit Agreement dated as of August 27, 2012, as amended and restated as of October 17, 2012,
($1,750,000 provided by Mr. Pappajohn and $1,250,000 provided by Mr. Mark Oman) was converted into 300,000 shares of common stock at the IPO price of $10 per share.
December 2012 Bridge Financing Transaction
On April 10, 2013, the entire $1 million outstanding under a credit agreement dated as of December 7, 2012, (all of which was provided by Mr. Pappajohn), was converted into
100,000 shares of common stock at the IPO price of $10.00 per share.
Business Line of Credit – DAM
On April 10, 2013, $1 million of indebtedness under this line with DAM Holdings, LLC was converted into 100,000 shares of common stock at the IPO price of $10 per share.
The remaining outstanding balance of $2.0 million was repaid on August 19, 2013 using a portion of the proceeds from our Secondary Offering.
Other Note Payable
On April 10, 2013, a $100,000 note payable and accrued interest payable to Dr. Chaganti was converted into 13,430 shares of common stock at the IPO price of $10.00 per
share.
Note 7. Letter of Credit
We maintain a $300,000 letter of credit in favor of our landlord pursuant to the terms of the lease for our Rutherford facility. At December 31, 2015 the letter of credit was
fully secured by the restricted cash disclosed on our Consolidated Balance Sheet.
Note 8. Fixed Assets
Fixed assets are summarized by major classifications as follows (in thousands):
Equipment
Furniture and fixtures
Leasehold improvements
Less accumulated depreciation
Net fixed assets
Note 9. Patents and Other Intangible Assets
Patents and other intangible assets consist of the following at December 31, 2015 and 2014:
2015
2014
$
$
8,442 $
1,083
932
10,457
(4,388 )
6,069 $
5,777
548
870
7,195
(2,885 )
4,310
(in thousands) (in thousands)
Patents
Patents - Response Genetics acquisition
Software - Response Genetics acquisition
$
Less accumulated amortization
Net patent and other intangible assets $
2015
2014
724 $
800
446
1,970
(243)
1,727 $
92
587
—
—
587
(84)
503
Weighted-Average
Amortization
Period
10 years
7 years
2 years
Table of Contents
Future amortization expense for legally approved patents (excluding patent applications in progress) and other intangible assets, is estimated as follows (in thousands):
2016
2017
2018
2019
2020
2021 and thereafter
Total
$
$
344
290
202
151
140
282
1,409
Note 10. Income Taxes
The provision for income taxes for the years ended December 31, 2015, 2014 and 2013 differs from the approximate amount of income tax benefit determined by applying the
U.S. federal income tax rate to pre-tax loss, due to the following (in thousands):
$
Income tax benefit at federal statutory rate
State tax provision, net of federal tax benefit
Tax credits
Stock based compensation
Derivative warrants
Investor consideration
Debt and warrant conversion costs
Change in valuation allowance
Foreign operations
Other
Income tax (benefit) provision
$
For the Year Ended
December 31, 2015
For the Year Ended December 31,
2014
For the Year Ended December 31,
2013
Amount
(in thousands)
% of
Pretax
Loss
Amount
(in thousands)
% of
Pretax
Loss
Amount
(in thousands)
% of
Pretax
Loss
(7,479)
(878)
(232)
201
(12)
(110)
—
6,617
283
426
(1,184)
35.0 % $
4.1 %
1.1 %
(0.9)%
0.1 %
0.5 %
— %
(31.0)%
(1.3)%
(2.1)%
5.5 % $
(6,648)
(807)
(154)
207
(146)
(69)
—
5,255
—
12
(2,350)
35.0 % $
4.2 %
0.8 %
(1.1)%
0.8 %
0.4 %
— %
(27.7)%
— %
— %
12.4 % $
(4,563)
(359)
(126)
229
(1,622)
—
3,454
2,356
—
(33)
(664)
35.0 %
2.8 %
1.0 %
(1.8)%
12.4 %
— %
(26.5)%
(18.1)%
— %
0.3 %
5.1 %
During November 2015, we sold $15,990,475 of gross State of New Jersey NOL carryforwards relating to the 2013 and 2014 tax years as well as $289,978 of research and
development tax credits, resulting in the receipt of $1,183,564, net of expenses. During January and December 2014, we sold $28,640,223 of gross State of New Jersey NOL
carryforwards relating to tax years 2009 through 2012, resulting in the receipt of $2,350,185. During 2013, we sold $8,018,107 of gross State of New Jersey NOL
carryforwards, resulting in the receipt of $663,900.
We transferred the NOL carryforwards through the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
Approximate deferred taxes consist of the following components as of December 31, 2015 and 2014 (in thousands):
93
Table of Contents
Deferred tax assets:
Net operating loss carryforwards
Accruals and reserves
Non-qualified stock options
Research and development tax credits
Derivative warrant liability
Investment in joint venture
Goodwill
Fixed assets
Other
Total deferred tax assets
Less valuation allowance
Net deferred tax assets
Deferred tax liabilities:
Fixed assets
Net deferred taxes
2015
2014
25,085 $
1,100
3,357
989
26
251
283
78
6
31,175
(31,175 )
—
—
— $
20,982
773
1,912
758
26
163
23
—
6
24,643
(24,558 )
85
(85 )
—
$
$
Due to a history of losses we have generated since inception, we believe it is more-likely-than-not that all of the deferred tax assets will not be realized as of December 31,
2015 and 2014. Therefore, we have recorded a full valuation allowance on our deferred tax assets. We have net operating loss carryforwards for federal income tax purposes
of approximately $69 million as of December 31, 2015. The net operating loss carryforwards will begin to expire in 2027. Utilization of these carryforwards is subject to
limitation due to ownership changes that may delay the utilization of a portion of the carryforwards.
94
Table of Contents
Note 11. Capital Stock
IPO
On April 10, 2013, we completed our IPO in which we issued and sold 690,000 shares of common stock (including the underwriter’s overallotment of 90,000 shares) at a
public offering price of $10.00 per share resulting in gross proceeds of $6.9 million. In connection with the offering, all outstanding shares of Series A preferred stock were
converted into 376,525 shares of common stock, and all outstanding shares of Series B preferred stock were converted into 910,800 shares of common stock. Concurrent with
the IPO, we issued 2,000 shares of common stock to Cleveland Clinic pursuant to our license agreement with Cleveland Clinic.
Secondary Offering
On August 19, 2013, we sold 1,500,000 shares of common stock at a public offering price of $10.00 per share resulting in gross proceeds of $15.0 million ($13.3 million of net
proceeds after offering expenses and underwriting discounts).
On September 5, 2013, we sold 105,000 additional common shares pursuant to the underwriter’s partial exercise of the over-allotment option which resulted in gross proceeds
of $1.1 million ($947,000 of net proceeds after offering expenses and underwriting discounts).
Follow-On Offering
On October 28, 2013, we sold 3,286,700 shares of common stock, (including the underwriter’s over-allotment of 428,700 shares), at a public offering price of $14.00 per share
resulting in gross proceeds of $46.0 million (net proceeds of $42.3 million).
Cantor Sales Agreement
In July 2015, we sold 2,800 shares of common stock that resulted in net proceeds to the Company of $34,000 through our sales agreement with Cantor Fitzgerald & Co. See
Note 19.
2015 Offering
On November 12, 2015, we sold 3,000,000 shares of common stock with warrants to purchase an aggregate of 3,000,000 shares of common stock at a combined public
offering price of $4.00 per share and warrant resulting in gross proceeds of $12.0 million ($10.3 million of net proceeds after offering expenses and underwriting discounts).
The underwriters also received 450,000 warrants pursuant to the partial exercise of the over-allotment option. The warrants have an exercise price of $5.00, became fully-
exercisable at issuance and expire on November 12, 2020.
Preferred Stock
We are currently authorized to issue up to 9,764,000 shares of preferred stock.
Note 12. Stock-Based Compensation
We have two equity incentive plans: the 2008 Stock Option Plan (the “2008 Plan”) and the 2011 Equity Incentive Plan (the “2011 Plan”, and together with the 2008 Plan, the
“Stock Option Plans”). The Stock Option Plans are meant to provide additional incentive to officers, employees and consultants to remain in our employment. Options granted
are generally exercisable for up to 10 years.
The Board of Directors adopted the 2011 Plan on June 30, 2011 and reserved 350,000 shares of common stock for issuance under the 2011 Plan. On May 22, 2014 and on May
14, 2015, the stockholders voted to increase the number of shares reserved by the plan to 2,000,000 and 2,650,000 shares of common stock, respectively, under several types
of equity awards including stock options, stock appreciation rights, restricted stock awards and other awards defined in the 2011 Plan.
The Board of Directors adopted the 2008 Plan on April 29, 2008 and reserved 251,475 shares of common stock for issuance under the plan. On April 1, 2010, the stockholders
voted to increase the number of shares reserved by the plan to 550,000. We are authorized to issue incentive stock options or non-statutory stock options to eligible
participants.
95
Table of Contents
We have also issued 48,000 options outside of the Stock Option Plans.
At December 31, 2015, 853,504 shares remain available for future awards under the 2011 Plan and 110,749 shares remain available for future awards under the 2008 Plan.
As of December 31, 2015, no stock appreciation rights and 275,500 shares of restricted stock had been awarded under the Stock Option Plans.
Prior to our IPO in April 2013, the Board of Directors authorized an offer to certain employee and non-employee options holders on the following terms: those holding stock
options with a strike price of $25.00 or more had the opportunity to exchange their options for 60% of the number of options currently held with an exercise price equal to the
IPO price, which was $10.00 per share, and those holding stock options with a strike price of $12.50 had the opportunity to exchange their options for 80% of the number of
options currently held with an exercise price equal to the IPO price which was $10.00 per share. On April 5, 2013, our initial public offering became effective and 336,300
options with exercise prices ranging from $12.50 to $33.80 were exchanged for 242,070 options with an exercise price of $10.00. The options did not result in the recognition
of incremental compensation cost. In addition, 53,500 options which were approved to be issued and priced at the IPO price were issued to employees with an exercise price of
$10.00 per share.
A summary of employee and non-employee stock option activity for the years ended December 31, 2015, 2014 and 2013 is as follows:
Options Outstanding
Number of
Shares
(in thousands)
Weighted-
Average
Exercise
Price
Weighted-
Average
Remaining
Contractual
Term (in years)
Aggregate
Intrinsic
Value
(in thousands)
Outstanding January 1, 2013
Granted
Canceled or expired
Outstanding December 31, 2013
Granted
Exercised
Canceled or expired
Outstanding December 31, 2014
Granted
Exercised
Canceled or expired
Outstanding December 31, 2015
Exercisable, December 31, 2015
$
$
553
427
(106 )
874
1,154
(30 )
(159 )
1,839
312
$
$
(4 ) $
(186 ) $
$
1,961
$
958
12.76
14.57
20.46
10.83
10.41
6.61
11.45
10.58
9.77
5.37
9.69
10.55
10.09
7.13 $
1,142
7.75 $
3,139
8.49 $
618
7.68 $
6.61 $
—
—
Aggregate intrinsic value represents the difference between the fair value of our common stock and the exercise price of outstanding, in-the-money options. During the year
ended December 31, 2015, 2014 and 2013, we received $23,480, $79,018 and $1,640, respectively, from the exercise of options. Also during the year ended December 31,
2014, an option holder exercised options to purchase 12,000 shares of common stock with an exercise price of $10.00 per share using the net issue exercise method whereby
the option holder surrendered 11,429 shares in payment in full of the exercise price resulting in net issuance of 571 shares of common stock.
As of December 31, 2015, total unrecognized compensation cost related to non-vested stock options granted to employees was $4,782,125, which we expect to recognize over
the next 3.10 years.
As of December 31, 2015, total unrecognized compensation cost related to non-vested stock options granted to non-employees was $150,000, which we expect to recognize
over the next 2.01 years.
The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock-based
compensation expense requires us to make assumptions and judgments about the
96
Table of Contents
variables used in the calculation, including the fair value of our common stock (see Note 14), the expected term (the period of time that the options granted are expected to be
outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. We also estimate forfeitures of unvested stock options. To the extent actual
forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period estimates are revised. No compensation cost is recorded for
options that do not vest. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment, and volatility is
based on an average of the historical volatilities of the common stock of three entities with characteristics similar to those of the Company. The risk-free rate is based on the
U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not
anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the plan design which has monthly vesting after an initial cliff
vesting period.
The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented:
Volatility
Risk free interest rate
Dividend yield
Term (years)
Weighted-average fair value of options granted during the period
Year Ended December 31,
2015
2014
2013
60.69 %
1.63 %
—
6.13
5.54
$
70.17 %
1.78 %
—
5.98
5.29
$
76.60 %
1.79 %
—
6.14
9.85
$
In 2010, we issued an aggregate of 80,000 options to non-employees with an exercise price of $25.00. As described above, on April 5, 2013, these options were exchanged for
48,000 options with an exercise price of $10.00. In October 2013, we issued 10,000 options to a non-employee with an exercise price of $15.39. In May 2014, we issued
200,000 options to a Director, with an exercise price of $15.89. See Note 18 for additional information. The following table presents the weighted-average assumptions used to
estimate the fair value of options reaching their measurement date for non-employees during the periods presented:
Volatility
Risk free interest rate
Dividend yield
Term (years)
Year Ended December 31,
2015
2014
2013
70.38 %
2.10 %
—
8.73
71.76 %
2.44 %
—
9.68
75.68 %
1.53 %
—
7.68
Starting in 2013, restricted stock awards have been granted to employees, directors and consultants as compensation for services. At December 31, 2015, there was $720,934
of unrecognized compensation cost related to non-vested restricted stock granted to employees; we expect to recognize the cost over 2.47 years.
The following table summarizes the activities for our non-vested restricted stock awards for the years ended December 31, 2015, 2014 and 2013:
97
Table of Contents
Non-vested Restricted Stock Awards
Non-vested at January 1, 2013
Granted
Vested
Non-vested at December 31, 2013
Granted
Vested
Forfeited/canceled
Non-vested at December 31, 2014
Granted
Vested
Forfeited/canceled
Non-vested at December 31, 2015
$
$
$
Number of Shares
(in thousands)
Weighted-Average
Grant Date Fair Value
—
13.50
15.39
12.55
9.01
10.19
12.04
8.14
9.50
9.09
9.03
8.25
— $
8
(3)
5 $
220
(80)
(12)
133 $
48
(47)
(13)
121
The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Statement of
Operations during the periods presented (in thousands):
Cost of revenues
Research and development
General and administrative
Sales and marketing
Total stock-based compensation
Year Ended December 31,
2015
2014
2013
233
360
2,106
135
2,834
$
$
149 $
473
3,058
155
3,835 $
41
114
516
64
735
$
$
98
Table of Contents
Note 13. Warrants
We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price
of the warrant. The warrants are described herein as derivative warrants. For all derivative warrants, in the event equity instruments are issued at a price lower than the
exercise price of the warrant, the exercise price is adjusted to the price of the new equity instruments issued (price adjustment feature). For certain of these warrants, the
number of shares underlying the warrant is also adjusted to an amount computed by dividing the proceeds of the warrant under its original terms by the revised exercise price
(share adjustment feature). These warrants are initially recorded as a warrant liability at fair value with a corresponding entry to the loan guarantee fee asset, debt discount,
additional paid-in capital or expense dependent upon the service provided in exchange for the warrant grant. Subsequently, any change in fair value is recognized in earnings
until such time as the warrants are exercised, amended or expire. As of December 31, 2015 and 2014 all warrants with a share adjustment feature have either expired or have
been exercised.
In connection with debt guarantees and extensions, we issued 1,051,506 warrants to Mr. Pappajohn, a member of our Board of Directors and stockholder, at various dates prior
to 2013 (see Note 18). These warrants were initially recorded at fair value as a loan guarantee fee amortized over the period of the guarantee to interest expense.
In connection with the 2012 Convertible Debt Financing Transaction, we granted 4,118 warrants to Mr. Pappajohn and 2,941 warrants to Mr. Oman on February 22, 2013. The
warrants have a ten-year term and an exercise price equal to the IPO price of $10.00 per share. Pursuant to a subsequent agreement, the warrants held by Mr. Pappajohn have
an exercise price of $15.00 per share. These warrants were initially recorded at fair value as a financing fee asset and were amortized over the period of the note to interest
expense. The issue date fair value of these warrants was $221,000.
In connection with the December 2012 Bridge Financing Transaction, we granted 2,353 ten-year warrants with an exercise price equal to the IPO price of $10.00 per share to
Mr. Pappajohn on March 7, 2013. Mr. Pappajohn subsequently agreed that if our final IPO price was below $15.00, there would be no further adjustment to the price or
number of shares covered by the warrants held by him. These warrants were initially recorded at fair value as a financing fee asset and were amortized over the period of the
note to interest expense. The issue date fair value of these warrants was $47,000.
On February 11, 2013, John Pappajohn agreed to limit certain anti-dilution rights in his warrants to purchase shares of the Company’s common stock. Subject to the
consummation of an IPO prior to April 13, 2013, Mr. Pappajohn agreed that if the final IPO price was below $15.00, the exercise price of the warrants held by him would
adjust to $15.00 and the number of shares underlying the warrants would be adjusted as if the IPO price were $15.00 and then there would be no further adjustment to the price
or number of shares covered by warrants held by him. In February 2013, certain warrant holders agreed to waive the price and share adjustment provisions of their warrants,
except for the anti-dilution provisions related to stock splits, subdivisions and combinations, with respect to an aggregate of 114,030 shares of common stock underlying such
warrants, effective immediately following the consummation of our IPO on April 10, 2013 at $10.00 per share.
On April 10, 2013, the Company completed the IPO at $10.00 per share. The shares of common stock issuable upon the exercise of warrants increased by 838,889 shares and
the exercise prices of 1,656,860 warrants were adjusted as a result of share and exercise price adjustment features in certain warrants.
On April 29, 2013, the Company received $96,000 from shareholders who exercised warrants to purchase 24,000 shares of common stock at $4.00 per share.
On July 6, 2013, a warrant holder exercised a warrant to purchase 6,000 shares of common stock at an exercise price of $4.00 per share using the net issuance exercise method
whereby 2,072 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 3,928 shares.
On July 8, 2013, the Company received $96,000 from shareholders who exercised warrants to purchase 24,000 shares of common stock at $4.00 per share.
On September 10, 2013 and September 27, 2013, the Company extended the expiration date of 42,468 warrants for 17 days and 11 days respectively.
On September 30, 2013, warrant holders exercised warrants to purchase 30,034 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise
method whereby 14,313 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 15,721 shares.
99
Table of Contents
On October 7, 2013 and October 8, 2013, warrant holders exercised warrants to purchase 33,868 shares of common stock, at exercise prices ranging from $10.00 – $14.10 per
share, using the net issuance exercise method whereby 23,188 shares were surrendered as payment in full of the exercise price resulting in a net issuance of 10,680 shares.
In January 2014, the Company received $950 from a warrant holder who exercised warrants to purchase 95 shares of common stock at $10.00 per share. In February 2014 a
warrant holder exercised warrants to purchase 3,320 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise method
whereby 1,661 shares were surrendered in payment in full of the exercise price resulting in a net issuance of 1,659 shares. In March 2014 a warrant holder exercised warrants
to purchase 12,500 shares of common stock at an exercise price of $10.00 per share using the net issuance exercise method whereby 7,230 shares were surrendered in payment
in full of the exercise price resulting in a net issuance of 5,270 shares. In June 2014, we received $177,154 from Mr. Pappajohn who exercised warrants to
purchase 44,288 shares of common stock at an exercise price of $4.00 per share.
In July 2014, warrant holders exercised warrants to purchase 130,000 shares of common stock at an exercise price of $4.00 per share using the net issuance exercise method
whereby 45,894 shares were surrendered in payment in full of the exercise price resulting in a net issuance of 84,106 shares.
In October 2014, 470,833 warrants expired unexercised, of which 233,333 were warrants held by Mr. Pappajohn.
On April 1, 2015, 19,138 warrants expired unexercised.
On November 12, 2015, the Company issued 3,000,000 warrants in conjunction with the 2015 Offering and an additional 450,000 warrants pursuant to the underwriter’s
partial exercise of the over-allotment option. The warrants have an exercise price of $5.00 per share and will expire November 12, 2020. See Note 11. We have evaluated the
terms and conditions of warrants issued with the 2015 Offering and determined the warrants should be included in equity and are not required to be reported as a liability.
On November 12, 2015, the exercise price of 75,215 warrants were adjusted from $10.00 per common share to $4.00 per common share due to 2015 Offering and the exercise
price adjustment feature in certain warrants.
On November 18, 2015, 14,665 warrants expired unexercised and the Company received $1,400 from a warrant holder who exercised warrants to purchase 350 shares of
common stock at $4.00 per share.
On December 9, 2015, 120,000 warrants held by Mr. Pappajohn expired unexercised.
100
Table of Contents
The following table summarizes the warrant activity for the years ending December 31, 2015, 2014 and 2013 (in thousands, except exercise price):
Exercise
Price
Warrants
Outstanding
January 1,
2013
2013
Warrants
Issued
2013
Warrants
Exercised
2013
Warrants
Expired
IPO
Adjustments
(E)
Warrants
Outstanding
December 31,
2013
2014
Warrants
Exercised
2014
Warrants
Expired
Warrants
Outstanding
December 31,
2014
2015
Warrants
Issued
2015 Offering
Adjustments
(F)
2015
Warrants
Exercised
2015
Warrants
Expired
Warrants
Outstanding
December 31,
2015
Issued With / For
Non-Derivative
Warrants:
Financing
Financing
Debt Guarantee
Debt Guarantee
Debt Guarantee
Series A Pref. Stock
Consulting
2015 Offering
$
10.00
15.00
4.00
10.00
15.00
14.10
10.00
5.00
$
6.82 G
Derivative Warrants:
Financing
Financing
Financing
Financing
Financing
Financing
Debt Guarantee
Debt Guarantee
Debt Guarantee
Debt Guarantee
Debt Guarantee
Debt Guarantee
Series B Pref. Stock
Series B Pref. Stock
Series B Pref. Stock
Consulting
Consulting
Consulting
4.00 B
10.00 B
25.00 B
42.50 BCD
42.50 AD
42.50 ACD
10.00 A
25.00 ACD
25.00 AD
32.45 AC
42.50 ACD
42.50 BCD
4.00 B
10.00 B
25.00 B
12.50 AD
14.10 AD
25.00 AD
4.00 G
6.78 G
$
$
________________________
A
—
—
228
—
—
66
—
—
294
—
—
60
75
55
121
—
212
100
40
38
37
—
—
52
4
10
4
808
1,102
—
—
—
—
—
—
—
—
—
—
—
—
—
3
6
—
—
—
—
—
—
—
—
—
—
—
—
9
9
—
—
(54 )
—
—
(30 )
—
—
(84 )
—
—
—
—
—
—
—
—
—
—
—
—
—
(34 )
—
—
—
—
(34 )
(118 )
—
—
—
—
—
(36 )
—
—
(36 )
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(36 )
243
436
—
238
586
—
29
—
1,532
—
60
(60 )
(75 )
(58 )
(127 )
13
(212 )
(100 )
(40 )
(38 )
(37 )
—
52
(52 )
(4 )
(10 )
(4 )
(692 )
840
243
436
174
238
586
—
29
—
1,706
—
60
—
—
—
—
13
—
—
—
—
—
—
18
—
—
—
—
91
1,797
—
—
(174 )
—
—
—
—
—
(174 )
—
—
—
—
—
—
(13 )
—
—
—
—
—
—
(3 )
—
—
—
—
(16 )
(190 )
—
—
—
(238 )
(233 )
—
—
—
(471 )
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(471 )
243
436
—
—
353
—
29
—
1,061
—
60
—
—
—
—
—
—
—
—
—
—
—
15
—
—
—
—
75
1,136
—
—
—
—
—
—
—
3,450
3,450
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
3,450
—
—
—
—
—
—
—
—
—
60
(60 )
—
—
—
—
—
—
—
—
—
—
15
(15 )
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(120 )
—
(19 )
—
(139 )
—
—
—
—
—
—
—
—
—
—
—
—
(15 )
—
—
—
—
—
(15 )
(154 )
243
436
—
—
233
—
10
3,450
4,372
60
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
60
4,432
These warrants are subject to fair value accounting and contain exercise price and number of share adjustment features. See Note
14.
These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note
14.
On February 11, 2013, these warrants held by John Pappajohn were amended to limit the adjustment feature(s) to $15.00 per share in an initial public offering (totaling 530,022
warrants).
The exercise price and/or number of share adjustment features of these warrants expired and are no longer subject to fair value accounting after our initial public
offering.
On April 10, 2013 the Company completed the IPO at $10.00 per share. The shares of common stock issuable upon the exercise of warrants outstanding as of April 10, 2013 increased by 838,889 shares and the exercise prices of 1,656,860 warrants were
adjusted as a result of the share and exercise price adjustment features described above.
On November 12, 2015 the Company completed the 2015 Offering and the exercise price of certain derivative warrants were adjusted to
$4.00.
Weighted average exercise prices are as of December 31,
2015.
B
C
D
E
F
G
101
Table of Contents
Note 14. Fair Value of Warrants
The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue during the years
ended December 31, 2015, 2014 and 2013 and at December 31, 2015, December 31, 2014, December 31, 2013, and April 5, 2013 (IPO valuation date). In computing the fair
value of the warrants, if the stated exercise price of the warrants exceeded the assumed value of the Company stock at the date the fair value was being computed, the exercise
price and number of shares (if applicable) underlying the warrants were adjusted to reflect an assumed trigger of the price and/or share adjustment features related to the
applicable warrants. Such adjustments were only applicable to 2013 due to the relative price of the warrants and the assumed Company stock price:
Debt Guarantee
Exercise Price
Expected life (years)
Expected volatility
Risk-free interest rate
Expected dividend yield
Exercised
During the Year
Ended
December 31,
2014
$
$
10.00
0.60
49.01%
0.08%
0.00%
IPO Date
April 5, 2013
13.56
2.42
66.37%
0.32%
0.00%
Series B
Exercise Price
Expected life (years)
Expected volatility
Risk-free interest rate
Expected dividend yield
Consulting
Exercise Price
Expected life (years)
Expected volatility
Risk-free interest rate
Expected dividend yield
$
$
Exercised During the Year
Ended December 31,
2014
2015
As of December
31, 2014
$
4.00
0.01
12.33%
0.07%
0.00%
$
10.00
1.72
46.60%
0.33%
0.00%
10.00
0.88
49.95%
0.25%
0.00%
As of December 31,
2015
2014
$
4.00
0.14
57.39%
0.16%
0.00%
$
10.00
1.14
49.25%
0.25%
0.00%
IPO Date
April 5, 2013
10.00
2.33
63.20%
0.27%
0.00%
Financing
Exercise Price
Expected life (years)
Expected volatility
Risk-free interest rate
Expected dividend yield
Issued During
the Year Ended
December 31,
2013
As of December 31,
2015
2014
$
$
13.34
9.78
74.70%
1.95%
0.00%
$
4.00
0.23
70.82%
0.16%
0.00%
$
10.00
1.23
50.23%
0.25%
0.00%
IPO Date
April 5, 2013
13.21
8.30
73.22%
1.44%
0.00%
102
Table of Contents
The assumed ranges of Company stock prices used in computing the warrant fair value for warrants issued during the year is as follows: in 2015, $3.30—$11.76 in 2014,
$6.68—$19.86; in 2013, $9.60—$20.26. In determining the fair value of warrants issued at each reporting date, the assumed Company stock price was $3.30 and $6.68 (the
closing price on the NASDAQ Capital Market) at December 31, 2015 and 2014.
The following table summarizes the derivative warrant activity subject to fair value accounting for the years ended December 31, 2015, 2014 and 2013 (in thousands):
Issued with
Series B
Preferred
Stock
Issued For
Debt
Guarantee
Issued For
Consulting
Issued For
Financing
Total
Fair value of warrants outstanding
as of January 1, 2013
Fair value of warrants issued
Fair value of warrants exercised
Reclassification to equity in IPO
Change in fair value of warrants
Fair value of warrants outstanding
as of December 31, 2013
Fair value of warrants exercised
Change in fair value of warrants
Fair value of warrants outstanding
as of December 31, 2014
Change in fair value of warrants
Fair value of warrants outstanding
as of December 31, 2015
$
230 $
—
(420)
—
307
117
(38)
(71)
8
(8)
5,679 $
—
—
(2,514)
(3,101)
64
(87)
23
—
—
147 $
—
—
(108)
(38)
1
—
(1)
—
—
6,493 $
268
—
(4,548)
(1,801)
412
—
(368)
44
(27)
$
— $
— $
— $
17 $
12,549
268
(420)
(7,170)
(4,633)
594
(125)
(417)
52
(35)
17
Note 15. Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Fair Value
Measurements and Disclosures Topic of the FASB Accounting Standards Codification requires the use of valuation techniques that are consistent with the market approach,
the income approach and/or the cost approach. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs
may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from
independent sources, or unobservable, meaning those that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances. In that regard, the Topic establishes a fair value hierarchy for valuation inputs that give the highest
priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.
The fair value hierarchy is as follows:
Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date.
Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or
other inputs that are observable or can be corroborated by observable market data.
Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability.
The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy
utilized to measure fair value (in thousands):
103
Table of Contents
Warrant liability
Notes payable
Warrant liability
Gentris contingent consideration
Notes payable
2015
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
—
—
—
2014
— $
—
— $
17
266
283
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
—
—
—
—
— $
—
—
— $
52
293
535
880
Total
Total
17
266
283
52
293
535
880
$
$
$
$
The warrant liability consists of stock warrants we issued that contain an exercise price adjustment feature. In accordance with derivative accounting for warrants, we
calculated the fair value of warrants and the assumptions used are described in Note 14, “Fair Value of Warrants.” Realized and unrealized gains and losses related to the
change in fair value of the warrant liability are included in other income (expense) on the Consolidated Statement of Operations and Comprehensive Loss.
The value of the Gentris contingent consideration was determined using a discounted cash flow of the expected payments required by the purchase agreement. During the year
ended December 31, 2015 we recognized a gain of $207,000 due to settling the contingent consideration for $86,400.
The ultimate payment to VenturEast will be the value of 84,278 shares of common stock at the time of payment. The value of the note payable to VenturEast was determined
using the fair value of our common stock less a discount for credit risk. During the years ended December 31, 2015 and 2014 we recognized a gain of $269,000 and $198,000,
respectively, due to the decrease in value of the note.
Realized and unrealized gains and losses related to the change in fair value of the Gentris contingent consideration are included in general and administrative expense, while
realized and unrealized gains and losses related to the VenturEast note are included in other income (expense) on the Consolidated Statement of Operations and
Comprehensive Loss.
A table summarizing the activity for the derivative warrant liability which is measured at fair value using Level 3 inputs is presented in Note 14. The following table
summarizes the activity of the notes payable to VenturEast and Gentris contingent consideration which were measured at fair value using Level 3 inputs (in thousands):
Fair value at January 1, 2014
Fair value at issuance
Change in fair value
Fair value at December 31, 2014
Change in fair value
Settlement of liability
Fair value at December 31, 2015
Note Payable
to VenturEast
Gentris Contingent
Consideration
— $
733
(198)
535 $
(269)
—
266 $
—
293
—
293
(207)
(86)
—
$
$
$
104
Table of Contents
Note 16. Contingencies
In the normal course of business, the Company is involved in various claims and legal proceedings. In the opinion of management, the ultimate liability or disposition thereof
is not expected to have a material adverse effect on our financial condition, results of operations or liquidity.
Note 17. Joint Venture Agreement
In November 2011, we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), subsequently amended. Under the
agreement, we formed a joint venture with Mayo in May 2013 to focus on developing oncology diagnostic services and tests utilizing next generation sequencing. The joint
venture is a limited liability company, with each party initially holding fifty percent of the issued and outstanding membership interests of the new entity (the “JV”). In
exchange for our membership interest in the JV, we made an initial capital contribution of $1.0 million in October 2013. In addition, we issued 10,000 shares of our common
stock to Mayo pursuant to our affiliation agreement and recorded an expense of approximately $175,000. We also recorded additional expense of approximately $231,000
during the fourth quarter of 2013 related to shares issued to Mayo in November of 2011 as the JV achieved certain performance milestones. In the third quarter of 2014 we
made an additional $1.0 million capital contribution.
The agreement also requires aggregate total capital contributions by us of up to an additional $4.0 million. We currently anticipate that we will make capital contributions of
$1.0 million in the second quarter of 2016. The timing of the remaining installments is subject to the JV's achievement of certain operational milestones agreed upon by the
board of governors of the JV. In exchange for its membership interest, Mayo’s capital contribution will take the form of cash, staff, services, hardware and software resources,
laboratory space and instrumentation, the fair market value of which will be approximately equal to $6.0 million. Mayo’s continued contribution will also be conditioned upon
the JV’s achievement of certain milestones.
The joint venture is considered a variable interest entity under ASC 810-10, but we are not the primary beneficiary as we do not have the power to direct the activities of the
joint venture that most significantly impact its performance. Our evaluation of ability to impact performance is based on our equal board membership and voting rights and day
to day management functions which are performed by the Mayo personnel.
Note 18. Related Party Transactions
John Pappajohn, a member of the Board of Directors and stockholder, had personally guaranteed our revolving line of credit with Wells Fargo Bank through March 31, 2014.
As consideration for his guarantee, as well as each of the eight extensions of this facility through March 31, 2014, Mr. Pappajohn received warrants to purchase an aggregate
of 1,051,506 shares of common stock of which Mr. Pappajohn assigned warrants to purchase 284,000 shares of common stock to certain third parties. Through December 31,
2015, warrants to purchase 440,113 shares of common stock have been exercised by Mr. Pappajohn and 353,333 warrants to purchase common stock have expired. After
adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of these warrants outstanding retained by Mr. Pappajohn was 232,312 at $15.00 per
share on December 31, 2015.
In addition, John Pappajohn also had loaned us an aggregate of $6,750,000 (all of which was converted into 675,000 shares of common stock at the IPO price of $10.00 per
share). In connection with these loans, Mr. Pappajohn received warrants to purchase an aggregate of 202,630 shares of common stock. After adjustment pursuant to the terms
of the warrants in conjunction with our IPO, the number of warrants outstanding was 436,079 at $15.00 per share at December 31, 2015.
Effective January 6, 2014, the board of directors appointed John Pappajohn to serve as the Chairman of the Board, a position previously held by Dr. Raju S.K. Chaganti. As
compensation for serving as the Chairman of the Board, the Company will pay Mr. Pappajohn $100,000 per year and granted to Mr. Pappajohn 25,000 restricted shares of the
Company's common stock, and options to purchase an aggregate of 100,000 shares of the Company's common stock. The options have a term of ten years from the date on
which they were granted. The restricted stock and the options each vest in two equal installments on the one year anniversary and the two year anniversary of the date on
which Mr. Pappajohn became the Chairman of the Board.
On October 14, 2015 the Board of Directors granted John Pappajohn and Dr. Chaganti 2,500 restricted shares each of the Company’s common stock and options to purchase
an aggregate of 10,000 shares each of the Company’s common stock as compensation for serving on the Board of Directors. The restricted stock vests on the one-year
anniversary date of the grant and the stock options vest in two equal installments on the one-year anniversary and the two-year anniversary date of the grant.
In August 2010, we entered into a consulting agreement with Equity Dynamics, Inc. (“EDI”), an entity controlled by John Pappajohn, pursuant to which EDI received a
monthly fee of $10,000. The consulting agreement was terminated effective March 31, 2014.
105
Table of Contents
Subsequently the Company entered into a new consulting agreement with EDI effective April 1, 2014 pursuant to which it receives a monthly fee of $10,000. We expensed
$120,000 annually for the years ended December 31, 2015, 2014 and 2013 related to this agreement.
On May 19, 2006, we issued a convertible promissory note in favor of our then Chairman and founder, Dr. Chaganti, the holder, which obligated us to pay the holder the sum
of $100,000, together with interest at the rate of 8.5% per annum, due April 1, 2014. Interest expense was $2,400 for the year ended December 31, 2013. On April 10, 2013 the
note and accrued interest converted into 13,430 shares of common stock at the IPO price of $10.00 per share. Pursuant to a consulting and advisory agreement, Dr. Chaganti
also received options to purchase a total of 36,000 shares of common stock at a price of $10.00 per share which vested over a two year period. Total non-cash stock-based
compensation recognized under the consulting agreement for the year ended December 31, 2013 was $76,220. Additionally, on September 15, 2010, we entered into a three
year consulting agreement with Dr. Chaganti which was subsequently renewed through December 31, 2016 pursuant to which Dr. Chaganti receives $5,000 per month for
providing consulting and technical support services. Total expenses for each of the years ended December 31, 2015, 2014 and 2013 were $60,000. Pursuant to the terms of the
renewed consulting agreement, Dr. Chaganti received an option to purchase 200,000 shares of our common stock at a purchase price of $15.89 per share vesting over a period
of four years. Total non-cash stock-based compensation recognized under this consulting agreement for the years ended December 31, 2015, 2014 and 2013 was $239,375,
$341,000 and $0, respectively. Also pursuant to the consulting agreement, Dr. Chaganti assigned to us all rights to any inventions which he may invent during the course of
rendering consulting services to us. In exchange for this assignment, if the USPTO issues a patent for an invention on which Dr. Chaganti is listed as an inventor, we are
required to pay Dr. Chaganti (i) a one-time payment of $50,000 and (ii)1% of any net revenues we receive from any licensed sales of the invention. In 2014 we paid
Dr. Chaganti $150,000 which was recognized as an expense in fiscal 2013 when three patents were issued. Also in February 2015, we paid Dr. Chaganti $150,000 for which
was recognized as an expense in 2014 when three additional patents were issued.
Andrew Pecora (indirectly through an investment company), when a member of our board of directors, and NNJCA, a limited liability company of which Dr. Pecora is a
member originally provided $0.5 and $1.5 million of financing, respectively, under a Credit Agreement dated as of December 21, 2011, as amended and restated as of
February 13, 2012. On April 10, 2013, NNJCA converted $0.5 million of its outstanding indebtedness into 50,000 shares of our common stock at the IPO price of $10.00 per
share concurrent with our IPO. On August 19, 2013, the remaining principal under these notes were repaid to Dr. Pecora and NNJCA using a portion of the proceeds from our
Secondary Offering. The loan bore an annual interest rate equal to the prime rate plus 6.25% (9.50% at August 19, 2013). We paid a pre-payment penalty due to Pecora and
NNJCA of $130,000 of which $32,667 was paid upon conversion of the notes and the remaining balance paid on August 19, 2013.
On November 12, 2015, John Pappajohn, Chairman of the Board and Edward Sitar, Chief Financial Officer purchased 100,000 and 5,000, respectively, of shares of common
stock with warrants to purchase 100,000 shares of common stock and 5,000 shares of common stock, respectively, in the 2015 Offering described in Note 11.
Note 19. Cantor Sales Agreement
On July 15, 2015, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., (“Cantor”) as sales agent,
pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $20.0 million. Subject to
the terms and conditions of the Sales Agreement, Cantor will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and
federal law, rules and regulations and the rules of The NASDAQ Capital Market to sell shares from time to time based upon the Company’s instructions, including any price,
time or size limits specified by the Company. Under the Sales Agreement, Cantor may sell shares by any method deemed to be an “at-the-market” offering as defined in Rule
415 under the U.S. Securities Act of 1933, as amended, or, with the Company’s prior consent, any other method permitted by law, including in privately negotiated
transactions. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by the Company from time to time. The
Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of
(a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will
receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification
and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement. During 2015, the
Company sold 2,800 shares of its common stock that resulted in net proceeds to the Company of approximately $34,000. In July 2015, we temporarily suspended selling
shares of common stock using the Sales Agreement. Furthermore, under the terms of our lock up agreement with Joseph Gunnar and Feltl, we were prohibited from selling our
common stock under the Sales Agreement until 90 days after the 2015 Offering, or February 5, 2016.
106
Table of Contents
Note 20. Subsequent Events
On January 28, 2016, the Line of Credit was amended with Silicon Valley Bank. See Note 6.
Item 9.
None.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
Item 9A.
Controls and Procedures.
Evaluation of Disclosure Controls and Procedures.
We evaluated, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934 (“Exchange Act”), as amended) as of
December 31, 2015, the end of the period covered by this report on Form 10-K. Based on this evaluation, our President and Chief Executive Officer (principal executive
officer) and our Chief Financial Officer (principal accounting and financial officer) have concluded that our disclosure controls and procedures were effective at December 31,
2015. Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act
(i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and were operating in an effective manner for the period
covered by this report, and (ii) is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow
timely decisions regarding required disclosures.
Management’s Report on Internal Control Over Financial Reporting.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) under the
Securities Exchange Act of 1934.
The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
•
•
•
Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the
Company;
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and
Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a
material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to
future periods are subject to risk that controls may become inadequate because of changes in conditions or because of declines in the degree of compliance with policies or
procedures.
We completed the acquisition of Response Genetics on October 9, 2015. Management's assessment of and conclusion on the effectiveness of our internal control over financial
reporting excludes the internal controls over the financial reporting of this acquisition. This acquisition contributed approximately 10 percent of our net sales for the year
ended December 31, 2015 and accounted for approximately 28 percent of our total assets as of December 31, 2015. Registrants are permitted to exclude acquisitions from their
assessment of internal controls over financial reporting during the first year if, among other circumstances and factors, there is not adequate time between the consummation
date of the acquisition and the assessment date for assessing internal controls.
Our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2015. In making this assessment, our management
used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013).
Based on management’s assessment, as of December 31, 2015, the Company’s internal control over financial reporting was effective.
107
Table of Contents
Item 9B.
Other Information.
None.
108
Table of Contents
PART III
Item 10.
Directors, Executive Officers and Corporate Governance.
The information required by this item will be contained in the Proxy Statement for our 2016 Annual Meeting of Stockholders, which we anticipate will be filed no later than
120 days after the end of our fiscal year ended December 31, 2015 and is incorporated herein by reference herein.
Item 11.
Executive Compensation.
The information required by this item will be contained in the Proxy Statement for our 2016 Annual Meeting of Stockholders, which we anticipate will be filed no later than
120 days after the end of our fiscal year ended December 31, 2015 and is incorporated by reference herein.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item will be contained in the Proxy Statement for our 2016 Annual Meeting of Stockholders, which we anticipate will be filed no later than
120 days after the end of our fiscal year ended December 31, 2015 and is incorporated by reference herein.
Item 13.
Certain Relationships and Related Transactions, and Director Independence.
The information required by this item will be contained in the Proxy Statement for our 2016 Annual Meeting of Stockholders, which we anticipate will be filed no later than
120 days after the end of our fiscal year ended December 31, 2015 and is incorporated by reference herein.
Item 14.
Principal Accounting Fees and Services.
The information required by this item will be contained in the Proxy Statement for our 2016 Annual Meeting of Stockholders, which we anticipate will be filed no later than
120 days after the end of our fiscal year ended December 31, 2015 and is incorporated by reference herein.
109
Table of Contents
PART IV
Item 15.
Exhibits, Financial Statement Schedules.
(a)(1) Financial Statements. The financial statements filed as part of this report are listed on the Index to the Consolidated Financial Statements.
(a)(2) Financial Statement Schedules. Schedules are omitted because they are not applicable or the required information is shown in the consolidated financial
statements or notes thereto.
(a)(3) Exhibits. Reference is made to the Exhibit Index. The exhibits are included, or incorporated by reference, in this annual report on Form 10-K and are numbered in
accordance with Item 601 of Regulation S-K.
110
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
Date: March 10, 2016
Date: March 10, 2016
Cancer Genetics, Inc.
(Registrant)
111
/s/ Panna L. Sharma
Panna L. Sharma
President and Chief Executive Officer
(Principal Executive Officer and duly authorized signatory)
/s/ Edward J. Sitar
Edward J. Sitar
Chief Financial Officer
(Principal Financial and Accounting Officer)
Table of Contents
SIGNATURES AND POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Panna Sharma and Edward Sitar, and each of
them, his true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities,
to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments to this annual report on Form 10-K together with all schedules and exhibits
thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith and, (iii) take any
and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he might or could do in person, hereby approving, ratifying and
confirming all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act, this annual report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.
Signature
/s/ Panna L. Sharma
Panna L. Sharma
/s/ Edward J. Sitar
Edward J. Sitar
/s/ John Pappajohn
John Pappajohn
/s/ Geoffrey Harris
Geoffrey Harris
/s/ Edmund Cannon
Edmund Cannon
/s/ Howard McLeod
Howard McLeod
/s/ Michael J. Welsh
Michael J. Welsh
/s/ Raju S. K. Chaganti
Raju S. K. Chaganti, Ph.D.
/s/ Franklyn G. Prendergast
Franklyn G. Prendergast, M.D., Ph.D.
Title
President, Chief Executive Officer and Director
(Principal Executive Officer)
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
Chairman of the Board of Directors
Director
Director
Director
Director
Director
Director
112
Date
March 10, 2016
March 10, 2016
March 10, 2016
March 10, 2016
March 10, 2016
March 10, 2016
March 10, 2016
March 10, 2016
March 10, 2016
Table of Contents
Exhibit
No.
INDEX TO EXHIBITS
Description
3.1
3.2
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
10.1
10.2
10.3
10.4
10.5
10.6
10.7
Third Amended and Restated Certificate of Incorporation of Cancer Genetics, Inc., filed as Exhibit 3.1 to quarterly report on Form 10-Q filed on May 15,
2013 and incorporated herein by reference.
Amended and Restated Bylaws of Cancer Genetics, Inc., filed as Exhibit 3.4 to Form S-1/A filed on April 30, 2012 (File No. 333-178836) and incorporated
herein by reference.
Specimen Common Stock certificate of Cancer Genetics, Inc., filed as Exhibit 4.1 to Form S-1/A filed on May 16, 2012 (File No. 333-178836) and
incorporated herein by reference.
Form of Short Form Cashless Exercise Warrant, filed as Exhibit 4.9 to Form S-1 filed on December 30, 2011 (File No. 333-178836) and incorporated herein
by reference.
Form of Medium Form Warrant, filed as Exhibit 4.10 to Form S-1 filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Form of Long Form Warrant, filed as Exhibit 4.11 to Form S-1 filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Form of Bridge Financing Warrant issued by Cancer Genetics, Inc. to John Pappajohn, NNJCA Capital, LLC, Pecora and Company and DAM Holdings,
LLC, filed as Exhibit 10.36 to Form S-1/A filed on March 13, 2012 (File No. 333-178836) and incorporated herein by reference.
Form of Modified Bridge Warrant issued by Cancer Genetics, Inc. to John Pappajohn and Mark Oman, filed as Exhibit 10.50 to Form S-1/A filed on October
23, 2012 (File No. 333-178836) and incorporated herein by reference.
Form of October 2012 Warrant issued by Cancer Genetics, Inc. to John Pappajohn and Mark Oman, filed as Exhibit 10.53 to Form S-1/A filed on October
23, 2012 (File No. 333-178836) and incorporated herein by reference.
Asset Purchase Agreement, by and among Cancer Genetics, Inc., Gentris, LLC and Gentris Corporation, dated July 15, 2014 (incorporated by reference to
Exhibit 4.1 of the Company’s current report on Form 8-K filed on July 22, 2014 with the Securities and Exchange Commission).
Share Purchase Agreement, by and among Cancer Genetics (India) Private Limited, Cancer Genetics, Inc., BioServe Biotechnologies (India) Pvt. Ltd.,
BioServe Biotechnologies Ltd., and each of the Selling Shareholders named therein, dated May 12, 2014 (incorporated by reference to Exhibit 4.1 of the
Company’s current report on Form 8-K filed on August 18, 2014 with the Securities and Exchange Commission).
Stock Purchase Agreement, by and between Cancer Genetics, Inc. and BioServe Biotechnologies Ltd., dated May 12, 2014 (incorporated by reference to
Exhibit 4.2 of the Company’s current report on Form 8-K filed on August 18, 2014 with the Securities and Exchange Commission).
Amended and Restated 2008 Stock Option Plan, filed as Exhibit 10.1 to Form S-1/A filed on October 23, 2012 (File No. 333-178836) and incorporated
herein by reference.
Form of Notice of Stock Option Grant under 2008 Stock Option Plan, filed as Exhibit 10.2 to Form S-1 filed on December 30, 2011 (File No. 333-178836)
and incorporated herein by reference.
Form of Stock Option Grant Agreement under 2008 Stock Option Plan, filed as Exhibit 10.3 to Form S-1 filed on December 30, 2011 (File No. 333-178836)
and incorporated herein by reference.
Form of Exercise Notice and Restricted Stock Purchase Agreement under 2008 Stock Option Plan, filed as Exhibit 10.4 to Form S-1 filed on December 30,
2011 (File No. 333-178836) and incorporated herein by reference.
Amended and Restated 2011 Equity Compensation Plan, dated May 22, 2014 (incorporated by reference to Exhibit 10.1 to the Company's current report on
Form 8-K filed on May 22, 2014 with the Securities and Exchange Commission)
Form of Stock Option Grant Agreement under 2011 Stock Option Plan, filed as Exhibit 10.6 to Form S-1 filed on December 30, 2011 (File No. 333-178836)
and incorporated herein by reference.
Form of Indemnification Agreement, filed as Exhibit 10.7 to Form S-1 filed on December 30, 2011 (File No. 333-178836) and incorporated herein by
reference.
113
Table of Contents
Exhibit
No.
Description
10.8
10.9
10.10
10.11
10.12
10.13
10.14
10.15
10.16
10.17
10.18
10.19
10.20
10.21
10.22
10.23
10.24
10.25
Medical Director Agreement, between Cancer Genetics, Inc. and Lan Wang, M.D., dated October 9, 2009, filed as Exhibit 10.9 to Form S-1 filed on
December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Consulting Agreement, between Cancer Genetics, Inc. and R.S.K. Chaganti, dated September 15, 2010, filed as Exhibit 10.15 to Form S-1 filed on December
30, 2011 (File No. 333-178836) and incorporated herein by reference.
Employment Agreement, between Panna Sharma and Cancer Genetics, Inc., effective as of April 1, 2010, filed as Exhibit 10.17 to Form S-1/A filed on
February 14, 2012 (File No. 333-178836) and incorporated herein by reference.
Employment Agreement, between Jane Houldsworth El Naggar, Ph.D. and Cancer Genetics, Inc., effective as of January 1, 2012, filed as Exhibit 10.19 to
Form S-1/A filed on February 14, 2012 (File No. 333-178836) and incorporated herein by reference.
Office Lease Agreement, between Cancer Genetics, Inc. and Onyx Equities, LLC, dated October 9, 2007, filed as Exhibit 10.20 to Form S-1/A filed on April
23, 2012 (File No. 333-178836) and incorporated herein by reference.
Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated April 29, 2008, filed as Exhibit 10.21 to Form S-1 filed on December
30, 2011 (File No. 333-178836) and incorporated herein by reference.
Security Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated April 29, 2008, filed as Exhibit 10.22 to Form S-1 filed on December
30, 2011 (File No. 333-178836) and incorporated herein by reference.
First Addendum to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated July 7, 2008, filed as Exhibit 10.23 to Form S-1
filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Second Addendum to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated March 30, 2009, filed as Exhibit 10.24 to Form
S-1 filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Third Addendum to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated July 2, 2009, filed as Exhibit 10.25 to Form S-1
filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference
Fourth Addendum to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated October 21, 2009, filed as Exhibit 10.26 to Form
S-1 filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Fifth Addendum to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated July 29, 2010, filed as Exhibit 10.27 to Form S-1
filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Credit Agreement, between Cancer Genetics, Inc. and DAM Holdings, LLC, dated March 23, 2011, filed as Exhibit 10.28 to Form S-1 filed on December 30,
2011 (File No. 333-178836) and incorporated herein by reference.
Inter-creditor Agreement, between Cancer Genetics, Inc., John Pappajohn and DAM Holdings, LLC, dated March 23, 2011, filed as Exhibit 10.29 to Form S-
1 filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
General Business Security Agreement, between Cancer Genetics, Inc. and DAM Holdings, LLC, dated March 23, 2011, filed as Exhibit 10.30 to Form S-1
filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Promissory Note, issued by Cancer Genetics, Inc. to DAM Holdings, LLC, dated March 23, 2011, filed as Exhibit 10.31 to Form S-1 filed on December 30,
2011 (File No. 333-178836) and incorporated herein by reference.
Sixth Addendum to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated June 6, 2011, filed as Exhibit 10.32 to Form S-1
filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Amended and Restated Credit Agreement, by and among Cancer Genetics, Inc., John Pappajohn, Pecora and Company and NNJCA Capital, LLC dated
February 13, 2012, filed as Exhibit 10.33 to Form S-1/A filed on March 13, 2012 (File No. 333-178836) and incorporated herein by reference.
114
Table of Contents
Exhibit
No.
Description
10.26
10.27
10.28
10.29
10.30
10.31
10.32
10.33
10.34
10.35
10.36
10.37
10.38
10.39
10.40
10.41
10.42
10.43
10.44
Form of Promissory Note issued by Cancer Genetics, Inc. to John Pappajohn, filed as Exhibit 10.34 to Form S-1/A filed on March 13, 2012 (File No. 333-
178836) and incorporated herein by reference.
Form of Promissory Note issued by Cancer Genetics, Inc. to NNJCA Capital, LLC and Pecora and Company, filed as Exhibit 10.35 to Form S-1/A filed on
March 13, 2012 (File No. 333-178836) and incorporated herein by reference.
Inter-Creditor Agreement, between Cancer Genetics, Inc., John Pappajohn, DAM Holdings, LLC, Pecora and Company, NNJCA Capital, LLC and Equity
Dynamics, Inc., dated February 13, 2012, filed as Exhibit 10.37 to Form S-1/A filed on March 13, 2012 (File No. 333-178836) and incorporated herein by
reference.
Seventh Addendum to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated February 15, 2012, filed as Exhibit 10.38 to
Form S-1/A filed on March 13, 2012 (File No. 333-178836) and incorporated herein by reference.
Amendment to Credit Agreement, between Cancer Genetics, Inc. and DAM Holdings, LLC, dated March 9, 2012, filed as Exhibit 10.33 to Form S-1/A filed
on March 13, 2012 (File No. 333-178836) and incorporated herein by reference.
Affiliation Agreement, between Cancer Genetics, Inc. and Mayo Foundation for Medical Education and Research dated November 7, 2011, filed as Exhibit
10.35 to Form S-1 filed on December 30, 2011 (File No. 333-178836) and incorporated herein by reference.
Consulting Agreement with Equity Dynamics, Inc., filed as Exhibit 10.38 to Form S-1/A filed on February 14, 2012 (File No. 333-178836) and incorporated
herein by reference.
Letter Agreement, between Meadows Office, L.L.C. and Cancer Genetics, Inc., dated January 10, 2008, filed as Exhibit 10.44 to Form S-1/A filed on April
23, 2012 (File No. 333-178836) and incorporated herein by reference.
Letter of Credit from JPMorgan Chase Bank, N.A., dated April 19, 2012, filed as Exhibit 10.46 to Form S-1/A filed on April 30, 2012 (File No. 333-178836)
and incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and John Pappajohn, filed as Exhibit 10.47 to Form S-1/A filed on May 7, 2012 (File No. 333-178836) and
incorporated herein by reference.
Amendment No. 1 to Affiliation Agreement, between Cancer Genetics, Inc. and Mayo Foundation for Medical Education and Research, dated September 29,
2012, filed as Exhibit 10.49 to Form S-1/A filed on October 23, 2012 (File No. 333-178836) and incorporated herein by reference.
Restated Credit Agreement, between Mark Oman and John Pappajohn and Cancer Genetics, Inc., dated October 17, 2012, filed as Exhibit 10.51 to Form S-
1/A filed on October 23, 2012 (File No. 333-178836) and incorporated herein by reference.
Form of Restated Promissory Note issued by Cancer Genetics, Inc. to John Pappajohn and Mark Oman, filed as Exhibit 10.52 to Form S-1/A filed on
October 23, 2012 (File No. 333-178836) and incorporated herein by reference.
Restated Registration Rights Agreement, between Cancer Genetics, Inc., Mark Oman and John Pappajohn, dated October 17, 2012, filed as Exhibit 10.54 to
Form S-1/A filed on October 23, 2012 (File No. 333-178836) and incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and Pecora, filed as Exhibit 10.55 to Form S-1/A filed on October 23, 2012 (File No. 333-178836) and
incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and NNJCA Capital, LLC, filed as Exhibit 10.56 to Form S-1/A filed on October 23, 2012 (File No. 333-
178836) and incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and DAM Holdings, Inc., filed as Exhibit 10.57 to Form S-1/A filed on October 23, 2012 (File No. 333-
178836) and incorporated herein by reference.
Eighth Addendum to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated October 18, 2012, filed as Exhibit 10.58 to Form
S-1/A filed on November 16, 2012 (File No. 333-178836) and incorporated herein by reference.
Credit Agreement between John Pappajohn and Cancer Genetics, Inc. dated December 4, 2012, filed as Exhibit 10.59 to Form S-1/A filed on December 14,
2012 (File No. 333-178836) and incorporated herein by reference.
115
Table of Contents
Exhibit
No.
Description
10.45
10.46
10.47
10.48
10.49
10.50
10.51
10.52
10.53
10.54
10.55
10.56
10.57
10.58
10.59
10.60
10.61
10.62
Promissory Note issued by Cancer Genetics, Inc. to John Pappajohn dated December 4, 2012, filed as Exhibit 10.60 to Form S-1/A filed on December 14,
2012 (File No. 333-178836) and incorporated herein by reference.
Amendment No. 2 to Affiliation Agreement between Cancer Genetics, Inc. and Mayo Foundation for Medical Education and Research, dated January 4,
2013, filed as Exhibit 10.61 to Form S-1/A filed on January 8, 2013 (File No. 333-178836) and incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and John Pappajohn dated February 11, 2013, filed as Exhibit 10.63 to Form S-1/A filed on February 12,
2013 (File No. 333-178836) and incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and John Pappajohn (on behalf of his spouse) dated February 13, 2013, filed as Exhibit 10.64 to Form S-
1/A filed on February 14, 2013 (File No. 333-178836) and incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and NNJCA Capital, LLC dated as of February 13, 2013, filed as Exhibit 10.65 to Form S-1/A filed on
February 14, 2013 (File No. 333-178836) and incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and DAM Holdings, LLC dated February 13, 2013, filed as Exhibit 10.66 to Form S-1/A filed on February
14, 2013 (File No. 333-178836) and incorporated herein by reference.
Letter Agreement between Cancer Genetics, Inc. and R.S.K. Chaganti, dated February 13, 2013, filed as Exhibit 10.67 to Form S-1/A filed on March 4, 2013
(File No. 333-178836) and incorporated herein by reference.
Form of Letter Agreement between Cancer Genetics, Inc. and certain warrant holders waiving certain anti-dilution rights, filed as Exhibit 10.68 to Form S-
1/A filed on March 4, 2013 (File No. 333-178836) and incorporated herein by reference.
Letter Amendment dated March 20, 2013 to Letter Agreement, between Meadows Office, L.L.C. and Cancer Genetics, Inc., dated April 6, 2012, filed as
Exhibit 10.72 to Form S-1/A filed on March 22, 2013 (File No. 333-178836) and incorporated herein by reference.
Amendment No. 3 to Affiliation Agreement between the Company and Mayo Foundation for Medical Education and Research, dated May 21, 2013, filed as
Exhibit 10.73 to Form S-1 filed on June 5, 2013 (File No. 333-189117) and incorporated herein by reference.
Limited Liability Company Agreement of OncoSpire Genomics, LLC, dated May 21, 2013, filed as Exhibit 10.74 to Form S-1/A filed on July 12, 2013 (File
No. 333-189117) and incorporated herein by reference.
Joint Development Intellectual Property Agreement, among the Company, Mayo Foundation for Medical Education and Research and OncoSpire Genomics,
LLC, dated May 21, 2013, filed as Exhibit 10.75 to Form S-1/A filed on July 12, 2013 (File No. 333-189117) and incorporated herein by reference.
Letter Agreement, between Cancer Genetics, Inc. and Andrew L. Pecora, effective February 18, 2014 (incorporated by reference to Exhibit 10.66 of the
Company's Annual Report on Form 10-K for the year ended December 31, 2013).
Consulting Agreement, between Cancer Genetics, Inc. and R.S.K. Chaganti, dated February 19, 2014 (incorporated by reference to Exhibit 10.67 of the
Company's Annual Report on Form 10-k for the year ended December 31, 2013).
Employment Agreement, between Cancer Genetics, Inc. and Edward J. Sitar, dated March 17, 2014 (incorporated by reference to Exhibit 10.69 of the
Company's Annual Report on Form 10-K for the year ended December 31, 2013).
Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated April 1, 2014 (incorporated by reference to Exhibit 10.1 of the
Company’s current report on Form 8-K filed on April 4, 2014 with the Securities and Exchange Commission).
Revolving Line of Credit Note, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated April 1, 2014 (incorporated by reference to Exhibit 10.2 of
the Company’s current report on Form 8-K filed on April 4, 2014 with the Securities and Exchange Commission).
Consulting Agreement, between Cancer Genetics Inc. and Equity Dynamics, dated November 6, 2014 and effective as of April 1, 2014 (incorporated by
reference to Exhibit 10.4 of the Company’s quarterly report on Form 10-Q for the period ended September 30, 2014 with the Securities and Exchange
Commission).
116
Table of Contents
Exhibit
No.
Description
10.63
10.64
10.65
10.66
10.67
10.68
10.69
10.70
Security Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated November 12, 2014 (incorporated by reference to Exhibit 10.5
of the Company’s quarterly report on Form 10-Q for the period ended September 30, 2014 with the Securities and Exchange Commission).
First Amendment to Credit Agreement, between Cancer Genetics, Inc. and Wells Fargo Bank, N.A., dated November 12, 2014. (incorporated by
reference to Exhibit 10.6 of the Company’s quarterly report on Form 10-Q for the period ended September 30, 2014 with the Securities and Exchange
Commission).
Loan and Security Agreement, between Cancer Genetics, Inc. and Silicon Valley Bank, dated May 7, 2015.(incorporated by reference to Exhibit 10.1 of
the Company’s quarterly report on Form 10-Q for the period ended March 31, 2015 with the Securities and Exchange Commission).
Amended and Restated Asset Purchase Agreement By and Between Response Genetics, Inc. a Delaware Corporation, and Cancer Genetics., a Delaware
Corporation, dated as of August 14, 2015 (incorporated by reference to the Company's current report on Form 8-K filed on August 21, 2015).
2011 Equity Incentive Plan, as amended and restated effective May 14, 2015, filed as Exhibit 10.1 to Form S-8 filed on July 28, 2015 (File Number
333-205903) and incorporated herein by reference.
Employment Agreement between Dr. Shaknovich and Cancer Genetics, Inc., effective as of July 1, 2015.(incorporated by reference to the Company’s
current report on Form 8-K filed on July 7, 2015).
Controlled Equity OfferingSM Sales Agreement, dated July 15, 2015, by and between Cancer Genetics, Inc. and Cantor Fitzgerald & Co. (incorporated
by reference to the Company’s current report on Form 8-K filed on July 16, 2015).
Form of Warrant Agreement of Cancer Genetics, Inc. (corrected) (incorporated by reference to Exhibit 4.1 of the Company’s quarterly report on Form
10-Q for the period ended September 30, 2015 with the Securities and Exchange Commission).
10.71*
Office Lease, between Response Genetics, Inc. and Health Research Association, dated September 16, 2014.
10.72*
Tenth Amendment to Office Lease, between Response Genetics, Inc. and University of Southern California, dated June 30, 2015.
10.73*
Consent and First Amendment to Loan and Security Agreement, between Cancer Genetics, Inc. and Silicon Valley Bank, dated January 28, 2016.
21.1*
23.1*
24.1
31.1*
31.2*
Subsidiaries of Cancer Genetics, Inc.
Consent of RSM US LLP.
Power of attorney (included on the signature page).
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities and Exchange Act of 1934, as
amended.
Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities and Exchange Act of 1934, as
amended.
32.1**
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*
The following financial statements from this annual report on Form 10-K of Cancer Genetics, Inc. for the year-ended December 31, 2015, filed on
March 10, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements
of Income, (iii) the Consolidated Statements of Cash, (iv) the Consolidated Statements of Stockholders' Equity and (v) the Notes to the Consolidated
Financial Statements.
*
**
Filed herewith.
Furnished herewith.
117
TENTH AMENDMENT TO LEASE AGREEMENT This Tenth Amendment to Lease Agreement (this "Tenth Amendment'o)o dated as of JuneQ,2015 (the "Amendment Date"), and effective as of JuneVt ,20t5 (the "Effective Date"), for reference purposes only, is entered into by and between the University of Southem California, a Califomia non-profit public benefit corporation ("Landlord") and Response Genetics, Inc., a Delaware corporation ("Tenant"). RECITALS A. Health Research Association, Inc., a California non-profit public benefit corporation ("Original Landlord"), and Tenant entered into an Office Lease Agreement dated as of September 16, 2004, as amended by that certain First Amendment to Office Lease dated February 1,2006, as further amended by that certain Second Amendment to Lease Agreement dated as of January 28,2010, as further amended by that certain Third Amendment to Lease Agreement dated as of March 37,2010, as further amended by that certain Fourth Amendment to Lease Agreement dated March 4,2011, as further amended by that certain Fifth Amendment to Lease Agreement dated August 19,2011, as further amended by that certain Sixth Amendment to Lease Agreement dated August 30,2011, as firther amended by that certain Seventh Amendment to Lease Agreement dated May 7,2012, as further amended by that certain Eighth Amendment to Lease Agreement dated June 28, 2012, and as further amended by that certain Ninth Amendment to Lease Agreement dated February 3,2014 (collectively, the "Lease"), for those certain premises known as Suites
400,40I,402,403,404,405,406,410,600, and 700 (collectively, the 'oPremises"), located at 1640 Marengo Blvd., Los Angeles, California 90033, all as more particularly set forth in the Lease. B. Landlord is successor in interest to that of Original Landlord; C. Tenant wishes to exercise Tenant's right to extend t the duration of the Lease for a term commencing on July 1,2015 and terminating on June 30, 2016. NOW THEREFORE, for good and valuable consideration received to the full satisfaction of the parties hereto, Landlord and Tenant do hereby covenant and agree as follows: 1. Recitals. The foregoing recitals are hereby incorporated into and made a part of this Tenth Amendment by this reference. 4\4# N\
2. Definitions. All capitalized terms in this Tenth Amendment (including the Recitals), shall have the same meanings ascribed thereto in the Lease, unless otherwise provided for herein. 3. Term. Pursuant to Tenant's right to extend the term of the Lease as provided in the Section 3 of the Ninth Amendment to Lease Agreement, the Term of the Premises is hereby extended to June 30,2016. 4. Base Rent. The monthly Base Rent for the period commencing on July I,20I5 and throughout the duration of the Term of this Lease shall be due and payable on the first day of each month and shall be in the sum of Sixty-Five Thousand and Forty-Seven Dollars and No Cents ($65,047). 5. Overstandard Tenant Use. Landlord acknowledges and consents to Tenant's installation of three additional transformers on the Premises (the "Transformers"). In lieu of the separate metering requirements in Section 6.2 of the Lease as it pertains to two of the three Transformers, Landlord and Tenant agree that Tenant shall pay Landlord a flat fee of $1,000.00 each month for such overstandard usage of power plus the actual cost of the third transformer per the monthly electrical reading (together the "Supplemental Power Fee"). Landlord shall have the right to require Tenant to remove the Transformer at Tenant's sole cost and expense; provided, however, upon removal of the Transformer, Tenant shall no longer be required to pay Landlord the Supplemental Power Fee. 6. Effect of Tenth Amendment. The Lease shall be deemed amended by this Tenth Amendment. Except as specifically modifred by this Tenth Amendment, all of the terms and conditions of the
Lease shall continue in full force and effect. In the event of any conflict between the terms of this Tenth Amendment and the terms of the Lease, the terms of this Tenth Amendment shall prevail. 7. Counterparts. This Tenth Amendment may be executed simultaneously in one (1) oÍ more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. Each party may execute a facsimile counterpart signature page, which shall constitute a valid and binding obligation of the party signing such facsimile counterpart. Any party signing by facsimile agrees promptly to furnish to the other party, upon request, an original counterpart of this Tenth Amendment. 8. Entire Agreement. This Tenth Amendment and the Lease contains the entire understanding and agreement between the parties relating to the matters covered hereby and supersedes all prior or contemporaneous negotiations, affangements, agreements, understandings, representations, and statements, whether oral or written, with respect to the matters covered hereby, all of which are merged herein and shall be of no further force or effect whatsoever. [Signature Page to Follow] ,\,x/ $s
IN WITNESS V/HEREOF, Landlord and Tenant have executed this Tenth Amendment as of the day and year first above written. Landlord UNIVERSITY OX' SOUTHERN CALIFORNIA a California non-profit public benefit corporation By: N Its: Tenant RESPONSE GENETICS, INC., By: Name: Its: /' Cr'-¡
AMENDMENT TO LEASE OF PARKING SPACES This Amendment to Lease of Parking Spaces (this "Parking Amendment"), dated and effective as of May ( ,2015 (the "Effective Date"), for reference purposes only, is entered into by and between the University of Southern California, a California non-profit public benefit corporation ("Landlord") and Response Genetics, Inc., a Delaware corporation ("Tenant"). RECITALS A. Landlord and Tenant are parties to that certain Lease of Parking Spaces Agreement dated as of February 3,2014 (the "Lease"), pursuant to which Tenant leases from Landlord up to forty-four (44) parking spaces within that certain parking lot located at the corner of Mission Avenue andZonal Avenue, Los Angeles, commonly referred to as "Lot 7L". B. Subject to the terms and conditions set forth in this Parking Amendment, Landlord and Tenant desire to amend the terms of the Lease. NO\il THEREFORE, for good and valuable consideration received to the full satisfaction of the parties hereto, Landlord and Tenant do hereby covenant and agree as follows: l. Recitals. The foregoing recitals are hereby incorporated into and made a part of this Parking Amendment by this reference. 2. Definitions. All capitalized terms in this Parking Amendment (including the Recitals), shall have the same meanings ascribed thereto in the Lease, unless otherwise provided for herein. 3. Lease: Use. Effective as of the Effective Date, the first sentence in Section 1.1 of the Lease shall be deleted in its entirety and replaced with the following: "Subject to the terms and conditions set forth in this Lease, Landlord hereby leases to Tenant
and Tenant hereby leases from Landlord a total of twenty-eight (28) unreserved parking spaces located in Lot 71 (collectively, the "Lot 7l Parking Spaces"). 4. Rent. Effective as of the Effective Date, Rent shall be reduced to One Thousand Nine Hundred and Sixty Dollars ($1960.00) per month at a.rate equal to Seventy Dollars ($ZO.OO; per Lot 71 Parking Space. 5. Effect of Amendment. The Lease shall be deemed amended by this Parking Amendment. Except as specifically modified by this Parking Amendment, all of the terms and conditions of the Lease shall continue in full force and effect. In the event of any conflict
between the terms of this Parking Amendment and the terms of the Lease, the terms of this Parking Amendment shall prevail. 6. Counterparts. This Parking Amendment may be executed simultaneously in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. Each party may execute a facsimile counterpart signature page, which shall constitute a valid and binding obligation of the party signing such facsimile counterpart. Any party signing by facsimile agrees promptly to furnish to the other party, upon request, an original counterpart of this Parking Amendment. 7. Entire Agreement. This Parking Amendment and the Lease contains the entire understanding and agreement between the parties relating to the matters covered hereby and supersedes all prior or contemporaneous negotiations, affangements, agreements, understandings, representations, and statements, whether oral or written, with respect to the matters covered hereby, all of which are merged herein and shall be of no further force or effect whatsoever. fSignature Page to Follow]
IN WITNESS V/HEREOF, Landlord and Tenant have executed this Parking Amendment as of the day and year first above written. Landlord UNIVERSITY OF SOUTHERN CALIFORNIA a California non-profit public benefit corporation By: Name: Its: Tenant RESPONSE GENETICS, INC., r-ÇCt
Subsidiaries of Cancer Genetics, Inc.
Exhibit 21.1
State of Incorporation
Name or Organization
Cancer Genetics Italia, S.r.l. Italy
Cancer Genetics (India) Private Limited India
Gentris, LLC Delaware
BioServe Biotechnologies (India) Private Limited India
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement Nos. 333-191520, 333-191521, 333-196198 and 333-205903 on
Form S-8 and in Registration Statement No. 333-196374 on Form S-3 of Cancer Genetics, Inc. and subsidiaries of our report dated
March 10, 2016, relating to our audits of the consolidated financial statements appearing in the Annual Report on Form 10-K of Cancer
Genetics, Inc. and subsidiaries for the year ended December 31, 2015.
Exhibit 23.1
/s/ RSM US LLP
New York, New York
March 10, 2016
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Panna L. Sharma, certify that:
1. I have reviewed this annual report on Form 10-K of Cancer Genetics, Inc. (the “Registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this
report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the Registrant and have:
a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
c. evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and
d. disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the
Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or
is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent
functions):
a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
b. any fraud, whether or not material, that involves management or other employees who have a significant role in the
Registrant’s internal control over financial reporting.
Date: March 10, 2016
/s/ Panna L. Sharma
Panna L. Sharma
President, Chief Executive Officer and
Director
(Principal Executive Officer)
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Edward J. Sitar, certify that:
1. I have reviewed this annual report on Form 10-K of Cancer Genetics, Inc. (the “Registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this
report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the Registrant and have:
a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;
c. evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and
d. disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the
Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or
is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent
functions):
a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
b. any fraud, whether or not material, that involves management or other employees who have a significant role in the
Registrant’s internal control over financial reporting.
Date: March 10, 2016
/s/ Edward J. Sitar
Edward J. Sitar
Chief Financial Officer
(Principal Financial Officer)
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.1
In connection with the annual report of Cancer Genetics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015
as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Panna L. Sharma, President, Chief Executive
Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of
1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
Date: March 10, 2016
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a
separate disclosure document.
/s/ Panna L. Sharma
Panna L. Sharma
President, Chief Executive Officer and Director
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.2
In connection with the annual report of Cancer Genetics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2015
as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Edward J. Sitar, Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my
knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of
1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company.
Date: March 10, 2016
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a
separate disclosure document.
/s/ Edward J. Sitar
Edward J. Sitar
Chief Financial Officer